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Abstract 
Introduction 
Doxorubicin (DOX) is an anthracycline that has significantly improved the outcome of 
cancer patients since its discovery. However, its clinical success remains limited due to the 
dose-dependent cardiotoxic side effects associated with its use. While the mechanisms 
responsible for this condition are still not well defined, oxidative stress alongside apoptosis, 
remain the classical but major contributors. Ghrelin, an endogenous brain-gut peptide, most 
well-known for its effects on appetite and growth hormone release, has been shown to exert 
anti-apoptotic, antioxidative, anti-inflammatory and anti-fibrotic effects in several models of 
cardiovascular disease. These cardioprotective effects offered by ghrelin have been indicated 
to occur through the activation of the pro-survival proteins, ERK1/2, Akt/PKB and STAT3. 
This study therefore investigated the protective effects of ghrelin in a chronic model of DOX-
induced cardiotoxicity.  
Methods 
Male Sprague-Dawley rats were acclimatized and divided into five experimental groups. 
While the control group remained untreated, the ghrelin group received 300 µg/kg ghrelin per 
week, the DOX group received 2.5 mg/kg per week, the combination group received both 
DOX and ghrelin at the previously mentioned doses and the vehicle group received saline. 
All injections were performed via intraperitoneal injection for eight weeks. One week after 
the last injection, the rats were euthanized, blood was collected and the hearts were subjected 
to a 40-minute working heart perfusion protocol to obtain functional data. The hearts were 
weighed and then cut transversely into two sections, where one half was snap frozen for 
biochemical analysis and the other half was preserved in formalin for histological analysis. 
Cardiovascular markers of damage and pro-inflammatory cytokines were measured in serum 
using a luminex assay, and fibrosis and general morphology were assessed using the 
Masson’s Trichrome and H&E stains, respectively. Cytochrome c expression was evaluated 
by immunohistochemistry, while oxidative stress was assessed using the TBARS, conjugated 
diene, ORAC, SOD and glutathione assays. Apoptosis was determined using the Caspase 
Glo® assay and the expression of pro-survival proteins was measured using Western blot 
analysis. 
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Results 
During the eight weeks of treatment, DOX significantly reduced weight gain and food 
consumption, whereas ghrelin maintained normal body weight and stimulated appetite. As 
expected, DOX induced significant oxidative stress when compared to the control, as 
demonstrated by the formation of conjugated dienes (1.64 ± 0.11 vs 0.55 ± 0.12 µmol/gram, p 
= 0.0003) and a reduction in the GSH:GSSG ratio (2.10 ± 0.47 vs 9.66 ± 1.08 arbitrary units, 
p< 0.05), whereas ghrelin attenuated these effects. Apoptotic cell death was also induced, as 
evident by an increase in cytochrome c staining, caspase activity (67877 ± 15686 vs 13421 ± 
1871 relative light units, p< 0.0001) and PARP cleavage (2.11 ± 0.24 vs 1.00 ± 0.09 fold 
change, p = 0.0081). The decrease in cell death and oxidative stress in this scenario was 
associated with a reduction in TNF-α and an improvement in cardiac function, which was 
otherwise worsened in the DOX group due to the decline cardiac output, coronary flow, rate-
pressure product, left ventricular developed pressure and total work. Even though ghrelin 
treatment in the presence of DOX did not induce noteworthy changes in the protein 
expression of ERK1/2 and Akt/PKB, the phosphorylation of STAT3 was improved with 
ghrelin administration. 
Discussion and Conclusion 
The observations presented in this study indicate that while DOX is a known effective 
chemotherapeutic agent, it produces cardiotoxic effects through the induction of oxidative 
stress and consequently apoptosis, possibly due to the downregulation of ERK1/2 and 
Akt/PKB. The co-administration of ghrelin with DOX significantly decreased the detrimental 
effects associated with DOX treatment alone. The effects of ghrelin were not only beneficial 
at organ level, but also at the organism level, as a result of improved general well-being of 
the experimental animals and through the maintenance of cardiac function, a decline in 
myocardial TNF-α production and the stimulation of the STAT3 signaling pathway. The fact 
that ghrelin alone did not exert any detrimental effects makes this peptide an appealing 
cardioprotective agent and may therefore have the potential to improve the high morbidity 
and mortality rates of cancer survivors. While ghrelin in this context may possess anti-
cardiotoxic effects, further research is required to determine the effects of ghrelin on cancer 
cell proliferation. 
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Uittreksel 
Inleiding 
Doksorubisien (DOX) is ‘n antrasiklien wat die uitkoms vir kankerpasiënte betekenisvol 
verbeter het sedert die ontdekking daarvan.  Die kliniese sukses is steeds beperk as gevolg 
van die dosis-afhangklike kardiotoksiese newe-effekte wat verband hou met die gebruik 
daarvan.  Terwyl die meganismes wat verantwoordelik is vir hierdie toestand steeds nie 
bekend is nie, is oksidatiewe stres, tesame met apoptose, die klassieke bydraers. Ghrelien,’n 
endogene brein-derm peptied wat wel bekend is vir sy effekte op aptyt en vrystelling van 
groeihormoon, vertoon anti-apoptotiese, antioksidatiewe, anti-inflammatoriese en anti-
fibrotiese effekte in verskeie kardiovaskulêre siekte modelle.  Hierdie kardio-beskermende 
effekte van ghrelien is te wyte aan die aktivering van die pro-oorlewingsproteïene, ERK1/2, 
Akt/PKB en STAT3. Hierdie studie het die beskermende effekte van ghrelien in ‘n chroniese 
model van DOX-geïnduseerde kardiotoksisiteit ondersoek.   
Metodes 
Manlike Sprague-Dawley rotte is geaklimatiseer en in vyf eksperimentele groepe verdeel.  
Terwyl die kontrole groep onbehandel is, het die ghrelien groep weekliks 300 µg/kg ghrelien, 
die DOX groep 2.5 mg/kg per week, die kombinasie groep beide DOX en ghrelien by 
dieselfde vorige dossisse, en die draer groep ‘n soutoplossing ontvang. Alle toedienings is via 
intraperitoneale inspuiting vir agt weke gedoen. Een week voor die laaste inspuiting, is die 
rotte doodgemaak, bloed is versamel, en die harte is blootgestel aan ‘n 40-minute werkende 
hartperfusie protokol om funksionele data te versamel.  Die harte is geweeg en transversaal in 
twee dele gedissekteer, waar die een helfte geklampvries is vir biochemiese analises, en die 
ander helfte is in formalien gepreserveer vir histologiese analises.  Kardiovaskulêre merkers, 
vir skade en pro-inflammatoriese sitokiene is in serum bepaal deur ‘n Luminex platvorm, 
terwyl fibrose en algemene morfologiese ondersoeke deur Masson se Trichrome en H&E 
kleuringstegniek onderskeidelik van gebruik te maak. Sitochroom-c uitdrukking is deur 
middel van immune-histochemie bepaal, en oksidatiewe stres deur van TBARS, 
gekonjugeerde diëne, ORAC, SOD en glutatioon toetse. Apoptose is deur middel die Caspase 
Glo® getoets, en uitdrukking van die pro-oorlewingsproteïene is bepaal deur Westerse 
kladtegniek. 
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Resultate 
Gedurende die agt weke behandeling het DOX toename in gewig. asook voedselinname 
betekenigsvol verlaag, terwyl ghrelien normale liggaamsgewig en aptyt gestimuleer.  Soos 
verwag, het DOX oksidatiewe stres betekenisvol geïnduseer vergeleke met die kontrole groep 
soos waargeneem deur die vorming van gekonjugeerde diëne (1.64 ± 0.11 vs 0.55 ± 0.12 
µmol/gram, p = 0.0003), en ‘n verlaging in die GSH:GSSG verhouding (2.10 ± 0.47 vs 9.66 ± 
1.08 AU, p< 0.05), terwyl ghrelien hierdie effekte verlaag het. Apoptotiese seldood is ook 
geïnduseer soos waargeneem deur die toename in sitochroom-c kleuring, kaspase aktiwiteit 
(67877 ± 15686 vs 13421 ± 1871 RLU, p< 0.0001) en PARP klowing (2.11 ± 0.24 vs 1.00 ± 
0.09 voudige verandering, p = 0.0081). Die verlaging in seldood en oksidatiewe stres in 
hierdie scenario is met ‘n verlaging in TNF-α vorming en verbeterde kardiale funksionering 
geassosiëer, wat nie in die DOX groep waargeneem is nie weens verlaagde kardiale omset. 
koronêre vloei, tempo-druk produk, linker ventrikulêre-ontwikkelde druk en totale arbeid. 
Hoewel ghrelien behandeling in die teenwoordigheid van DOX behandeling geen 
waarneembare veranderinge in die proteïenuitdrukking van ERK1/2 en Akt/PKB vertoon het 
nie, het ghrelien toediening wel die fosforilering van STAT3 verbeter. 
Bespreking en gevolgtrekking 
Die waarnemings wat in hierdie studie rapporteur word wys daarop dat terwyl DOX ‘n 
welbekende effektiewe chemoterapeutiese middel is, veroorsaak dit kardiotoksiese effekte 
deur die induksie van oksidatiewe stres, en gevolglik apoptose, moontlik deur die 
afregulering van ERK1/2 en Akt/PKB. Die toediening van ghrelien met DOX verlaag die 
skadelike effekte betekenisvol vergeleke met enkel behandeling van DOX. Die effek van 
ghrelien is beide voordelig op orgaanvlak sowel organisme vlak, weens verbeterde algemene 
welstand van die eksperimentele diere en deur die handhawing van kardiale funksie, ‘n 
afname in miokardiale TNF-α vorming, en die stimulering van die STAT3 seinweg. Die feit 
dat ghrelien as ‘n enkel middel geen skadelike effekte vertoon het nie, maak van hierdie 
peptied ‘n gepaste kardiobeskermende middel en kan dus daarom die potensiaal hê om die 
hoë morbiditeit en mortaliteit van kanker pasiente te verbeter.  Alhoewel ghrelien in hierdie 
konteks anti-kardiotoksiese effekte vertoon het, daar word voorgestel dat die effek van 
ghrelien op kankerselle eers ondersoek word alvorens enige behandelingsvoorstelle toegepas 
kan word. 
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Chapter 1  
Literature Review 
1.1 Introduction 
It is predicted that by the year 2020, the world’s population will increase to 7.5 billion 
people. Cancer continues to be a worldwide disease burden (Anand et al., 2008) with an 
incidence of 17 million cases. By 2050 it is predicted that two thirds of these cases will occur 
in the developing regions of the world (Bray & Møller, 2006). This is exacerbated by the 
growing concern for communicable diseases such as human immunodeficiency virus 
(HIV)/acquired immunodeficiency syndrome (AIDS) and tuberculosis in African countries 
(Jemal et al., 2012). Fortunately, the discovery of anthracyclines has aided a steadily 
increasing population of cancer survivors (Lipshultz et al., 2008). Doxorubicin (DOX) is an 
anthracycline antibiotic, previously isolated as a natural product of Streptomyces peucetius in 
the late 1960s (Arcamone et al., 1969). It has a broad spectrum of therapeutic activities and is 
thus the most effective and widely used drug for the treatment of cancers such as leukemias, 
lymphomas and solid tumours (Barrett-Lee et al., 2009; Blum & Carter, 1974; Bonadonna et 
al., 1970; Weiss, 1992). The chemical structure of DOX (Figure 1.1) consists of aglyconic 
and sugar moieties (Minotti et al., 2004). Doxorubicinone, the aglycone, is made up of 
tetracyclic rings (A – D) that contain adjacent quinone-hydroquinone moieties in rings B and 
C. Daunosamine, the sugar moiety, attaches to carbon number 7 by glycosidic bonds 
(Arcamone et al., 1969). These structural features are important for its topoisomerase-
targeting and DNA-intercalating abilities (Minotti et al., 2004), the mechanisms by which 
DOX kills cancer cells.  
 
Figure 1.1: The chemical structure of DOX. 
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DOX consists of quinone and hydroquinone moieties in rings B and C and a sugar moiety attached to carbon 
number 7 of ring A. Adapted from Carvalho et al., (2014), with permission from Wiley. 
The heart is a truly remarkable organ with the ability to meet the demands of the body during 
exercise, and withstand lifetime stressors such as hypertension (Ewer & Ewer, 2010). 
However, various toxic substances can cause irreversible damage to this otherwise robust 
pump. One of the measures of the success of DOX is the fact that cancer survivors have an 
increased lifespan, however, the side effects associated with DOX treatment have become a 
significant clinical problem. Even though the survival rate is now approximately 80% 
(Vander Heide & L’Ecuyer, 2007), the use of DOX is limited by several toxic side effects, 
with dose-dependent cardiotoxicity being the most prominent and the most feared (Swain et 
al., 2003; Lefrak et al., 1973; Von Hoff et al., 1979). The progressive myocardial damage of 
this condition can lead to heart failure, a reduced quality of life, and eventually death (Lefrak 
et al., 1973). Although there is no single accepted definition for cardiotoxicity, it can be 
defined as a “broad range of adverse effects on heart function induced by chemotherapeutic 
molecules” (Montaigne et al., 2012). Cardiotoxicity was not initially detected during pre-
clinical animal studies and was only reported during early clinical trials (Lefrak et al., 1973). 
Late into the 1970s, clinical studies identified that the observed cardiac abnormalities that 
occurred during DOX treatment were directly proportional to the dose of the drug received. 
DOX-induced cardiotoxicity has also been demonstrated in cell culture (Das et al., 2011), in 
isolated heart studies (Rajagopalan et al., 1988), in in vivo studies (Arola et al., 2000) and in 
humans (Von Hoff et al., 1979). In all instances, the magnitude of DOX-induced cardiac 
damage was directly proportional to the cumulative dose of the drug received. 
Since treatment with DOX has been met with a significant fall in cancer-related mortality 
rates, the cardiotoxicity that accompanies its use, and the impact thereof, has now emerged as 
a noticeable problem. It is estimated that the incidence of DOX-induced cardiotoxicity ranges 
from 4% to more than 36% (Figure 1.2), with these estimates being directly proportional to 
the dose of drug received (Lefrak et al., 1973). Indeed, Hudson et al., (2013) showed that 
56.4% of childhood cancer survivors treated with anthracyclines showed signs of cardiac 
dysfunction 10 – 47 years after diagnosis. Various other risk factors for the development of 
cardiotoxicity also exist, including a cumulative lifetime dose of 450 – 600 mg/m2 (Minotti et 
al., 2004), previous or concurrent radiation treatment (Bristow et al., 1978), young or old age 
at the time of diagnosis (Mulrooney et al., 2016; Bowles et al., 2012) and a history of other 
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cardiovascular disease (Bovelli et al., 2010). In addition, lifestyle factors such as smoking, 
inactivity and excess body weight may contribute to the development of DOX-induced 
cardiotoxicity, however, further evidence is needed to support these claims (Lipshultz et al., 
2015).  
 
Figure 1.2: Cumulative risk of developing DOX-induced heart failure. 
The risk of developing DOX-induced heart failure increases with the cumulative dose of drug received, as well 
as with young or old age. Taken from Barrett-Lee et al., (2009), by permission of Oxford University Press. 
There are four types of cardiomyopathies: dilative, hypertrophic, restrictive and arthymogenic 
right ventricular cardiomyopathy (Olsen, 1975; Marcus et al., 2010). However, an additional 
type known has secondary cardiomyopathy has now been recognized as a consequence of 
conditions such as inflammation or toxic agents (Sisakian, 2014). Patients diagnosed with 
DOX-induced cardiotoxicity may be classified into three groups: i) acute cardiotoxicity, 
which usually presents as reversible cardiac dysfunction during or within one week after 
treatment with an incidence of less than 1%, ii) early chronic, which occurs within the first 
year at an incidence of 1.6 – 2.1 % and iii) late onset chronic cardiotoxicity, which can occur 
between 1 and 30 years after treatment at an incidence of 16 – 20%, presenting as dilated 
cardiomyopathy and heart failure  (Bovelli et al., 2010; Carvalho et al., 2014; Scully & 
Lipshultz, 2007). The major morphological characteristics of cardiotoxicity include 
myofibrillar loss, dilatation of the sarcoplasmic reticulum and swelling of the mitochondria 
(Tokarska-Schlattner et al., 2006). Acute cardiotoxicity is not a clinical concern as it usually 
resolves on its own shortly after treatment, whereas chronic cardiotoxicity drastically affects 
the morbidity and survival outcome of patients requiring long-term therapy (Šimùnek et al., 
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2009). Signs of cardiomyopathy show a prevalence of 7.4% in cancer survivors exposed to 
DOX at least 20 years earlier (Mulrooney et al., 2016), however, a much larger 
cardiovascular morbidity rate of 19% was reported in a cohort of cancer survivors (Toro-
Salazar et al., 2015). It has also been reported that childhood cancer survivors face a 5.8-fold 
greater chance of death due to cardiac disease than the general population (Tukenova et al., 
2010), emphasizing the serious clinical implications of DOX-induced cardiotoxicity. The 
unanticipated complication of DOX use brings with it a poor prognosis for cancer survivors, 
as cardiotoxicity has proven to be fatal in at least 50% of cases (Bristow et al., 1978; Von 
Hoff et al., 1979). The discipline of cardio-oncology is thus essential for the survival of 
cancer patients, as a cancer survivor should not have to become a patient with heart failure. 
This emphasizes the need for novel adjuvant therapies that can remain effective against 
cancer but carry minimal cardiotoxic side effects. 
1.2 Mechanisms and treatment strategies 
Over the years, researchers have invested their time and research funds to investigate the 
targets and molecular mechanisms involved in the pathogenesis of DOX-induced 
cardiotoxicity, however, based on the long list of potential, yet controversial mechanisms, it 
is clear that the development of cardiotoxicity is a complex and multifactorial process. 
Amongst others, increased systemic and cardiac cholesterol levels have been newly identified 
as contributors to the development of cardiotoxicity (Monzel et al., 2017), however, one of 
the mostly wide accepted and commonly quoted mechanisms is the generation of oxygen-
derived free radicals, with cardiomyocyte apoptosis being the resultant terminal downstream 
event (Minotti et al., 2004; Olson et al., 1981; Kalyanaraman et al., 2002; Alderton et al., 
1992). Oxygen radicals can induce cellular damage to lipid membranes, mitochondria, DNA 
and proteins once they overwhelm the hearts natural antioxidant defense systems (Doroshow, 
1983). This coalition of events all contribute to the ultimate death of the cardiomyocyte 
(Sinha, 1989; Valko et al., 2007). DOX generates free radicals in two ways: i) via the 
mitochondrial respiratory chain and ii) via a non-enzymatic pathway involving iron (Olson & 
Mushlin, 1990). Only a few years after its discovery, various studies reported that DOX was 
involved in reduction-oxidation reactions by cycling between its quinone and semiquinone 
form (Goodman & Hochstein, 1977; Bachur et al., 1978). Several oxidoreductases within 
mitochondria convert DOX into a semiquinone through the reduction of ring C (Figure 1.3). 
In the presence of oxygen,  superoxide (O2●-) and hydrogen peroxide (H2O2) radicals are 
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produced (Olson et al., 1981; Olson & Mushlin, 1990). Electrons are then donated back to 
DOX and the parent compound is regenerated. Since no net consumption of DOX takes 
place, the process of “redox cycling” is endless and generates many molecules of free 
radicals (Keizer et al., 1990). 
 
Figure 1.3: The process of redox cycling. 
During redox cycling, the reduction of ring C converts DOX into a semiquinone form and produces various 
oxygen radicals. The parent compound of DOX is regenerated. Adapted from Tokarska-Schlattner et al., (2006), 
with permission from Elsevier. 
Alternatively, free radicals can be generated through enzyme-independent mechanisms, as 
DOX has the ability to chelate iron (Zweier, 1984). Fe3+ reacts with the ketone and hydroxy 
groups of carbon-11 and -12 (rings B and C) of DOX. In this redox reaction, Fe3+ accepts an 
electron and an Fe2+-DOX complex is generated (Olson & Mushlin, 1990).  This complex 
then reduces oxygen into superoxide radicals, after which an electron flows from Fe2+ to 
DOX, producing a Fe3+-DOX complex free radical. The Fe3+-DOX complex can induce the 
peroxidation of lipids and the destruction of the respiratory chain enzymes (Demant & 
Jensen, 1983). Although there is very little freely available iron within cardiomyocytes, it is 
believed that DOX is able to release iron from cytosolic ferritin stores (Thomas & Aust, 
1986). 
Stellenbosch University  https://scholar.sun.ac.za
- 6 - 
 
 
Mitochondria are the most extensively damaged organelles affected by DOX-induced 
cardiotoxicity (Hasinoff et al., 2003; El-Mehy et al., 2008). One of the major reasons for this 
is due to the high affinity that DOX has for cardiolipin, an abundant phospholipid embedded 
in the inner mitochondrial membrane (Schlame et al., 2000), allowing DOX to accumulate in 
the mitochondrion (Goormaghtigh et al., 1980). Cardiolipin is almost exclusively associated 
with membranes involved in ATP production and may therefore play a role in mitochondrial 
bioenergetics. The fact that the heart is densely populated with mitochondria, which are both 
a source and target of free radical production, leaves it vulnerable to oxidative stress-induced 
damage and sensitive to oxidative stress due to the highly oxidative environment and limited 
antioxidant defense compared to other organs. Compared to other metabolic organs such as 
the liver and kidneys, the heart contains reduced levels of intracellular superoxide dismutase 
(SOD), glutathione (GSH) and catalase, increasing the chances of cardiovascular damage 
(Doroshow et al., 1980; Quiles et al., 2002). It is therefore plausible that DOX-induced 
cardiotoxicity could be reduced if these defense systems were upregulated. SOD is an 
enzyme responsible for the dismutation of O2●- radicals into H2O2 or molecular oxygen 
(Scandalios, 1993; Perry et al., 2010). H2O2 is then scavenged into water and molecular 
oxygen by catalase. H2O2 can also be reduced to water by GSH, which donates a reducing 
equivalent in a reaction catalyzed by glutathione peroxidase 1 (GSH-Px1).  During this 
reaction, GSH is converted to the oxidized form, glutathione disulphide (GSSG).  Once 
oxidized, GSSG can be regenerated into GSH by glutathione reductase (GR), using electrons 
donated by NADPH (Figure 1.4). 
 
Figure 1.4: The pathways involved in free radical scavenging. 
Stellenbosch University  https://scholar.sun.ac.za
- 7 - 
 
 
SOD is responsible for converting superoxide radicals into hydrogen peroxide. Hydrogen peroxide can then be 
reduced to water and oxygen by catalase or glutathione. Abbreviations: O2●-, superoxide; SOD, superoxide 
dismutase; H2O2, hydrogen peroxide; H2O, water; O2, oxygen; GSH-Px1, glutathione peroxidase 1; GSH, 
glutathione; GSSG, glutathione disulphide; GR, glutathione reductase. 
One of the earliest antioxidants investigated was vitamin E (Myers et al., 1977), which was 
shown to protect against DOX-induced cardiomyopathy by enhancing the activity of GSH-
Px1 in the rat myocardium (Siveski-Iliskovic et al., 1994; Kumral et al., 2016). 
Unfortunately, research then showed that vitamin E treatment is only effective in acute 
studies and does not offer protection from the chronic forms of this condition (Mimnaugh et 
al., 1979). Similarly, N-acetylcysteine (NAC) was highly effective in acute studies 
(Doroshow et al., 1981), but failed to show protection in the chronic setting (Herman et al., 
1985). The positive results observed in animal studies after treatment with various 
antioxidants were not echoed in clinical trials, suggesting that the experimental models 
studied and the type and dose of antioxidants utilized may affect their efficacy (Singal et al., 
1997).  
After several decades of intensive research, Dexrazoxane (DXZ/ICRF-187) is the only drug 
that has been approved for clinical use as a pharmacological cardioprotective agent. This drug 
has repeatedly been shown to protect the myocardium from anthracyclines in experimental 
models and clinical trials (Lipshultz et al., 2004; Xiang et al., 2009; Asselin et al., 2016). 
DXZ has the ability to chelate iron, which then decreases the DOX-induced damage to DNA 
and the mitochondria (Lebrecht et al., 2007), without jeopardizing its anti-cancer efficacy 
(Speyer et al., 1992). DXZ enters the cell where it undergoes rapid hydrolysis into ADR-925, 
its metal ion-binding form. By chelating free iron and displacing the iron associated with 
DOX-iron complexes, DXZ limits the production of reactive species and ultimately reduces 
mitochondrial dysfunction (Hasinoff et al., 2003). In phase III clinical trials, the incidence of 
cardiac events associated with DOX use was less than 15% in women receiving DXZ, 
compared to 16 – 50%  in women who did not receive it (Swain et al., 1997b). The incidence 
of congestive heart failure (CHF) was also significantly reduced from almost 30% in women 
not receiving DXZ, to 0 – 3% in women who were (Swain et al., 1997a). However, the 
success of DXZ is hampered by the development of severe myelosuppression (Curran et al., 
1991),  thus limiting its use as a cardioprotective agent. 
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The severity of cardiotoxicity has highlighted the clinical importance and awareness of this 
condition, such that it has prompted the development of several experimental models. 
However, one of the reasons that the mechanisms of chronic cardiotoxicity remain unclear is 
due to the selection of inappropriate models. Many studies aiming to identify the molecular 
pathogenesis of cardiotoxicity evaluate the effects of DOX in vitro or in vivo. These studies 
usually employ high drug concentrations and examine effects within hours or days, ultimately 
only simulating the reversible, acute form of cardiotoxicity. The in vivo effects of chronic 
cardiotoxicity require weeks to appear and are associated with lower, but cumulative drug 
concentrations. Such studies require large sample sizes that need to be monitored over 
extended periods of time, increasing experimental costs. Still, to realistically simulate the 
clinical setting, studies of chronic cardiotoxicity should be a high priority. Long-term studies 
of chronic cardiotoxicity are also important to accurately evaluate the cardioprotective 
potential of adjuvant therapies so that clinically relevant routes of administration and doses of 
drugs can be evaluated (Gianni et al., 2008). The current strategy for treatment of this 
condition is aimed at maintaining the efficiency of the weakening myocardium, and a few of 
the treatment options are outline in Table 1, however, none of these have proven to be ideal. 
Table 1: Current treatment strategies for cardiotoxicity. 
Drug Function Model Authors 
Digoxin/digitalis Improve contractility Humans Guthrie and Gibson, (1977) 
Diuretics Reduce fluid retention Humans Antman et al., (1984) 
ACE-inhibitors Reduce workload of the heart Rat Sacco et al., (2001) 
β-blockers Prevent arrhythmias Human Kalay et al., (2006) 
Abbreviations: ACE, angiotensin-converting enzyme 
Considering that there is no consensus on an effective strategy to prevent or even treat DOX-
induced cardiotoxicity other than a heart transplant (Thomas et al., 2002), the best approach 
is early detection of cardiomyopathies (Pereira et al., 2011), however, cardiac damage is 
usually only detected after the functional impairment has already occurred. An ideal marker 
of cardiac damage should i) be found at high concentrations in the myocardium but low 
concentrations in other organs, ii) be released rapidly after myocardial injury, iii) be released 
at concentrations that are directly proportional to the extent of myocardial injury and iv) 
remain in the blood long enough to provide a diagnostic window (Adams et al., 1993a). The 
elevation of cardiac markers such as cardiac troponin tropomyosin (cTnT), cardiac troponin 
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inhibitory (cTnI) and creatine kinase–myocardial band (CK-MB) are pivotal for correct 
diagnosis, as they correlate with the extent of myocardial injury and the subsequent risk of 
adverse events (Chin et al., 2012). The troponins are myofibrillar proteins that form a 
complex that controls the interaction of actin and myosin. They are the most cardiac-specific 
markers of all the currently available markers for myocardial damage (Rottbauer et al., 1996; 
Adams et al., 1993b). cTnI is not expressed by injured skeletal muscle and is therefore 
uniquely specific to cardiac injury. Due to their specificity and the very low concentrations in 
the serum of healthy individuals (Wallace et al., 2006), the troponins are incredibly sensitive 
to even mild myocardial injury. Indeed, Cardinale et al., (2002) reported that cTnI is a risk 
marker for the development of left ventricular dysfunction after chemotherapy. Since it can 
take several months for the full cardiotoxic side effects of DOX to impact on cardiac 
function, it is usually too late to make use of conventional heart failure therapy (Kantrowitz 
& Bristow, 1984). The current approach to reduce DOX-induced cardiotoxicity is to 
minimize oxidative stress through the use of various antioxidants. However, the positive 
results of only some antioxidants against DOX-induced cardiotoxicity in vivo indicate that 
oxidative stress may not be the primary culprit for the development of cardiotoxicity. This 
suggests that several mechanisms are at play, and highlights the need for a cardioprotective 
agent with mechanisms of action that can target multiple steps of this complex process.  
Ghrelin, an orexigenic hunger hormone discovered in 1999, has whet the appetites of many 
researchers through its diverse array of biological functions. The beneficial effects of ghrelin 
have been attributed to its ability to stimulate appetite and positive energy balance, affect 
glucose metabolism, modulate cell proliferation and survival, and influence cardiovascular 
performance (Van Der Lely et al., 2004). It is therefore not surprising that ghrelin has clinical 
and therapeutic potential in the fields of cardiology and oncology. This review explores the 
role of ghrelin in the context of chronic DOX-induced toxicity, including its effects on 
oxidative stress and cell death, the fundamental mechanisms responsible for cardiovascular 
dysfunction in this condition. Furthermore, this review will investigate the link between 
ghrelin and two well-known pro-survival pathways, the RISK and SAFE, to not only 
delineate its influence on these pathways, but to also assess its potential beneficial effects in 
relation to cardioprotection. 
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1.3 Identifying a role for ghrelin 
Ghrelin, a 28-amino acid acyl peptide, is most well-known for inducing the release of growth 
hormone (GH) from the pituitary gland and stimulating food intake and adiposity (Tschöp et 
al., 2000; Kishimoto et al., 2012; Kojima et al., 2001). However, numerous studies (García & 
Korbonits, 2006; Granata et al., 2011) are now highlighting just how multifunctional this 
peptide hormone is (Figure 1.5). Ghrelin and its messenger RNA (mRNA) are mainly 
synthesized in X/A-like cells in the oxyntic mucosa of the stomach (Date et al., 2000), where 
the 28-amino acid mature form is cleaved off the pre-cursor, pre-proghrelin. Circulating 
ghrelin levels exhibit a pre-prandial (fasting) increase, suggesting a role in meal initiation, 
and a post-prandial (feeding) decrease (Cummings et al., 2001), which are directly 
proportional to the calories ingested. From the submucosal layer of the stomach, ghrelin is 
then secreted into the blood stream where it acts on the anterior pituitary gland (Kojima et al., 
1999). In healthy humans, plasma ghrelin circulates at a concentration of 117.2 ± 37.2 
fmol/mL (Kojima et al., 1999).  
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Figure 1.5: A summary of the known biological actions of ghrelin. 
Ghrelin exerts various beneficial effects which may also extend to DOX-induced cardiotoxicity. 
Ghrelin mediates its endocrine activities via the growth hormone secretagogue receptor 1α 
(GHSR-1α), a G-protein coupled receptor mainly located in the pituitary gland and the 
hypothalamus. Acylation of ghrelin with octanoic acid on Serine 3 (Figure 1.6) is essential 
for receptor binding (Kojima et al., 1999), and the fact that this modification site is 
evolutionarily conserved emphasizes its importance for ghrelin activity (Kojima et al., 2001). 
In circulation, des-acyl (unacylated) ghrelin also exists. Although des-acyl ghrelin is far more 
abundant within the cell (3 - 4: 1), it does not bind to GHSR-1α and exerts functions which 
are currently unknown (Kojima & Kangawa, 2005; Nagaya & Kangawa, 2003; Tong et al., 
2013). However, it has been reported that both ghrelin and des-acyl ghrelin recognize a 
common binding site that is distinct from GHSR-1α (Baldanzi et al., 2002; Yu et al., 2014). 
The action of ghrelin is regulated by several mechanisms, including i) the transcriptional and 
translational regulation of the ghrelin gene, ii) the enzymatic activity of ghrelin O-acyl 
transferase that is responsible for the octanoylation on Serine 3, iii) the secretion rate of 
active ghrelin, iv) enzymatic processes involved in deactivating ghrelin, v) the influence of 
ghrelin binding proteins on its bioactivity, vi) the accessibility of a target tissue, vii) clearance 
and degradation of ghrelin by the kidneys or liver, viii) the concentrations of additional 
circulating endogenous ligands, ix) the level of ghrelin receptor expression and x) the 
sensitivity of these receptors to ghrelin (Van Der Lely et al., 2004). 
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Figure 1.6: Structure of acyl-ghrelin (left) and des-acyl ghrelin (right). 
Adapted from Orbetzova, (2012). © Published in Insulin Resistance under CC BY 3.0 license. Available 
from: http://dx.doi.org/10.5772/50977.  
 
1.4 Ghrelin and the heart – an adjuvant therapy for heart failure 
Although ghrelin is predominantly produced in the stomach, both ghrelin and its various 
receptors have been detected in other tissues (lungs, pancreas, kidney, brain) including the 
heart, albeit at lower levels (Gnanapavan et al., 2002; Kojima et al., 1999). In addition, 
Iglesias et al., (2004) have reported the presence of ghrelin receptors within cardiomyocytes 
and that these cultured cells can actually synthesize ghrelin, supporting a role for ghrelin in 
the cardiovascular system. The fact that ghrelin mRNA and its receptors are abundantly 
expressed in rat ventricles, atria, aorta, coronary arteries, carotid arteries and vena cava 
confirms that the heart is also a target for ghrelin (Gnanapavan et al., 2002; Zhang et al., 
2010). Accumulating evidence indicates that ghrelin exerts several functions on the 
cardiovascular system, including protection against myocardial infarction and ischemia-
reperfusion injury (IRI). In in vivo models of heart failure, induced as a result of the 
previously mentioned conditions, treatment with ghrelin resulted in improved systolic 
dysfunction and reduced systemic vascular resistance and arterial pressure (Chang et al., 
2004a; Nagaya et al., 2001c). In patients with CHF, twice daily treatment with ghrelin caused 
a significant increase in left ventricular ejection fraction, from 27% to 31% (Nagaya et al., 
2004). Ghrelin has further been shown to increase posterior wall thickness, inhibit 
progressive left ventricular enlargement associated with heart failure, and thereby reduced 
left ventricular wall stress (Wang et al., 2014). In ghrelin knock-out mice with heart failure, 
ghrelin administration substantially improved survival, myocardial remodeling and 
dysfunction. Interestingly, heart failure deteriorated in knock-out control mice (Mao et al., 
2013). In the context of DOX-induced cardiotoxicity, the survival rate after five weeks of 
treatment with DOX was a mere 37.5%, versus 87.5% in mice that received co-treatment 
with ghrelin (Wang et al., 2014). Furthermore, ghrelin treatment increased ejection fraction 
and heart rate, both of which were negatively affected during DOX treatment. These findings 
thus emphasize an important role for ghrelin in improving cardiovascular function and 
reducing mortality during pathological conditions.  
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It is a well-known phenomenon that individuals who suffer from diseases such as heart 
failure and cancer experience significant weight loss (Fearon et al., 2011; Fülster et al., 
2013), therefore in addition to its potential cardioprotective effects, ghrelin’s appetite-
inducing effects may prove beneficial in this context. Indeed, previous studies have shown 
that ghrelin not only increases appetite in healthy individuals (Enomoto et al., 2003), but also 
in patients with CHF (Nagaya et al., 2004). In healthy individuals, ghrelin decreases mean 
arterial pressure without affecting heart rate, decreases vascular resistance and increases 
stroke volume (Nagaya et al., 2001a). These effects suggest that ghrelin may inhibit the 
activation of the sympathetic nervous system (Mao et al., 2013). The GH-releasing effect of 
ghrelin appears to occur as a result of ghrelin binding to the GHSR-1α in the anterior 
pituitary gland, whereafter ghrelin activates growth hormone releasing hormone (GHRH)-
containing neurons (Popovic et al., 2003). Interestingly, ghrelin can trigger GH production 
through the phospholipase C (PLC) pathway, where PLC catalyzes the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2), yielding inositol 1,4,5-trisphosphate (IP3) and 
diacyl glycerol (DAG) (Lopez et al., 2001). IP3 and DAG are crucial intercellular second 
messengers that regulate several cellular processes, as well as serving as substrates for the 
synthesis of other signaling molecules. When IP3 binds to its receptors on calcium (Ca2+) 
channels, it initiates a surge in cytosolic Ca2+ from intracellular stores. Ca2+ then facilitates 
GH release from the somatotrophic cells by docking GH secretory granules to the plasma 
membrane (Smith et al., 1997),  or by stimulating GHRH on hypothalamic neurons (Lall et 
al., 2004). Ca2+ is a second messenger  that is involved in processes such as muscle 
contraction (Berridge et al., 2000). Considering that one of the symptoms associated with 
DOX-induced cardiotoxicity is a decline in cardiac output and contractility (Wang et al., 
2014; Xiong et al., 2006), it is likely that treatment with ghrelin could be of potential benefit 
by counteracting this decline through enhanced up-regulation of Ca2+ ATPase (Tajima et al., 
1999). Ghrelin may also exert a protective effect on the cardiovascular system through the 
anabolic effects of GH and its mediator,  insulin-like growth factor-1 (IGF-1), both of which 
are necessary for myocardial growth and metabolic homeostasis (Kishimoto et al., 2012; 
Ledderose et al., 2011). 
As mentioned previously, ghrelin has been reported to increase appetite and consequently 
food intake, amongst other functions. Its use was demonstrated to be particularly 
advantageous in patients suffering from CHF with complications of cachexia, a commonly 
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observed wasting syndrome associated with this disease. These patients displayed signs of 
improved weight gain, muscle mass and muscle strength, as well as a positive energy balance 
(Nagaya et al., 2004). In patients undergoing a combined treatment of Cisplatin and DOX, 
plasma glucose levels were transiently decreased, whilst exogenous administration of ghrelin 
caused a significant increase in food intake and appetite, preventing the adverse side effects 
associated with chemotherapy (Hiura et al., 2012). During cachexia, ghrelin increases both 
lean and fat mass in order to re-establish physiological body composition and weight 
(Strassburg et al., 2008). Additionally, body fat is lost more rapidly than lean mass during 
cancer cachexia, and as such, it is a predictor of survival (Fouladiun et al., 2005). Ghrelin 
promotes food intake either by stimulating vagal afferent nerve fibers (Date et al., 2002) or 
through the blood stream (Banks et al., 2002), where after the signal reaches the arcuate 
nucleus of the hypothalamus. Here, ghrelin-containing neurons send efferent fibers to the 
neurons that contain the appetite stimulating (orexigenic) peptides neuropeptide Y (NPY) and 
agouti-related protein (AgRP), subsequently activating these neurons (Chen et al., 2004). 
This results in an increase in NPY and AgRP mRNA expression (Shintani et al., 2001; 
Kamegai et al., 2001) and subsequently stimulates food intake (Figure 1.7). However, the 
exact mechanism by which these neurons stimulate food intake is still unknown. 
Cardiomyocyte size is reduced during DOX treatment in vitro and in vivo, indicating a 
cachectic state (Wang et al., 2014). Ghrelin restored cardiomyocyte size, inducing a parallel 
increase in body weight, suggesting that ghrelin is able to exert a potent anti-cachectic effect 
during cardiotoxicity. Since the ultimate fate of patients with DOX-induced cardiotoxicity is 
also heart failure, ghrelin may exert cardioprotective and anti-cachectic effects in the same 
manner as it does during conventional heart failure, substantiating the merit in further 
exploring this multifaceted peptide. 
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Figure 1.7: Ghrelin regulates energy balance and appetite by at least two mechanisms. 
Ghrelin can act as a peripheral hormone from the stomach that sends signals via the vagus nerve or crosses the 
blood-brain barrier and ii) as a neuropeptide in the arcuate nucleus of the hypothalamus that sends efferent nerve 
fibers to NPY/AgRP neurons.  NPY, neuropeptide Y; AgRP, agouti-related protein. 
Since evidence does exist that ghrelin can exert its effects on cardiovascular function, it is 
likely that the expression of ghrelin and its receptors may be abnormal in certain pathologies. 
In healthy human myocardial specimens, strong immunoreactivity for ghrelin was 
demonstrated, as opposed to weak immunoreactions in samples taken from patients with CHF 
(Beiras-Fernandez et al., 2010). This data suggests that myocardial function is directly 
proportional to ghrelin expression, as a failing heart appears to be associated with impairment 
in ghrelin production. Contrasting reports show that ghrelin is increased in cachectic patients 
with CHF, as evident by elevated plasma ghrelin levels of 237 fM (Nagaya et al., 2001b) as 
opposed to approximately 100 fM in healthy subjects (Kojima et al., 1999). Likewise, the 
level of ghrelin mRNA and GHSR-1α were elevated in an isoproterenol-induced model of 
heart failure (Li et al., 2006b). The protein and mRNA levels of ghrelin may therefore be 
upregulated or down-regulated depending on the severity and stage of the disease model 
being studied. 
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1.5 The role of ghrelin in myocardial energy homeostasis 
Metabolism is essential for the normal contractility of the heart, which in turn necessitates 
large amounts of mitochondrial ATP production. Once glucose and free fatty acids are taken 
up by the cell, they are broken down in the mitochondria into acetyl CoA, which then enters 
the citric acid cycle. The next process is oxidative phosphorylation in which mitochondria 
produce ATP from ADP molecules. ATP then leaves the mitochondrion and is available for 
contraction. In the fed-state, circulating glucose and insulin levels are high, whilst ghrelin 
levels remain low (Cummings et al., 2001) and the level of circulating fatty acids are 
suppressed. The uptake of fatty acids by the heart therefore falls, allowing glucose oxidation 
to increase. In contrast, in the fasted state when glucose and insulin levels are low, ghrelin 
levels are high, and circulating free fatty acid levels are elevated, the high rate of free fatty 
acid uptake by the heart results in their preferential use in metabolism (Willis et al., 2014).  
Des-acyl ghrelin, but not acylated ghrelin, increases the uptake of medium length fatty acids 
in cardiomyocytes, which are necessary for the acylation of ghrelin by ghrelin O-acyl 
transferase (Lear et al., 2010). This suggests that des-acyl ghrelin has the ability to indirectly 
promote the acylation of ghrelin by increasing the uptake of the fatty acids that are used in 
the process. However, ghrelin is known to decrease fat utilization and increase glucose 
utilization (Tschöp et al., 2000), thereby increasing fat mass and overall body weight 
(Strassburg et al., 2008). This finding suggests that ghrelin signals to the hypothalamus when 
an increase in metabolic efficiency is needed, as a positive energy balance is necessary to 
maximize the anabolic effect of GH. Furthermore, the increased use of glucose during fasting 
(when ghrelin levels are high), suggests a shift towards a more energy efficient form of 
metabolism during times of starvation or fasting. Interestingly, in the failing myocardium, the 
heart’s ability to supply sufficient energy to meet its demands significantly deteriorates 
(Sharov et al., 2000). Although fatty acids are the heart’s substrate of choice for ATP 
production under aerobic conditions, the heart is often forced to metabolize less optimal 
substrates. While the use of fatty acids generates more ATP than glucose (Lopaschuk et al., 
2010), it comes at the expense of a greater requirement for oxygen. It is thus more energy 
efficient for the heart to metabolize glucose rather than fatty acids during pathological 
conditions or energy deficits (Tokarska-Schlattner et al., 2006). Therefore, shifting the 
heart’s substrate preference away from fatty acids can improve heart function and slow the 
progression of heart failure (Chandler et al., 2002; Bristow, 2000; Bersin & Stacpoole, 1997). 
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DOX has been reported to reduce cardiac energy reserves by reducing ATP and 
phosphocreatine (Jeyaseelan et al., 1997; Xu et al., 2007), while ghrelin administration has 
been shown to inhibit the decrease in the intracellular ATP : ADP ratio induced by DOX (Xu 
et al., 2008). In addition, treatment with DOX has been shown to impair both glucose and 
fatty acid metabolism in the heart, ultimately causing the heart to fail (Wakasugi et al., 1993). 
Therefore, since ghrelin has the ability to reduce fatty acid utilization and elevate glucose 
utilization, it is plausible that ghrelin may protect the myocardium from unnecessary energy 
expenditure and excess ROS production, preserving contractile function and metabolic 
efficiency. Considering that the mitochondria are responsible for the production of 
approximately 90% of the energy used by the heart (Mootha et al., 1997), it comes as no 
surprise that impaired mitochondria results in an inability of the heart to perform work 
(Pereira et al., 2011). Moreover, it is generally accepted that the mitochondria are a primary 
source of ROS (Vanden Hoek et al., 1997), which then cause oxidative damage to the 
mitochondria and trigger cell death modalities (Cocco et al., 2002). 
1.6 The role of ghrelin during DOX-induced oxidative stress 
The term “oxidative stress” refers to a state of elevated ROS levels, and is associated with a 
decline in antioxidant defenses (Suzuki et al., 2011). Although the mechanisms for the 
development of cardiotoxicity are still under debate, one of the widely accepted hypotheses is 
that DOX generates free radicals which damage the myocardium through oxidation of cell 
membranes and various cytosolic components (Olson et al., 1981). Free radical scavengers 
such as vitamins E, A and C (Myers et al., 1977; Ravi et al., 2013; Shimpo et al., 1991; El-
Mehy et al., 2008), which provide protection from DOX in vivo, support the oxidative stress 
theory. In addition, the overexpression of the antioxidant enzyme, glutathione peroxidase, 
protects mice hearts against acute DOX-induced cardiotoxicity and prevents the dysfunction 
of mitochondrial respiration (Xiong et al., 2006). Furthermore, an increase in mitochondrial 
ROS after DOX treatment has also been deemed responsible for the catabolism of C2C12 
myotubes, via the upregulation of the redox-sensitive E3 ubiquitin ligases, muscle atrophy F-
box (MAFbx) and muscle ring finger 1 (MuRF1), and caspase-3 activation (Gilliam et al., 
2012). Taken together, these studies suggest the involvement of ROS in the development of 
DOX-induced cardiotoxicity. However, the inconsistent and often negative results of such 
studies suggests that alternative, non-oxidative mechanisms may also be at play (D’Andrea, 
2005). It is also difficult to maintain high plasma antioxidant levels due to inactivation of the 
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antioxidants by organs such as the liver, and antioxidants of high molecular weights, 
including SOD and catalase, may be unable to enter intracellular compartments to carry out 
their functions (Kang et al., 1996). 
With the above in mind, several researchers have investigated the antioxidant properties of 
ghrelin in various models of disease (Eter et al., 2007; Li et al., 2013; Wang et al., 2014). 
Ghrelin administration was associated with a dose-dependent reduction in malondialdehyde 
(MDA) and an increase in GSH content and GSH-Px1 activity in vivo and in vitro. In models 
of IRI (Chang et al., 2004a) and isoproterenol-induced-injury (Chang et al., 2004b), 
myocardial MDA was substantially increased, whereas administration of ghrelin reduced this 
by-product of lipid peroxidation. Ghrelin significantly increased catalase activity by 79.9% 
and 184.3%, while SOD activity was elevated by 64.1% and 373.3% in plasma and cell 
lysates, respectively, when compared to DOX-treated groups. These findings were further 
echoed when mRNA expression was studied, indicating that ghrelin upregulates the 
expression of various antioxidants at both a transcriptional and translational level during 
DOX treatment. An increase in the intrinsic activity of SOD and catalase by ghrelin in 
primary cardiomyocytes may be a mechanism by which ghrelin counteracts DOX-induced 
oxidative stress (Xu et al., 2008). Together, these data suggest that ghrelin inhibits oxidative 
stress by augmenting endogenous antioxidants, although it is possible that ghrelin itself may 
exert a direct antioxidant effect.  
1.7 The effect of ghrelin on DOX-induced cardiomyocyte death 
Heart failure is the end result for a number of heart diseases and, over the years, extensive 
research from human and animal studies has highlighted evidence that suggests that 
cardiomyocyte apoptosis may be a key modulator in the pathogenesis of heart failure 
(Takemura & Fujiwara, 2006; Gustafsson et al., 2003). Moreover, since DOX-induced 
cardiotoxicity only manifests itself years to decades after treatment, it is reasonable to think 
that the chronic loss of terminally differentiated cardiomyocytes with a limited regenerative 
capacity (Tokarska-Schlattner et al., 2006) will drastically affect myocardial function and 
eventually lead to heart failure. Therefore, a common endpoint is apoptosis, although this is 
likely to be the final response to a variety of upstream events, such as oxidative stress. 
Apoptosis, first described by Kerr et al., (1972), is a form of programmed cell death during 
which the nucleus and cytoplasm condense, DNA fragments and the cell shrinks. These 
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fragments are enclosed by the plasma membrane so that the contents of the cell can be 
phagocytosed in its entirety. Apoptosis therefore occurs swiftly and unnoticed and as a result, 
is not accompanied by an inflammatory response. Research over the last decade has brought 
to life the various signaling pathways involved in cellular apoptosis. The intrinsic apoptotic 
pathway is activated when intracellular homeostasis is disturbed by death signals such as 
DNA damage and oxidative stress. At any given time, the fate of a cell depends on the 
expression levels of the B-cell lymphoma 2 (Bcl-2) family, which can be both pro- and anti-
apoptotic. The anti-apoptotic proteins, Bcl-2 and Bcl-XL, function to antagonize the pro-
apoptotic proteins such as Bax and Bad.  
 
An apoptotic signal such as oxidative stress or treatment with a cytotoxic agent like DOX, 
causes Bax to translocate to the mitochondrial membrane where it facilitates the opening of 
the mitochondrial permeability transition pore (mPTP) (Jiang et al., 2014). The subsequent 
collapse in mitochondrial membrane potential results in cytochrome c release (Childs et al., 
2002). Bcl-2 is able to prevent the activation of apoptosis through an interaction with Bax 
(Marie Hardwick & Soane, 2013).  Free radicals produced during redox cycling, particularly 
H2O2,  are actively involved in facilitating cytochrome c release through the mPTP (Green & 
Leeuwenburgh, 2002). After its release, cytochrome c forms a complex with pro-caspase-9, 
an adaptor protein known as apoptosis protease activator protein-1 (Apaf-1) and ATP, 
forming an apoptosome. Pro-caspase-3 is cleaved by active caspase-9 into active caspase-3 
which, together with caspases-6 and -7 are known as executioner caspases. These caspases 
cleave and inactivate poly (ADP-ribose) polymerase (PARP), preventing it from responding 
to and repairing DNA strand breaks (Cohen, 1997). The caspases also activate DNase, which 
is responsible for the fragmentation of DNA (Zhang et al., 2011). This sequence of events 
forms part of the intrinsic (Figure 1.8), mitochondrial apoptotic pathway (Zhang et al., 2009). 
In the context of cardiotoxicity, DOX has been shown to induce apoptosis through caspase-3 
activation both in vitro (Wu et al., 2002) and in vivo (Ueno et al., 2006). Apoptosis was 
associated with a substantial decline in left ventricular function, suggesting an important role 
for apoptosis in myocardial dysfunction induced by DOX therapy. Interestingly, Arola et al., 
(2000) reported that apoptosis peaked on the first day after a single DOX injection and 
declined thereafter, implying that apoptosis may not be a major contributor to the 
development of heart failure, at least in the acute stages. Moreover, cardiomyocytes may die 
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via necrosis due to depleted energy stores as a result of repeated exposure to DOX (Zhang et 
al., 2009). 
 
Figure 1.8: The intrinsic apoptotic pathway. 
DOX induces oxidative stress that triggers the release of cytochrome c from the mitochondria. Through the 
formation of an apoptosome, caspase-9 activates the executioner caspases which in turn initiate DNA 
fragmentation.  
Ghrelin has previously been shown to possess anti-apoptotic properties. When 
cardiomyocytes are treated with high concentrations of glucose, caspase-3 and hence 
apoptosis, was elevated. However, this observation was reversed after ghrelin administration 
(Kui et al., 2009). A similar phenomenon was observed when the TUNEL index was 
increased to 467% in the ventricles of DOX-treated mice, but reduced in the mice that 
received ghrelin (Pei et al., 2014). Hexarelin, a synthetic GH secretagogue, prevents DOX-
induced cell death in H9c2 cells (Filigheddu et al., 2001). Similarly, des-acyl ghrelin and 
acylated ghrelin are effective at reducing DOX-induced apoptosis  (Baldanzi et al., 2002). 
Not only is cell viability improved under these conditions, but H9c2 cellular morphology is 
maintained (Wang et al., 2014). Considering that H9c2 cells are devoid of GHSR-1α, it is 
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believed that an unknown receptor, that binds to both forms of ghrelin, can act directly on 
these cells to prevent cell death by activating pro-survival pathways.  
The death of cardiomyocytes by apoptosis causes the loss of myofibres and a substantial 
increase in fibrosis, contributing to the development of cardiovascular dysfunction during 
cardiotoxicity (Takemura & Fujiwara, 2006; Miyata et al., 2010). Collagen accumulation was 
reduced by ghrelin in a model of DOX-induced cardiotoxicity (Pei et al., 2014). This finding 
extends previous reports on the ability of ghrelin to reduce collagen formation in models of 
myocardial infarction (Soeki et al., 2008), isoproterenol-induced myocardial injury (Li et al., 
2006b) and diabetic cardiomyopathy (Pei et al., 2015). However, the underlying mechanisms 
by which ghrelin reduces fibrosis are still unclear and remain to be elucidated. Collectively, 
this data demonstrates that ghrelin can significantly modulate the cardiotoxic effects of DOX, 
including apoptotic cell death and fibrosis. However, it is important to note that these studies 
generated data using acute models of cardiotoxicity. Further research is therefore warranted 
to investigate these effects after prolonged exposure to DOX and whether ghrelin can be used 
as an adjuvant therapy to mitigate chronic DOX-induced cardiotoxicity. As ghrelin alone 
does not appear to be toxic in control samples, (Wang et al., 2014; Baldanzi et al., 2002), it 
exhibits an appealing property when compared to many other adjuvant therapies. Considering 
the aforementioned anti-apoptotic effects of ghrelin, a critical aspect that should be 
considered in this context is the timing of ghrelin administration. Despite the many beneficial 
effects on the myocardium, the effects of ghrelin on different cancer types is rather 
contradictory (see Chopin et al., (2011) for review). Further research is therefore needed to 
determine i) the effects of ghrelin on cancer progression and tumour growth and ii) whether 
simultaneous administration or administration after chemotherapy reduces cardiovascular 
damage.  
1.8 Ghrelin: a novel RISK pathway activator? 
The contribution of oxidative stress during DOX-induced cardiotoxicity has already been 
discussed, however, during IRI, the restoration of blood flow and reoxygenation of the 
ischemic myocardium causes a burst of ROS in a phenomenon known as the “oxygen 
paradox” (Zweier, 1988; Hearse et al., 1973; Kalogeris et al., 2014). Since ischemia-
reperfusion is paradoxical in nature, strategies such as pre- and post-conditioning have been 
developed to protect the heart (Murry et al., 1986; Zhao et al., 2003). Both pre- and post-
conditioning have been shown to provide protection through the activation of pro-survival 
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kinases Akt/PKB (protein kinase B) and ERK1/2 (extracellular regulated kinase) (Hausenloy 
& Yellon, 2004). These kinases also form part of the well-known reperfusion injury salvage 
kinase (RISK) pathway. Literature has demonstrated that the activation of these kinases by 
pre- and post-conditioning reduces infarct size by 40 – 50% (Hausenloy, 2009). Furthermore, 
the activation of this pathway down-regulates pro-apoptotic proteins and promotes 
mitochondrial integrity (Xiang et al., 2009). 
ERK1/2 forms part of the mitogen activated protein kinase (MAPK) cascade which, in 
cardiomyocytes, is initiated by stress stimuli,  G-protein coupled receptors and receptor 
tyrosine kinases (Sugden & Clerk, 1998). This pathway has been implicated in cell survival 
in response to IRI, oxidative stress and exposure to anthracyclines. Inhibition of ERK1/2 
signaling was shown to exacerbate Daunomycin-induced apoptosis in cardiomyocytes (Zhu et 
al., 1999), whereas ERK1/2 activation in a model of IRI attenuated the apoptosis associated 
with this condition (Yue et al., 2000). However, although these reports do suggest that 
ERK1/2 activation is protective, little is known about how ERK1/2 signaling promotes 
protection. Akt is a serine/threonine protein kinase that exerts a wide variety of functions 
including the promotion of cell survival by regulating apoptosis within the cell (Cross et al., 
2000). This is evident in studies that have demonstrated a reduction in DOX-induced 
apoptosis via Akt activation (Chen et al., 2012; Fukazawa et al., 2003). Furthermore, the 
heart was protected against DOX-induced cardiomyopathy when constitutively active Akt 
was delivered to the heart through the use of an adenovirus  (Taniyama & Walsh, 2002). 
Considering that ghrelin administration protects the heart against IRI by maintaining cardiac 
function and ATP levels (Chang et al., 2004a), ghrelin may exert its effects against DOX by 
activating the RISK pathway. In advanced glycation end product (AGE)-induced apoptosis of 
human umbilical vein endothelial cells, ERK1/2 and Akt/PKB phosphorylation are thought to 
be responsible for the anti-apoptotic effects of ghrelin, as indicated by reduced caspase-3 
activation (Xiang et al., 2011). When ERK1/2 and Akt inhibitors were employed, the effects 
of ghrelin were attenuated and the levels of caspase-3 increased. Similarly, ghrelin prevented 
apoptotic cell death in serum-starved osteoblasts through ERK1/2 and Akt/PKB activation 
(Liang et al., 2013). Western blot analysis also showed that the activation of ERK1/2 and 
Akt/PKB by ghrelin occurred in a time- and dose-dependent manner in serum-starved 
pancreatic cells (Zhang et al., 2007). In the presence of inhibitors, however, the 
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cytoprotective effects of ghrelin were abolished, indicating that ghrelin inhibits cell death by 
activating these pro-survival kinases. Literature on the effects of ghrelin on ERK1/2 and 
Akt/PKB expression in the context of chronic DOX-induced cardiotoxicity is limited 
(Baldanzi et al., 2002; Pei et al., 2014; Kui et al., 2009). While it is known that DOX reduces 
pro-survival activation (Das et al., 2011; Xiang et al., 2009; Lou et al., 2005), others have 
shown that ghrelin reverses these effects in acute models of cardiotoxicity (Pei et al., 2014; 
Mousseaux et al., 2006). However, the fact that endogenous ghrelin is increased during the 
progression of DOX-induced heart failure (Xu et al., 2007) suggests that ghrelin contributes 
to a protective, compensatory mechanism by exerting anti-apoptotic and antioxidative effects 
to maintain cardiac morphology and function. 
The signaling pathways involved in ghrelin-mediated ERK1/2 activation are still unclear, 
however, the signaling events can be classified into various pathways including i) the Ras-
dependent activation of ERK1/2 via receptor tyrosine kinases (RTKs), ii) the Ras-
independent ERK1/2 activation via the protein kinase C (PKC) family that converges with 
the RTK signaling at the Raf level and iii) the modulation of ERK1/2 activation via the 
cAMP/protein kinase A (PKA) pathway. Binding of ghrelin to the GHSR-1α has also been 
shown to transactivate the tyrosine kinase receptor via the β and γ subunits, leading to 
activation of ERK1/2 via the Ras–Raf–MEK pathway (Nanzer et al., 2004). IP3 and DAG 
result from the hydrolysis of PIP2 by PLC. While IP3 induces Ca2+ release from the 
endoplasmic reticulum, DAG activates PKC (Lopez et al., 2001), shown to be critical for 
ERK1/2 activation during ghrelin treatment (Mousseaux et al., 2006). Through the α-subunit 
of the GHSR-1α, ghrelin induces the activation of the PLC-PKC-Raf-MEK pathway, thereby 
mediating ERK1/2 activation. Finally, ghrelin and des-acylated ghrelin have been shown to 
exert their effects through stimulation of cyclic adenosine monophosphate (cAMP)/ protein 
kinase A (PKA) pathway (Rossi et al., 2009; Granata et al., 2007). cAMP is an important 
second messenger which, together with PKA exerts a wide variety of functions (Insel et al., 
2012). PKA indirectly activates Ras, subsequently activating the Raf-MEK-ERK1/2 cascade 
(Bos, 2003). As mentioned previously, ghrelin induces the activation of PIP2 after binding to 
its receptor. PIP2 is not only involved in the hydrolysis reaction of the PLC pathway, but also 
acts as a substrate for the synthesis of phosphatidylinositol 3,4,5-trisphosphate (PIP3). The 
catalytic domain of phosphoinositide-3-kinase (PI3K) converts PIP2 to PIP3 (Hemmings & 
Restuccia, 2012). Akt then binds to PIP3, allowing phosphoinositide-dependent protein kinase 
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(PDK1) to phosphorylate Akt on threonine 308, inducing partial activation. Phosphorylation 
of Akt at serine 473 is required for full activation (Alessi et al., 1997). It is highly possible 
that ghrelin may activate AKT/PKB directly, via an unknown receptor, since Baldanzi et al., 
(2002) illustrated AKT activation in H9c2 cells which lack GHSR-1α (Figure 1.9). The anti-
apoptotic downstream events of these pro-survival kinases include inhibiting the release of 
cytochrome c from the mitochondria and inhibiting the activation of caspases (Zhou et al., 
2000; Xia et al., 2016). 
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Figure 1.9: The potential signaling pathways induced by ghrelin.  
Ghrelin (yellow circles) binds to its receptor (GHSR-1α), inducing the hydrolysis of PIP2 to IP3 and DAG. 
Cytosolic Ca2+ increases, resulting in growth hormone release. PIP2 is also converted into PIP3, activating Akt. 
DAG activates PKC which stimulates the Ras-Raf-MEK-ERK1/2 cascade, also activated by PKA. Ghrelin can 
also activate ERK1/2 and Akt via an unknown receptor. The SAFE pathway (JAK2/STAT3) could potentially 
be activated through PI3K, ERK1/2 or TNF-α. All of these pathways ultimately reduce cell death and oxidative 
stress. GHSR-1α, growth hormone secretagogue receptor 1 alpha; PIP2, Phosphatidylinositol 4,5-bisphosphate; 
IP3, Inositol trisphosphate; DAG, diacyl glycerol; Ca2+, calcium; PIP3, Phosphatidylinositol (3,4,5)-
trisphosphate; PKC, protein kinase C; PKA, protein kinase A; JAK2, janus kinase 2; STAT3, signal transducer 
and activator of transcription 3; TNF-α, tumor necrosis factor alpha; ER, endoplasmic reticulum; PI3K, 
Phosphatidylinositol-4,5-bisphosphate 3-kinase; PDK, pyruvate dehydrogenase kinase; RTK, receptor tyrosine 
kinase. 
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1.9 Can ghrelin keep the heart ‘SAFE’? 
In addition to the RISK pathway, pre- and post-conditioning activate another intrinsic pro-
survival pathway known as the survivor activating factor enhancement (SAFE) pathway 
(Lecour, 2009b, 2009a). This pathway is activated when a ligand such as interleukin-6 (IL-6) 
or tumor necrosis factor (TNF-α) binds to and induces dimerization of the receptor, activating 
various Janus kinases (JAKs) (Figure 1.9). JAKs induce phosphorylation of the receptor, 
thereby creating docking sites for signal transducer and activator of transcription proteins 
(STATs). STATs are phosphorylated on tyrosine 705 by the activated JAKs, where after they 
dimerize and then translocate to the nucleus to upregulate the transcription of various genes 
(Boengler et al., 2008). Phosphorylation on a specific serine residue (serine 727) enhances 
the transcriptional activity of STAT. Whilst several JAKs and STATs have been identified in 
the heart (see Kiu & Nicholson, (2012) for review), it is JAK2 and STAT3 that are 
specifically involved in the SAFE pathway (Lecour, 2009a). This pathway, and the 
subsequent cellular protection that it offers, is activated by TNF-α (Lacerda et al., 2009). 
TNF-α is a pro-inflammatory cytokine that is mainly produced by macrophages (Bradley, 
2008; Chu, 2013), however, TNF-α and the tumor necrosis factor receptors 1 and 2 (TNFR1 
and TNFR2) have been identified in virtually all cell types (Vandenabeele et al., 1995).   
The role of this cytokine is complex and multifunctional, since TNF-α can exert both 
protective and harmful effects depending on the context of its activation (Monden et al., 
2007). TNF-α is involved in apoptotic cell death through the death receptor pathway 
(Gustafsson et al., 2003). The death receptors in this pathway form part of the TNF-α 
superfamily which, upon ligand binding, activate the apoptotic machinery of the cell. 
Subsequent to this, the TNFR-associated death domain (TRADD) adaptor protein is recruited 
which leads to the activation of caspase-8 (Hsu et al., 1995). Caspase-8 then activates the 
downstream caspases, ultimately resulting in cell death. Neither TNF-α protein nor mRNA 
appear to be expressed in the heart under normal conditions, however, both are expressed in 
the failing human heart (Torre-Amione et al., 1996) and have therefore been implicated in the 
pathophysiology of this disease. Evidently, TNF-α is upregulated in patients with CHF, 
particularly in those with cardiac cachexia (Nagaya et al., 2001b). Ghrelin has been shown to 
exert anti-inflammatory effects in vivo and in vitro by suppressing the production of pro-
inflammatory cytokines (Eter et al., 2007; Dixit et al., 2004; Huang et al., 2009; Li et al., 
2013). Even at very low concentrations of ghrelin, both basal and TNF-α-induced IL-8 
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production is inhibited (Li et al., 2004). Furthermore, ghrelin administration reduces both the 
production and mRNA of several pro-inflammatory cytokines including TNF-α and IL-6. 
Ghrelin also inhibits nuclear factor ĸB (NFĸB) activation (Waseem et al., 2008), a 
transcriptional regulator of pro-inflammatory cytokine gene expression, suggesting that 
ghrelin plays an important role in the transcriptional regulation of pro-inflammatory cytokine 
production. Since many cardiovascular diseases, including cardiotoxicity (Teng et al., 2010), 
are accompanied by an amplified inflammatory response, ghrelin may promote 
cardioprotection through its anti-inflammatory actions. 
Whilst high levels of TNF-α are toxic to the heart (Kubota et al., 1997), low levels may 
actually protect cardiomyocytes from subsequent exposure to IRI, a form of preconditioning 
by TNF-α (Lecour et al., 2002).  It was demonstrated that post-conditioning failed to protect 
against IRI in the hearts of TNF-α knock-out mice. Similarly, low, non-toxic levels of TNF-α 
have been shown to precondition cardiomyocytes against toxicity from higher concentrations 
of TNF-α (Cacciapaglia et al., 2014).  These studies indicate that TNF-α can exert protective 
effects that are concentration dependent. In the context of DOX-induced cardiotoxicity, heart 
failure may be worsened when myocardial TNF-α is down regulated (Lou et al., 2004). 
Several efforts have been made to “neutralize” TNF-α in patients with heart failure, however,   
heart failure was worsened with anti-TNF therapy and resulted in a time- and dose-dependent 
increase in hospitalization and death (Mann, 2002). Since TNFR1 and TNFR2 exert opposing 
effects (Hamid et al., 2009), knocking out TNF-α not only abolishes the detrimental effects, 
but also the beneficial effects. It appears that endogenous TNF-α may protect against DOX-
induced cytotoxicity by up-regulating mitochondrial/manganese SOD (MnSOD) (Watanabe 
et al., 1996). Xu et al., (2008) observed a time- and dose-dependent decrease in TNF-α 
production after DOX treatment, however, ghrelin reversed this observation. Although TNF-
α is generally considered to be a harmful cytokine, it is also known to exert anti-apoptotic and 
antioxidative effects through NFĸB (Xu et al., 2008). By activating NFĸB, TNF-α induces 
many anti-apoptotic genes such as cellular inhibitor of apoptosis protein (cIAP1), Bcl-2 and 
MnSOD that strongly oppose its pro-apoptotic potential.  The protective effects of ghrelin 
may therefore be dependent on the upregulation of anti-apoptotic and antioxidative molecules 
by TNF-α. Like most interventions, TNF-α may appears to exert different effects depending 
on the species and type of cell studied, it’s concentration and the nature of its stimulus. The 
effects of ghrelin on TNF-α production by cardiomyocytes therefore requires further 
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investigation. Moreover, whether ghrelin administration leads to TNF-α-induced activation of 
the SAFE pathway warrants additional research. 
There is over-whelming evidence to suggest that STAT3 activation is beneficial to the heart 
(Negoro et al., 2000). During acute myocardial infarction in vivo, treatment with a JAK2 
inhibitor reduced the phosphorylation of STAT3 and induced a significant increase in the 
expression of caspase-3 and Bax, suggesting that this pathway plays a pivotal role in 
cardioprotection. In addition, infarct size is greater in STAT3 knock-out mice (Hilfiker-
Kleiner et al., 2004) or when STAT3 is pharmacologically inhibited using AG-490 (Suleman 
et al., 2008; Hattori et al., 2001). In the context of DOX-induced cytotoxicity, DNA 
fragmentation was substantially increased in anti-STAT3 small interfering RNA (siRNA) 
transfected cells (Frias et al., 2008). Mice with cardiac-specific over-expression of STAT3 
exhibit better survival rates and a reduced inhibition of contractile genes after DOX treatment 
(Kunisada et al., 2000), whereas mice with cardiac-specific knock-out of STAT3 are more 
susceptible to DOX-induced injury and the development of heart failure (Jacoby et al., 2003). 
Considering that STAT3 activation is critical for the cardioprotection offered by pre- and 
post-conditioning (Hattori et al., 2001), stimulating STAT3 activity is likely to be beneficial 
during DOX treatment.  
Although ghrelin has not been shown to be involved in JAK2/STAT3 signaling in the heart 
after DOX treatment specifically, ghrelin has been shown to induce the phosphorylation of 
STAT3 in rat hippocampal neural stem cells (NSCs) (Chung et al., 2013). Ghrelin was also 
shown to up-regulate TNF-α (Xu et al., 2008), a known SAFE pathway activator (Lacerda et 
al., 2009), and may activate JAK2 and STAT3 via this mechanism. While ghrelin has not yet 
been shown to activate the SAFE pathway after DOX treatment, the crosstalk between the 
RISK and SAFE pathway may still allow for the activation of the SAFE pathway. There is a 
large body of evidence that suggests the existence of crosstalk between these two pathways. 
This is demonstrated by the ability of the p85 regulatory subunit of PI3K to promote STAT3 
phosphorylation (Pfeffer et al., 1997; Suleman et al., 2008) and by the fact that JAK2 can 
phosphorylate Akt after binding to PI3K (Nguyen et al., 2001). Chung et al., (1997) also 
reported that ERK1/2 is responsible for the serine 727 phosphorylation of STAT3 which 
enhances the transcriptional activity of STAT3. Ghrelin therefore has the potential to activate 
the SAFE pathway through crosstalk between the SAFE and RISK pathways however, 
whether this occurs in the context of cardiotoxicity remains to be elucidated.  
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1.10 Conclusion 
Despite decades of research and the development of over 200 analogs, DOX remains an 
integral part of chemotherapeutic regimes. Consequently, cardiotoxicity is still a pressing 
issue for cancer survivors. Mitochondrial dysfunction, oxidative stress, inflammation and 
apoptotic cell death have all been shown to play a role in the pathogenesis of DOX-induced 
cardiotoxicity. The consequences of these processes are cardiac cachexia, myocardial fibrosis 
and reduced cardiac function and contractility. It is therefore crucial to assess the mechanisms 
of DOX-induced cardiotoxicity and identify potential preventative strategies. Further research 
into the effects of ghrelin during DOX treatment will broaden our understanding of its 
beneficial effects. To date, the therapeutic role of ghrelin in chronic DOX-induced 
cardiotoxicity has not been demonstrated in vivo. Exogenous administration of ghrelin may 
serve as a novel therapeutic strategy for DOX-induced cardiotoxicity, as it has a broad 
spectrum of functions. From drug-induced heart damage and myocardial infarction, to 
pathological states in several other organs, it is clear that ghrelin exerts beneficial effects such 
as antioxidative, anti-apoptotic and anti-inflammatory activity, in every scenario. Simply put, 
ghrelin appears to exhibit significant cytoprotective activity regardless of the model studied, 
and is therefore an extremely promising peptide that is worth exploring. Indeed, the 
mechanisms and effects of ghrelin during chronic DOX-induced cardiotoxicity remain 
undefined at present as studies on this topic are limited. Since ghrelin is a naturally produced, 
endogenous hormone, it also has advantages over other medications that usually prove to be 
toxic. This therefore highlights the huge therapeutic potential that ghrelin possesses and 
warrants further research for its use as a cardioprotective agent for DOX-induced 
cardiotoxicity.  
 
Considering the complex and life-threatening nature of cardiotoxicity, it is important to 
carefully study the molecular mechanisms of this condition, as well as to identify novel 
therapeutic interventions that are unlike the currently utilized strategies. Although cell culture 
is simple to perform, it does not accurately simulate the effects that are observed in human 
patients, and it is therefore necessary to establish clinically relevant pre-clinical animal 
models. However, many of the studies performed to date have employed supraphysiological 
concentrations of DOX or have only assessed the effects of acute cardiotoxicity, and 
therefore the results of such studies should be interpreted with caution. According to Herman 
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and Ferrans (1998), the use of smaller cumulative doses of DOX in animals adequately 
simulates the chronic myocardial changes that are observed in patients. Typically, the 
cumulative dose cited by these authors is 15 mg/kg for rats, which should be administered 
over a couple of weeks. The two main role players in the development of DOX-induced 
cardiotoxicity are believed to be oxidative stress and apoptotic cell death. Ghrelin is an 
endogenous peptide more commonly known for its growth-hormone-releasing and appetite-
inducing effects, however, ghrelin has also been reported to possess cardioprotective abilities. 
This has been attributed to its anti-apoptotic, anti-fibrotic and antioxidative effects. DOX has 
the potential to increase survival rates and improve the quality of life of cancer patients, 
however, its cardiotoxic side effects drastically affect these parameters. Since the exact 
mechanisms that cause this condition still remain largely undefined, this study intended to 
elucidate the activity of the SAFE and RISK pathways in vivo, as they have been 
demonstrated to be cardioprotective in other forms of cardiovascular injury. In addition, the 
cardioprotective effects of ghrelin will be investigated in this scenario as a potential 
cardioprotective agent. 
Therefore it was hypothesized that the SAFE and RISK pathways would be down-regulated 
after treatment with DOX and that stimulation of these pathways by ghrelin will confer 
protection to the heart. We have established an in vivo rat model of chronic cardiotoxicity 
which utilizes doses of DOX that are within the clinically relevant range, thus adding to the 
novelty of this study. This study aimed to: 
i) establish a chronic in vivo model of DOX-induced cardiotoxicity 
ii) assess the protein expression of the RISK and SAFE pathways 
iii) identify the extent of DOX-induced myocardial damage with or without ghrelin 
treatment 
iv) investigate the effects of ghrelin treatment on myocardial fibrosis, apoptosis and 
oxidative stress. 
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Chapter 2  
Materials and methods 
2.1 Ethical Considerations and Animal Care 
All experiments were ethically approved  and carried out according to the guidelines for the 
care and use of laboratory animals implemented at Stellenbosch University (reference 
number: SU-ACUD15-00038) and conformed to the accepted standards for the use of 
animals in research and teaching as reflected  in the South African National Standards 10386: 
2008. Male Sprague-Dawley rats were obtained at four weeks old (90 – 130 g) and were 
allowed one week to acclimatize to the animal facility. Since chronic cardiotoxicity is most 
commonly observed in the survivors of childhood cancers decades after their treatment is 
complete, this study was performed on rats that were at an equivalent age to late childhood in 
humans so that early adulthood was reached by the end of the protocol (Sengupta, 2013). The 
rats were housed in sterilized cages with controlled humidity and a 12-hour day/night cycle, 
at 25 °C. Standard rat chow and tap water were provided ad libitum.  
2.2 Experimental protocol 
As mentioned above, wild-type, male Sprague-Dawley rats were used in this study as they are 
a multipurpose rodent model and are one of the most widely used in animal research, 
including cardiology. Additionally, Sprague-Dawley rats are a commonly used strain in the 
study of DOX-induced cardiotoxicity (Taniyama & Walsh, 2002; Zhang et al., 2013; Teng et 
al., 2010) Finally, their docile disposition makes them calm and easy to handle. Male rats 
were used in order to limit the influence of hormonal status on the development of 
cardiotoxicity, as female rats are believed to be protected by the presence of estrogen (Moulin 
et al., 2015).  
After one week of acclimatization and handling, animals were randomly divided into control 
(n = 7), vehicle (n = 7), ghrelin (n = 7), DOX (n = 9) and DOX + ghrelin (n = 9) groups. The 
ghrelin group received three injections of 100 µg/kg ghrelin (LKT Laboratories, G2869) per 
week, for eight weeks (rat ghrelin of 95% purity).  This dosage is based on several other 
studies (Yang et al., 2014; Huang et al., 2009; Li et al., 2006b; Nagaya et al., 2001c), 
however, we only administered one injection per day, as opposed to two, to minimize animal 
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suffering. The DOX-treated group received 2.5 mg/kg DOX (LKT Laboratories, D5794) per 
week for eight weeks (Xiang et al., 2009), resulting in a cumulative dose of 20 mg/kg. This 
dose of DOX falls within the range of 60 - 75 mg/m2 that is administered to humans (human 
equivalent dose) (Von Hoff et al., 1979; Desai et al., 2013). Animals in the DOX + ghrelin 
group were administered three injections of ghrelin in addition to a single injection of DOX 
per week for eight weeks. Vehicle-control animals received an equal volume of physiological 
phosphate buffered saline four times per week (to account for the maximum number of 
injections experienced) for eight weeks. All injections were administered via the 
intraperitoneal (i.p) route using a 25 gauge needle (Lasec, HLSCDN-25, Cape Town, South 
Africa). Control animals remained untreated for the duration of the treatment protocol. Body 
weight was recorded each morning prior to preparing the injections, and food consumption 
was measured three times per week. Food intake was measured by weighing out 500g of food 
per cage and then re-weighing what was not consumed. The difference between the food 
given and the food consumed was the amount of food consumed per cage. This was divided 
by the number of rats in each cage to determine the average amount of food consumed per 
rat. No rats died during the experimental protocol. 
2.3 Working heart perfusions 
One week after the last injection of DOX, the animals were euthanized one at a time and at 
random, using an i.p injection of 60 mg/kg sodium pentobarbitone (Euthapent, Kyron 
Laboratories, 130540). When the pedal reflex was no longer observed, the heart was rapidly 
excised by making an incision in the skin at the xyphisternum, which was extended to the 
lateral ends of the left and right costal margins. An incision was made through the ribs at the 
left and right axillary lines to create a thoracotomy (Figure 2.1). The chest wall was deflected 
upwards, after which the heart was removed and arrested in ice cold Krebs-Henseleit buffer 
(KHB: 119 mM NaCl, 24.8 mM NaHCO3, 4.72 mM KCl, 1.19 mM KH2PO4, 0.6 mM 
MgSO4.7H2O, 0.59 mM Na2SO4, 2.39 mM CaCl2.2H20 and 10 mM glucose). The heart was 
then transferred to a working heart perfusion apparatus where the aorta was cannulated, 
followed by retrograde perfusion of the heart with KHB equilibrated with 95% O2 and 5% 
CO2 at a perfusion pressure of 100 cm KHB. The temperature of both the perfusate and the 
air surrounding the heart was maintained at 37 °C.  After retrograde perfusion was initiated, 
the pulmonary vein was cannulated, providing an opening to the left atrium. After a 
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stabilization period of ten minutes in the retrograde perfusion mode, the heart was switched 
to the working heart mode, during which the heart rate, systolic and diastolic blood pressure, 
aortic output and coronary flow was recorded every five minutes for 40 minutes. This 
protocol was based on a previously established perfusion protocol by Wergeland et al., 
(2011). Blood pressure was measured by connecting a pressure transducer as a side branch of 
the aortic cannula. The transducer converts the movement of fluid across a membrane into an 
electric signal which is mathematically converted back to pressure using Powerlab and 
LabChart 5 software. Left ventricular developed pressure (LVDP) was obtained by 
calculating the difference between diastolic pressure and systolic pressure (systolic pressure – 
diastolic pressure). The rate-pressure product (RPP) was calculated by multiplying the heart 
rate with systolic pressure and cardiac output was calculated as the sum of the aortic output 
and the coronary flow. The final parameter that was measured with regards to the functional 
data was the total work performed by the myocardium. The total work performed by the heart 
can be determined using a formula by Kannengiesser et al., (1979), where the mean external 
power produced by the left ventricle (mWatts) is: 
0.002222 Aortic	Pressure − 11.25Cardiac	Output. 
At the end of the perfusion protocol, the hearts were weighed, photographed and then cut into 
two transverse sections, from apex to base, ensuring that each half contained both atria and 
ventricles. One half was snap frozen in liquid nitrogen for biochemical analysis and the other 
half was preserved in formalin for histological analysis. Tissue samples in the liquid nitrogen 
were transferred into cryoboxes and stored at – 80 °C until needed.  
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Figure 2.1: Diagram to illustrate the isolation of a rat's heart. 
2.4 Blood collection 
Simultaneous to the excision of the heart, blood was collected from the thoracic cavity using 
a 10 mL syringe and quickly placed into serum separation (Lasec, VGRV450470R, Cape 
Town, South Africa) and plasma (Lasec, VGRV450474R, Cape Town, South Africa) tubes. 
The tubes were inverted five times and then allowed to stand for ten minutes on ice. The 
tubes were centrifuged at 4000 RPM (1.4 x g) for ten minutes at 4 °C. After centrifugation, 
the serum and plasma was aliquoted into microfuge tubes at 200 µL volumes and frozen at – 
80 °C until further analysis. 
2.4.1 Blood analysis 
Serum samples from each rat were tested for various analytes using Milliplex® MAP 
Multiplex assays. TNF-α, ghrelin and IL-6 were measured using a rat metabolic hormone 
magnetic bead panel (Merck Millipore, RMHMAG-84K). cTnT, cTnI and CK-MB were 
measured using a rat cardiac injury magnetic bead panel (Merck Millipore, RCI1MAG-87K-
03). The assay is based on the Luminex XMAP® technology that makes use of fluorescent-
coded magnetic beads known as MagPlex®-C microspheres. The microspheres are internally 
color-coded with fluorescent dyes and coated with specific capture antibodies. After an 
analyte in the test sample is captured by the beads, a biotinylated detection antibody is added. 
Streptavidin-Phycoerythrin conjugate, the reporter molecule, is used to complete the reaction. 
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Each microsphere is identified using the Bio-Plex® MAGPIX™ Multiplex reader (Bio-Rad, 
MAGPX13046706, California, USA) and the result of the bioassay on each microsphere is 
quantified using a fluorescent signal. The assays were carried our according to the 
manufacturer’s instructions. Please refer to Appendix D, pages 150 and 154 for the full 
protocols. 
2.5 Brain natriuretic peptide (BNP) 
In addition to the cardiac markers of damage that were measured in the serum, B-type 
natriuretic peptide (BNP) was measured in heart tissue homogenates. BNP is a cardiac 
hormone that is released by the myocardium in response to increased filling pressure of the 
left ventricle during left ventricular dysfunction. BNP levels are increased even when the 
symptoms of heart failure are not yet apparent, and they increase even further in direct 
proportion to the severity of heart failure. High levels of BNP correlate with the left 
ventricular dysfunction associated with chemotherapy and are therefore a useful marker in 
assessing heart failure (Bovelli et al., 2010) . 
The BNP 45 ELISA (Abcam, ab108816, Biocom Biotech, Pretoria) is designed for the 
quantitative measurement of BNP 45 in tissue extracts. Standards and test samples bind to a 
BNP 45 specific antibody that is pre-coated onto a 96-well plate. After the addition of a 
biotinylated detection antibody and a Streptavidin-Peroxidase conjugate, 3,3′,5,5′-
Tetramethylbenzidine (TMB) was added to visualize the enzymatic reaction using the EL800 
Universal Microplate reader (Bio-Tek Instruments Inc., Vermont, USA). The intensity of the 
color produced is directly proportional to the amount of BNP 45 in the samples. The 
concentration of BNP in each sample was normalized to the total protein concentration of 
each sample as determined using the Direct Detect™ system (Merck Millipore, DDHW00010-
WW, Darmstadt, Germany). This system measures the absorbance of amide bonds in protein 
chains using infrared quantitation.  Briefly, 2 µl of blank (assay buffer) and 2 µl of samples 
were pipetted onto the windows of the Direct Detect™ card. The card was then placed 
vertically inside the sampling accessory, which dries and then measures each sample as 
mg/mL of protein. 
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2.6 Histological analysis 
2.6.1 Tissue processing and sectioning 
Isolated cardiac tissue samples were fixed in 4% formaldehyde solution (Merck Millipore, 
1.00496.5000) for a minimum of seven days. After processing through a series of dehydration 
steps in a tissue processor (Tissue Tek II, 4634, Sakura Finetechnical Co., Ltd, Japan), the 
tissue was infiltrated with Paraplast® wax (Sigma-Aldrich, A6330-4LB, Johannesburg, South 
Africa). Once embedded on a cassette (Lasec, PLPS191023, Cape Town, South Africa) using 
a tissue embedding centre (Leica EG 1160, Leica Biosystems, Germany), 5 µm thick sections 
were prepared using a microtome (Leica RM 2125RT, Leica Biosystems, Germany). Heart 
sections were placed onto glass microscope slides (Lasec, GLAS4S22M3000F, Cape Town, 
South Africa) and allowed to air-dry and adhere on a 20 °C heating block.  
2.6.2 Hematoxylin & Eosin Staining 
In order to view the overall cardiac structure and identify signs of damage, the hematoxylin & 
eosin (H&E) staining technique was employed. Over 100 years later, this stain is still one of 
the most frequently used in laboratories worldwide (Cook, 1997). H&E is based on the 
principle whereby cationic/basic hematoxylin binds to and stains all anionic DNA and RNA 
molecules blue, and is primarily employed to demonstrate nuclei. Eosin, an anionic/acidic 
dye, has an affinity for positively charged cytoplasmic constituents such as filaments, 
membranes and mitochondria and counterstains them in various shades of pink (Young et al., 
2006; Kingsbury & Johannsen, 1935; Titford, 2009).  
Prior to staining, the Mayer’s Hematoxylin solution (Merck Millipore, SAAR2822001LC, 
Modderfontein, South Africa) was filtered, and the eosin solution (Leica Biosystems, 
3801600E) was freshly prepared. The H&E staining procedure was performed using an 
automated staining machine (Leica ST5010 Autostainer XL, Leica Biosystems, Germany). 
For this stain, 5µm sections of heart were prepared as described in section 2.6.1. The slides 
were placed briefly into a 60 °C oven to allow the wax surrounding the tissue sections to 
melt. The slides were then submerged into freshly prepared reagents as indicated in the 
protocol found in Appendix D, page 159. 
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After staining, the slides were mounted using DPX mountant (Associated Chemical 
Enterprises, D0738NN00500) and covered with a cover slip (Lasec, GLAS2C29M2250REC, 
Cape Town, South Africa). The slides were left to dry thoroughly overnight. To measure the 
cross-sectional area of the myofibres in each section, the slides were viewed on a bright-field 
Nikon ECLIPSE E400 microscope fitted with a Nikon DS-Fi2 camera, and processed using a 
Nikon Digital Sight DS-U3 processor (Nikon®, Japan). Image processing was performed 
using NIS elements v4.10 software. Images were captured at 4x magnification from five 
randomly selected regions of interest (ROIs) in the left ventricle (Figure 2.2). Using ImageJ 
v1.6.0 software (Schneider et al., 2012), the cross-sectional area of 30 myofibres was 
measured in each of the five ROIs, giving a total of 150 myofibres per heart section (Gilliam 
et al., 2009; Monden et al., 2007). This analysis was not performed blinded. 
 
Figure 2.2: Example of the measurement of cross-sectional area in a ROI. 
The border of 30 randomly selected myofibers was traced (yellow circle). Once the cross-sectional area was 
generated, the myofiber area was filled with a solid color to avoid duplicate measurements. This process was 
repeated in all five ROIs, resulting in a total of 150 myofibers measured per section. Abbreviation: ROI, region 
of interest. 
2.6.3 Masson’s Trichrome Stain 
The Masson’s staining technique is a ‘connective tissue technique’ as it is employed to 
demonstrate collagen deposition. As the name suggests, this stain produces three colors 
including black/blue-stained nuclei, green- or blue-stained collagen and red-stained 
cytoplasm and muscle (Young et al., 2006; Titford, 2009). This stain was employed for the 
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histological visualization of fibrosis in myocardial sections. Skin samples were used as 
positive control slides. 
For the Masson’s Trichrome stain, positively charged Histobond microscope slides were 
utilized (Lasec, GLAS2S13M0810401, Cape Town, South Africa). 5µm sections of heart 
tissue were again prepared, which were then deparaffinized and rinsed in distilled water. 
After incubation in hematoxylin, the slides were placed into ordinary tap water to ‘blue’ the 
sections, and then rinsed in distilled water. The slides were then stained in fuchsin Ponceau-
orange G, where after they were rinsed in acetic acid water (Radchem, 600113, Illinois, 
USA). The slides were flushed in 5% phosphotungtic acid (Merck Millipore, 100582, 
Modderfontein, South Africa) solution (the mordant) and then rinsed in acetic acid water to 
differentiate the color tones. After staining in Light Green solution (Sigma-Aldrich, L1886, 
Johannesburg, South Africa), the slides were again washed in acetic acid solution. The slides 
were dehydrated through a series of alcohols, cleared in xylene (Merck Millipore, 
1086619190, Modderfontein, South Africa) and then mounted. The same microscope and 
software as indicated in section 2.6.2 was used to acquire and process the images obtained. 
Several images of the tissue were captured at 4x magnification and stitched together to create 
an image of the entire section. The acquired images were analysed using ImageJ software and 
brightened to make each color stand out. Color thresholding was used to select the entire 
heart, for which a measurement was given in pixels (Figure 2.3A). The threshold slider was 
then adjusted to only select the red-stained myocardium and exclude the blue-stained 
connective tissue (Figure 2.3B). A measurement in pixels was again generated, which was 
subtracted from the pixel measurement of the entire heart, to give the pixels of only the blue-
stained area. The blue-stained area (fibrosis) was then expressed as a percentage of the area 
of the entire section. Considering that this method of quantification is very subjective, a blind 
analysis was also performed by an independent researcher. A full protocol for this stain can 
be found in Appendix D, page 161. 
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Figure 2.3: Color thresholding to measure fibrosis in histological samples. 
Color thresholding was performed in order to measure the pixels of the entire heart (A) and the pixels of the red-
stained myocardium (B) so that the amount of blue-stained fibrosis could be calculated. Magnification: 4x 
2.6.4 Immunohistochemistry (IHC) 
For the immunohistochemical stains, positively charged Histobond slides were utilized 
(Lasec, GLAS2S13M0810401, Cape Town, South Africa) and 5µm sections of heart tissue 
were again prepared. These were then deparaffinized, rinsed in distilled water and the IHC 
staining protocol was carried out using the Bond-Max™ Autostainer (Leica Biosystems, 
Germany) and the Bond™ Polymer Refine Detection kit (Leica Biosystems, DS9800). This 
kit is an HRP-linked antibody conjugated system for the detection of tissue-bound IgG 
primary antibodies. Briefly, the slides were incubated in H2O2 to quench endogenous 
peroxidase activity, followed by incubation in 1: 100 cytochrome c primary antibody (Cell 
Signaling Technology, 11940). After secondary binding, the 3, 3’-diaminobenzidine 
tetrahydrochloride hydrate (DAB) chromogen enabled visualization via a brown precipitate. 
Hematoxylin was used as a counterstain to visualize nuclei. In order to control for the natural 
peroxidase activity in the heart, negative control slides were prepared by excluding the 
primary antibody. Due to the time-consuming and bias nature of the grading methods of 
analysis, the automated digital image analysis ImageJ plugin ‘IHC Profiler’ was used 
(Varghese et al., 2014). In any digital image analysis software, the pixel intensity ranges from 
0 to 255, where 0 represents the darkest shade of color and 255 represents the lightest shade 
of color. With the assistance of pathologists, color shades were manually graded and assigned 
a score [high positive (3+), positive (2+), low positive (1+) and negative (0)] that correlated 
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with the pixel intensity. The software then calculates how many pixels fall within each 
category; if 60% or more of the pixels fell into a specific grading category then the image 
was assigned to that category (Figure 2.4). This software therefore uses color deconvolution 
and computerized pixel profiling to assign an automated score to the image.  
Pixel Count: 40868424 
Percentage contribution of High Positive: 88.9749 
Percentage contribution of Positive: 0.7811 
Percentage contribution of Low Positive: 2.3084 
Percentage contribution of Negative: 7.9357 
The score is High Positive 
Figure 2.4: Pixel intensity is graded into one of four categories. 
The final score is assigned to the category that contains 60% or more of the pixels. 
2.7 Oxidative stress analysis 
Oxidative stress is a physiological condition that arises when the balance between ROS and 
antioxidants is shifted. During low levels of oxidative stress, the antioxidants within a cell are 
able to compensate for any ROS production that may fluctuate above the norm, however, 
when ROS production becomes excessive, antioxidant defense mechanisms are unable to 
maintain the redox status of the cell, leading to DNA, protein and membrane damage 
(Doroshow, 1983). Three different assays were employed in this study in order to obtain a 
complete picture of the redox state within each treatment group. The oxygen radical 
absorbance capacity (ORAC) assay gives an indication of ‘antioxidant power’, the 
glutathione (GSH) assay assesses antioxidant status and the measurement conjugated dienes 
and thiobarbituric acid reactive substances (TBARS) are known as early and late markers of 
oxidative stress, respectively. The SOD activity assay gives an indication of which 
antioxidant may be responsible for any shifts observed in antioxidant capacity. 
2.7.1 Sample preparation 
For use in the ORAC, GSH, SOD and TBARS assays, tissue samples were thawed on ice, 
where after 100 mg of each sample was weighed out and placed into chilled microfuge tubes. 
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For every 100 mg of tissue, 1 mL of ice cold phosphate buffer (50 mM, pH 7.5) was added. 
The tissue was homogenized on ice for approximately ten seconds using a Polytron PT 2100 
homogeniser (Kinematica AG, Switzerland). After homogenization, samples were sonicated 
at an amplitude of 10 Hz, for five to ten seconds using an Ultrasonic Liquid Processor 
(Misonix Incorporated, USA). The foam produced was first allowed to subside, where after 
the samples were centrifuged at 12 000 RPM (13.3 x g) for ten minutes at 4 °C. The 
supernatants were pipetted into new, chilled microfuge tubes and frozen at -80 °C until 
needed. To determine oxidized glutathione (GSSG) in the glutathione assay, 100 mg of each 
tissue was again weighed out, however for this assay 10 µL 1-methyl-2-vinyl-pyridium 
trifluoromethane sulfonate (M2VP) was added to the phosphate buffer prior to 
homogenization. The same homogenization, sonication and centrifugation steps were then 
followed, and the supernatant was stored at -80 °C until needed.  
2.7.2 ORAC Assay (Antioxidant capacity) 
To evaluate the capacity of intracellular antioxidants to overcome DOX-induced oxidative 
stress, and the potential ability of ghrelin to maintain or improve this capacity, the ORAC 
assay was used, as previously described by Ou et al. (2001). The assay employs the 
fluorophore, ‘fluorescein’, as the target, which becomes oxidized after the addition of the 
peroxyl radical 2,2’-Azobis (2-methylpropionamidine) dihydrochloride (AAPH). 
Antioxidants present in the test samples will prevent the oxidation of the fluorophore until the 
antioxidant activity becomes depleted. The samples’ antioxidant capacity correlates with the 
fluorescence decay curve, represented as the area under the curve (AUC). ‘Trolox™’ (Sigma-
Aldrich, 238831, Johannesburg, South Africa), a water-soluble analog of Vitamin E, is used 
as the standard so that the antioxidant capacity of each sample can be expressed as µmol 
Trolox standard equivalents per gram of tissue analysed.  
 
The Fluoroskan Ascent™ microplate fluorometer (Thermo Fisher Scientific, Massachusetts, 
U.S.A.), equipped with an incubator, was set at 37 °C. All samples were first centrifuged at 
14 000 RPM (16.5 x g) for ten minutes to remove turbidity, followed by deproteinization 
using perchloric acid (0.5M) precipitation. A fluorescein stock solution (Sigma-Aldrich, 
F6377, Johannesburg, South Africa) was prepared in phosphate buffer and further diluted for 
use in the assay. Fluorescein, test samples and AAPH (Sigma-Aldrich, 440914, 
Johannesburg, South Africa) were added to each well of a black 96-well plate using a 
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multichannel pipette. The fluorescence was read immediately, every five minutes for two 
hours. Fluorescence filters with an excitation wavelength of 485 nm and emission 
wavelength of 538 nm were used. The final ORAC values were calculated using the 
regression equation y = ax2 + bx + c between the Trolox concentration (µM) and the area 
under the curve. Refer to Appendix D, page 168 for the full protocol. 
2.7.3 Conjugated Dienes 
To extract and purify myocardial lipids for conjugated diene determination, frozen heart 
tissue was homogenized in a 1: 2 solution of chloroform and methanol. The homogenate was 
then centrifuged at 10 000 RPM (9.2 x g) for ten minutes at 4 °C, revealing two layers. The 
bottom organic chloroform layer was transferred to a new microfuge tube and allowed to 
evaporate overnight at 4 °C. Cyclohexane was then added to each of the dried residues. 
Thereafter, the samples were transferred to the wells of a 96-well plate and the absorbance 
was determined spectrophotometrically at 234 nm using the Multiskan® Spectrum microplate 
spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). The concentration of 
conjugated dienes was determined using the following equation: 
 !"#$ −  !"#%
&  
Where A234S: absorbance of the sample at 234 nm 
 A234B: absorbance of the blank at 234 nm 
 : extinction co-efficient of 2.95 x 104 
 
2.7.4 TBARS Assay 
It is well known that cell death can occur as a result of lipid peroxidation, since this process 
induces damage in both plants and animals. Malondialdehyde (MDA) is one if the end 
products of this process and thus the measurement of these natural bi-products is a commonly 
used method of assessing oxidative damage and the level of oxidative stress (Bernheim et al., 
1948). TBARS is a widely used assay for assessing lipid peroxidation since MDA forms a 1:2 
adduct with TBA which can be measured colorimetrically. Test samples were added to 4 mM 
butylated hydroxytoluene (BHT) in order to prevent oxidation during processing. 0.2 M 
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ortho-phosphoric acid (Merck Millipore, 1.00573.2500, Modderfontein, South Africa) and 
0.11 M TBA (Sigma-Aldrich, T5500, Johannesburg, South Africa) were then added, where 
after the reaction mixture was boiled at 90 °C for 45 minutes, followed by immediate cooling 
in an ice bath. Butanol and saturated salt were added to each sample to separate the phases, 
where after the top phase of the samples were transferred to a 96-well plate and the 
absorbance was measured at 532 nm in the Multiskan® Spectrum microplate 
spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). The MDA concentration 
of the samples was then calculated using an extinction coefficient of 1.56 x 105 M/cm. Refer 
to Appendix D, 169 for the full protocol. 
2.7.5 GSH Assay (Antioxidant status) 
The ratio of reduced (GSH) and oxidized (GSSG) glutathione was determined according to 
the method previously described by Asensi et al., (1999). Samples for GSH were diluted 
100x in GSH buffer, while samples for GSSG were diluted 50x in GSH buffer. In a clear, 96-
well plate, the GSH standards (Sigma-Aldrich, G4251, Johannesburg, South Africa),  1U 
glutathione reductase (Sigma Aldrich, G3664, Johannesburg, South Africa), 0.3 mM DTNB 
(Sigma-Aldrich, D21820, Johannesburg, South Africa) and samples for GSH or samples 
treated with M2VP (Sigma-Aldrich, 69701, Johannesburg, South Africa) for GSSG, were 
incubated at 25 °C for five minutes. The reaction was then initiated with 1mM NADPH 
(Sigma-Aldrich, N6785, Johannesburg, South Africa) and measured at 412 nm for 5 minutes 
at 30 second intervals in a Multiskan® Spectrum microplate spectrophotometer (Thermo 
Fisher Scientific, Massachusetts, USA). The concentration of total glutathione, GSH and 
GSSG were determined using the GSH standard (Sigma-Aldrich, G4251, Johannesburg, 
South Africa). Refer to Appendix D, page 170 for the full protocol. 
2.7.6 SOD Activity Assay 
The SOD activity assay quantifies the auto-oxidation of 6-hydroxydopamine (6-HD). Prior to 
this assay, the protein concentration of each sample was determined using the Direct Detect™ 
system described in section 2.5. 1.6 mM 6-HD (Sigma-Aldrich, H8523, Johannesburg, South 
Africa) was prepared in distilled water containing perchloric acid (PCA), and 0.1 mM 
diethylenetriaminepentaacetic acid [(DETAPAC) Sigma-Aldrich, D6518, Johannesburg, 
South Africa] was prepared in 50 mM phosphate buffer (pH 7.4). The samples, 6-HD and 
DETAPAC were added to the wells of a 96-well plate, which was then read immediately at 
490 nm for four minutes, at one minute intervals using the Multiskan® Spectrum microplate 
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spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). The activity of SOD was 
determined using an equation obtained from the standard curve, where one unit of SOD is 
defined as the amount of the enzyme that is needed to exhibit 50% dismutation of the 
superoxide radical. It should be noted, however, that this assay does not differentiate between 
the different types of SOD enzymes. 
2.8 Caspase-Glo® 
The Caspase-Glo® Assay (Promega, G8091, Wisconsin, USA) is a luminescent assay that 
measures caspase-3 and -7 activities. These caspases are members of the cysteine aspartic 
acid-specific protease family that play important roles in the execution of apoptotic cell 
death. The assay makes use of a proluminescent substrate which is cleaved by active caspases 
to yield aminoluciferin, a substrate of luciferase, and thus enabling the production of light. 
Heart tissue was homogenized using the Polytron PT 2100 homogeniser (Kinematica AG, 
Switzerland) and 100 µg protein of each sample was used. The Caspase-Glo® buffer was 
added to the Caspase-Glo® substrate (as per the manufacturer’s instructions) to produce the 
Caspase-Glo® reagent. This was then added in equal volumes to the lysates (i.e. 100 µl tissue 
lysate and 100 µl Caspase-Glo® reagent). The plate was mixed by gentle agitation on a belly 
dancer, where after it was incubated at room temperature for one hour. After incubation, the 
luminescent signal was measured using the GloMax® 96 Microplate Luminometer (Promega, 
Wisconsin, USA) at an excitation wavelength of 490 nm and an emission wavelength of 510 
– 570 nm. 
2.9 Western blot analysis 
2.9.1 Preparation of cell lysates  
Snap-frozen heart tissue samples were pulverized into pieces in a chilled mortar and pestle. 
For protein isolation, small pieces of the crushed tissue were incubated in  450 µL modified 
radio-immunoprecipitation (RIPA) buffer (pH 7.4) containing 50 mM Tris-HCL, 150 mM 
NaCl, 1% NP40 (Sigma-Aldrich, 74385, Johannesburg, South Africa), 0.25% Na-
deoxycholate (Sigma-Aldrich, D6750, Johannesburg, South Africa), 1 mM EDTA (Merck 
Millipore, SAAR2236020EM, Modderfontein, South Africa), 1 mM NaF (Merck Millipore, 
1.93270.0500, Modderfontein, South Africa), 1 mM PMSF (Sigma-Aldrich, 94382, 
Johannesburg, South Africa), 1mM sodium orthovanadate (Sigma-Aldrich, S6508, 
Johannesburg, South Africa) and  a protease inhibitor cocktail (cOmplete, 11873580001, 
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Sigma-Aldrich, Johannesburg, South Africa). Tissue was homogenized for ten seconds in 
chilled microfuge tubes on ice using a Polytron PT 2100 homogeniser (Kinematica AG, 
Switzerland). Once the foam had subsided, the lysates were centrifuged twice at 11 000 RPM 
(11.2 x g) at 4 °C for 15 minutes and the supernatant was transferred into new chilled 
microfuge tubes. Protein concentration was determined using the Direct Detect™ system as 
described in section 2.5. 50 µg protein samples were prepared in Laemmli’s loading buffer, 
boiled at 95 °C for five minutes and stored at -80 °C until needed.  
2.9.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
Samples prepared in Laemmli’s buffer were thawed on ice and then boiled again at 95 ˚C for 
five minutes. 50 µg protein of each sample was separated by 12% TGX stain-free™ FastCast™ 
acrylamide gels (Bio-Rad, 1610183, California, USA) for ten minutes, at 100 V, 400 mA 
(constant), followed by 120 V for approximately 60 minutes. The stain-free gel was activated 
by placing the gel directly onto the Bio-Rad UV transilluminator plate (ChemiDoc™ XRS+ 
system) and selecting the ‘gel activation’ step in the Image Lab™ software (Version 5.2.1). 
After activation, the proteins were transferred onto polyvinylidene fluoride (PVDF) 
membranes (Trans-Blot® Turbo™ ready-to-assemble mini low fluorescent PVDF transfer kit, 
Bio-Rad, 1707274, California, USA) using the TransBlot® Turbo™ Transfer System (Bio-
Rad, California, USA) for 12 minutes at 15 V. After transfer, the stain-free blot was imaged 
for use in total protein normalization. Membranes were then blocked for one hour at room 
temperature in 3% bovine serum albumin (BSA) (phosphorylated proteins) or 5% fat free 
milk (total proteins) dissolved in Tris buffered saline-Tween®20 Solution (TBS-T). 
After blocking, the membranes were washed three times for five minutes in TBS-T and 
incubated overnight at 4 °C with gentle agitation in primary antibody (1:1000) solutions 
dissolved in 5% BSA-TBS-T. Subsequent to primary antibody incubation, the wash step was 
repeated and the membranes were incubated in HRP-linked anti-rabbit or anti-mouse 
secondary antibody dissolved in 5% fat free milk for one hour at room temperature. 
Membranes were washed with TBS-T (3 x 5 minutes) and incubated with Clarity™ ECL 
western blotting substrate (Bio-Rad, 1705061, California, USA). The bands were detected 
using the ChemiDoc™ XRS+ System with the Image Lab™ Software and discrepancies in 
loading were corrected for by using total protein normalization (Colella et al., 2012; Gilda & 
Gomes, 2013). For proteins with double bands, the band intensity was calculated as the sum 
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of the two bands. For proteins with both phosphorylated and total forms, the results were 
expressed as the ratio of the phosphorylated protein to the total protein. 
Table 2: The antibodies utilized and their respective dilutions. 
PRIMARY Company Catalogue 
Number 
Primary 
antibody 
dilution 
Secondary 
Antibody 
Secondary 
antibody 
dilution 
P-
STAT3Ser727 
CST 9134 1 : 1000 7074 1 :10 000 
P-STAT3Tyr 
705
 
CST 9131 1 : 1000 7074 1 : 2000 
T-STAT3 CST 9139 1 : 1000 7076 1 :10 000 
P-Akt CST 9271 1 : 1000 7074 1 : 2000 
T-Akt CST 9272 1 : 1000 7074 1 :10 000 
P-ERK1/2 CST 4370 1 : 1000 7074 1 :10 000 
T-ERK1/2 CST 4695 1 : 1000 7074 1 :10 000 
Cytochrome 
c 
CST 11940 1 : 1000 7074 1 :10 000 
SOD1 CST 2770 1 : 1000 7074 1 :10 000 
SOD2 CST 13141 1 : 1000 7074 1 :10 000 
Cleaved 
PARP 
CST 5625 1: 1000 7074 1: 10 000 
• Abbreviations: CST; Cell Signaling Technology 
2.10 Statistical analysis 
All values are presented as the mean ± standard error of the mean (SEM). A one-way or two-
way analysis of variance (ANOVA) was used where appropriate and a Bonferroni post hoc 
analysis was then employed to test for significance. Significance was accepted when p < 
0.05.  
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Chapter 3  
Results  
3.1 Ghrelin promotes increased weight gain by stimulating appetite during 
DOX treatment 
3.1.1 Body weight 
The treatment protocol was initiated in week one and terminated at the end of the eighth 
week, as indicated by the black arrows in the figure below. One week after the last treatment, 
the rats were killed for further analyses (red arrow). After approximately four weeks of DOX 
treatment, subjective but clinical signs of heart failure became evident, including paw and tail 
cyanosis, inactivity, passive behaviour and boney frame. These observations were not 
apparent in the DOX+ghrelin group. 
 DOX suppressed the growth rate from as early as week four of the treatment protocol (Figure 
3.1), however, this effect only became significant in week eight (205.97 ± 33.03%, p< 0.05) 
and week nine (204.89 ± 32.76%, p< 0.05) when compared to the control in week eight 
(393.96 ± 100.72) and week nine (397.91 ± 99.23), respectively. The weight gain between the 
control rats and the vehicle rats was not statistically different, whereas the weight gain of the 
DOX group (204.89 ± 32.76%, p< 0.05) was significantly lower than that of the vehicle 
group (385.55 ± 103.82%) after nine weeks. Weight gain was maintained in the group that 
received both DOX and ghrelin, as the body weight of this group did not differ from the 
control and the percentage change in body weight continued to increase during treatment. 
While weight gain in this group was higher than the DOX alone group, the results obtained 
were not statistically different from one another. 
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Figure 3.1: The percentage change in body weight during the treatment protocol. 
Body weight was recorded and expressed as the percentage change from the baseline weight. Treatment 
commenced and ended at weeks one and eight (black arrows), respectively. Animals were untreated (control) or 
treated with physiological saline (vehicle), DOX (2.5 mg/kg/week), ghrelin alone (300 ug/kg/week) or a 
combination of DOX and ghrelin, for a total of eight weeks. The animals were killed in week nine (red arrow). 
All values are presented as mean ± SEM, *p< 0.05 vs control, $p< 0.05 vs vehicle, n = 7 – 9. 
A similar result can be seen when looking at the raw body weight data (Figure 3.2). 
Treatment with DOX, regardless of whether ghrelin was also administered, resulted in a 
significantly reduced body weight from week three of the treatment protocol. Although 
ghrelin does not appear to increase weight gain in combination with DOX, from these results  
it was calculated that the DOX-treated group gained 48% less weight than the control, 
whereas the combination group only gained 22% less than the control. This equates to the 
combination group gaining 33% more weight than the DOX-alone group. In addition, the 
ghrelin alone group gained 13% more weight overall when compared to the control. 
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Figure 3.2: The change in body weight throughout the treatment protocol 
Body weight was recorded three times per week. Animals were untreated (control) or treated with physiological 
saline (vehicle), DOX (2.5 mg/kg/week), ghrelin alone (300 ug/kg/week) or a combination of DOX and ghrelin, 
for a total of eight weeks. The animals were killed in week nine. All values are presented as mean ± SEM, *p< 
0.05 vs control, **p< 0.01 vs control, ***p< 0.001 vs control, n = 7 – 9. 
3.1.2 Heart weight 
In addition to recording body weight, heart weight was also measured after the eight week 
treatment period, upon harvesting of the heart. This data was then expressed as the ratio of 
heart weight to body weight, however, there was no significant change in this ratio between 
any of the groups (Table 3). This may be due to timing, as extensive remodeling of the 
myocardium might not yet have taken place after eight weeks of treatment to produce 
detectable differences in heart size.  
Table 3: Heart weight to body weight ratio. 
The heart weight of each rat was expressed as a ratio to the body weight.  
 CONTROL VEHICLE GHRELIN DOX DOX+ghrelin 
Heart weight: 
body weight 
(AU) 
0.0044 ± 
0.0002 
0.0043 ± 
0.0003 
0.0042 ± 
0.0002 
0.0043 ± 
0.0002 
0.0044 ± 
0.0003 
All values are presented as mean ± SEM, n = 7 – 9. Abbreviations: AU, arbitrary units. 
3.1.3 Food consumption 
In an effort to correlate our body weight data to how much food was consumed by each 
group, the average weekly food consumption was determined (Figure 3.3). Treatment with 
Stellenbosch University  https://scholar.sun.ac.za
- 50 - 
 
 
DOX resulted in significantly reduced food intake from week six (137.45 ± 14.03 g, p< 0.05), 
and this was maintained throughout the duration of the study when compared to the 
respective controls. This result may have accounted for the reduced body weight observed in 
this group. A similar result was observed when the DOX group was compared to the vehicle 
group. Although co-administration with ghrelin modestly elevated food consumption when 
compared to DOX treatment alone, the results obtained were not statistically significant. 
However, it appears that ghrelin prevents loss of appetite by promoting food intake, as is 
evident from the percentage change in body weight described in section 3.1.1. 
 
Figure 3.3: Food consumption over the treatment protocol. 
Food intake was recorded three times a week throughout the eight week treatment protocol and calculated as the 
average food consumed per rat per week. All values are presented as mean ± SEM, *p< 0.05; **p< 0.01 vs 
control, $p< 0.05 vs vehicle, n = 7 – 9. 
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3.2 Ghrelin maintains cardiac function during DOX treatment 
3.2.1 Cardiac Output, Aortic Output, Coronary Flow and Stroke Volume 
It is a well-known phenomenon that DOX treatment results in cardiotoxicity which can 
culminate in heart failure in some individuals. However, despite chronic cardiotoxicity being 
the most detrimental form of this condition, very few studies have evaluated the effects of 
DOX in an appropriate, prolonged treatment protocol. While there is no ‘accepted’ definition 
for the term ‘chronic cardiotoxicity’ when referring to pre-clinical models (in vivo), it is 
extremely difficult to ascertain the dose, the duration and the frequency of the treatment 
regimen that induces the typical signs and symptoms of this condition. Hence we have tried 
to establish an in vivo model of chronic cardiotoxicity in order to more closely simulate 
clinical observations. Functional heart data was obtained by making use of working heart 
perfusions, where cardiac output was measured as the amount of blood pumped by the heart 
per minute (aortic output plus coronary flow) (Vincent, 2008). Here we demonstrate that 
treatment with DOX significantly reduced cardiac output (Figure 3.4) in the isolated rat heart. 
Cardiac function declined to a minimum at the end of the 40-minute protocol (42.30 ± 4.82 
mL/minute, p< 0.01) when compared to the control (58.80 ± 2.78 mL/minute). While no 
significant changes were observed between the DOX and DOX+ghrelin groups, it is apparent 
from the data obtained that ghrelin, in the presence of DOX, prevents the decline in cardiac 
output, thus implying a protective effect. 
 
Figure 3.4: Cardiac output (mL/minute). 
After ten minutes of stabilization in the retrograde perfusion mode, heart function was assessed over a 
40-minute working heart perfusion protocol. All values are presented as mean ± SEM, *p< 0.05; **p< 
0.01 vs control, n = 5 – 9. 
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When looking at aortic output alone (Figure 3.5), the aortic flow rate of DOX-treated hearts 
was significantly reduced by the end of the perfusion protocol (25.50 ± 3.64 mL/minute, p< 
0.05) when compared to the control (36.60 ± 1.47 ml/minute). Furthermore, the aortic flow 
rate was significantly reduced in the DOX hearts when compared to DOX+ghrelin (34.07 ± 
0.97 mL/minute, p< 0.05), substantiating the protective effect of ghrelin. 
 
Figure 3.5: Aortic flow rate (mL/minute) 
After ten minutes of stabilization in the retrograde perfusion mode, heart function was assessed over a 40-
minute working heart perfusion protocol. All values are presented as mean ± SEM, *p< 0.05 vs control; #p< 
0.05 vs DOX+ghrelin, n = 5 – 9. 
Coronary flow is the amount of blood perfusing the myocardium through the coronary 
arteries and was measured by the timed collection of the coronary effluent from the heart. In 
a similar manner to the cardiac output and aortic output results described above, DOX 
significantly reduced coronary flow (Figure 3.6) for the majority of the perfusion protocol, 
beginning at ten minutes (16.33 ± 0.73 mL/minute vs 22.60 ± 1.60 mL/minute, p< 0.05) and 
remaining reduced until 35 minutes (16.47 ± 1.30 mL/minute vs 22.2 ± 1.80 mL/minute, p< 
0.05) when compared to the control. Even though coronary flow in the combination group 
was modestly reduced, the values obtained did not differ statistically from the DOX group, 
despite remaining above the levels of the DOX group.  
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Figure 3.6: Coronary flow rate (mL/minute). 
After ten minutes of stabilization in the retrograde perfusion mode, heart function was assessed over a 40-
minute working heart perfusion protocol. All values are presented as mean ± SEM, *p< 0.05 vs control, n = 5 – 
9. 
Stroke volume is the amount of blood pumped by the left ventricle with each heartbeat and 
can be calculated by dividing the cardiac output by the heart rate. As indicated in Figure 3.7, 
DOX treatment significantly decreased the stroke volume from 30 minutes into the perfusion 
protocol (179.17 ± 20.93 µL/beat, p< 0.05) when compared to the control (244.09 ± 12.79 
µL/beat). Stroke volume continued to decline until the end of the perfusion protocol (171.81 
± 20.61 µL/beat, p< 0.01), when compared to the control (247.55 ± 12.68 µL/beat). No 
significant changes were observed between the DOX and DOX+ghrelin group despite the 
combination group’s values remaining above the DOX group’s values. These results indicate 
that while no differences were observed with the intervention (ghrelin) in the presence of 
DOX, ghrelin does appear to maintain left ventricular function.  
5 10 15 20 25 30 35 40
0
5
10
15
20
25
30
DOX
Control
Vehicle
Ghrelin
DOX+ghrelin
* * * * * *
Perfusion time (minutes)
Co
ro
n
ar
y 
Fl
o
w
 
Ra
te
 
(m
L/
m
in
u
te
)
Stellenbosch University  https://scholar.sun.ac.za
- 54 - 
 
 
 
Figure 3.7: Stroke volume (µL/heartbeat). 
After ten minutes of stabilization in the retrograde perfusion mode, heart function was assessed over a 40-
minute working heart perfusion protocol. All values are presented as mean ± SEM, *p< 0.05; **p< 0.01 vs 
control, n = 5 – 9. 
3.2.2 Blood pressure and Heart Rate 
Although previous studies have demonstrated the effects of DOX on blood pressure 
(Yagmurca et al., 2003), only the systolic pressure was reduced in our study (Figure 3.8A). 
Systolic pressure was significantly reduced at 25 minutes into the perfusion protocol (131.89 
± 4.14 mmHg, p< 0.05) when compared to the control (147.80 ± 1.66 mmHg). However, 
significance was lost as the perfusion protocol continued. No other differences were observed 
with regards to diastolic blood pressure (Figure 3.8B) and heart rate (Figure 3.8C). 
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Figure 3.8: (A) Systolic blood pressure, (B) diastolic blood pressure and (C) heart rate 
After ten minutes of stabilization in the retrograde perfusion mode, heart function was assessed over a 40-
minute working heart perfusion protocol. All values are presented as mean ± SEM, *p< 0.05 vs control, n = 5 – 
9. 
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3.2.3 Left Ventricular Function 
Considering that one of the signs and symptoms of chronic DOX-induced cardiotoxicity is 
left ventricular dysfunction (Carver et al., 2007), measuring this parameter was of critical 
importance. As such, the performance of the left ventricle was assessed by calculating the 
LVDP, which is the diastolic pressure subtracted from the systolic pressure (Lecour et al., 
2002). From this calculation, the RPP was also measured by multiplying the LVDP by the 
heart rate, thereby providing an indication of both the chronotropic (changes in heart rate and 
rhythm) and inotropic (changes in contractile force) activity within the myocardium. These 
parameters essentially provide an indication of cardiac ‘effort’ (Aksentijevi et al., 2016). As 
expected, LVDP (Figure 3.9A) and RPP (Figure 3.9B) were significantly reduced after DOX 
treatment when compared to the respective controls. The intervention group (DOX+ghrelin) 
produced no significant changes when compared to the DOX group, despite remaining above 
DOX values for both LVDP and RPP. 
 
 
Figure 3.9: DOX treatment reduces (A) LVDP and (B) RPP. 
Left ventricular performance was measured by the LVDP and the RPP. All values are presented as mean ± 
SEM, *p< 0.05; **p< 0.01 vs control, n = 5 – 9. Abbreviations: LVDP, left ventricular developed pressure; 
RPP, rate-pressure product. 
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3.2.4 Total work performance 
Our results show that the mean external power produced by the left ventricle was 
significantly reduced in the DOX group for the majority of the perfusion protocol when 
compared to the control (Figure 3.10). The performance of the hearts that were co-treated 
with ghrelin resulted in no significant change when compared to the DOX treatment group. 
The fact that all functional data and the various parameters, both measured and calculated, 
follow the same trend indicates not only that the perfusion protocol was performed correctly, 
but that the intervention of using ghrelin in the presence of DOX was able to offer protection 
to the heart. Finally, it must be acknowledged that the sample size for the perfusion results is 
reduced because some hearts were lost upon euthanasia or during mounting on the perfusion 
apparatus (aortic edema, tearing of the coronary sinus, arrhythmias, ruptured atrium). 
 
Figure 3.10: Mean external power (total work performance). 
After ten minutes of stabilization in the Langendorff mode, heart function was assessed over a 40-minute 
working heart perfusion protocol. Cardiac function is expressed as the mean external power of the left ventricle. 
All values are presented as mean ± SEM, *p< 0.05; **p< 0.01 vs control, n = 5 – 9. 
3.3 Blood and Tissue Analysis 
3.3.1 Metabolic Parameters 
As mentioned in Chapter 1, ghrelin is most well-known for its appetite-inducing effects and 
its levels therefore fluctuate in response to feeding and fasting. Blood was collected at the 
time of euthanasia, which was the light-phase for the rats. This means that the rats were 
sleeping and therefore in a fasted state. The serum concentration of ghrelin was measured 
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using a luminex-based assay. As demonstrated in Figure 3.11, ghrelin levels were 
significantly elevated in the group that received exogenous injections of ghrelin (42.40 ± 9.53 
pg/mL, p< 0.05) when compared to the control (3.49 ± 1.20 pg/mL). Surprisingly, ghrelin 
was undetectable in the group that received DOX, suggesting that DOX may interfere with 
the processes that govern ghrelin production or secretion. Supporting this argument, 
detectable amounts of ghrelin were observed in the group that received both DOX and ghrelin 
treatment. It may be this increase in serum ghrelin that is accountable for the increase in body 
weight in this group. 
 
Figure 3.11: Serum ghrelin concentration (pg/mL). 
One week after the last injections, blood was collected from the thoracic cavity upon euthanasia. Ghrelin was 
measured in the serum using a luminex-based assay. All values are presented as mean ± SEM, *p< 0.05 vs 
control, n = 7 – 9. 
3.3.2 Markers of Cardiac injury. 
Various well-known markers can be used to assess the extent of cardiovascular injury. In this 
study, the serum concentrations of cTnT, cTnI and CK-MB, and the myocardial tissue 
concentration of BNP were measured in order to obtain a holistic view of the sensitivity of 
these markers in detecting cardiotoxicity. The most significant results obtained came from the 
analysis of CK-MB (Figure 3.12), which was upregulated in the presence of DOX (6742 ± 
664.80 pg/mL, p< 0.01) and in the combination group (7059 ± 608.10 pg/mL, p< 0.001) 
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when compared to the control (3884 ± 422.60 pg/mL). Other markers such as cTnI, cTnT and 
BNP did not yield significant differences between groups (Table 4). 
 
Figure 3.12: Serum CK-MB concentration (pg/mL). 
The concentration of muscle creatine kinase was determined in the serum of the rats using a luminex-based 
assay. All values are presented as mean ± SEM, **p< 0.01; ***p< 0.001 vs control, n = 7 – 9. Abbreviations: 
CK-MB; creatine kinase-myocardial band. 
Table 4: cTnI, cTnT and BNP. 
After the eight week treatment protocol, blood was collected and heart tissue was harvested. cTnI and cTnT 
were measured in the serum and BNP was measured in homogenized heart tissue lysates.  
 CONTROL VEHICLE GHRELIN DOX DOX+ghrelin 
cTnI 
(pg/mL) 
2420 ± 276.80 2606 ± 885.00 2200 ± 389.40 1938 ± 389.6 1410 ± 210.10 
cTnT 
(pg/mL) 
412.6 ± 83.38 498.8 ± 219.10 545 ± 180.50 413.3 ± 175.50 259.4 ± 56.71 
BNP 
(ng/mL) 
0.064 ± 0.02 0.049 ± 0.01 0.046 ± 0.03 0.061 ± 0.04 0.061 ±0.004 
Abbreviations: cTnI, cardiac troponin inhibitory; cTnT, cardiac troponin tropomyosin; BNP, brain natriuretic 
peptide. All values are presented as mean ± SEM, n = 7 – 9. 
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3.4 Morphological assessment of the myocardium 
3.4.1 Masson’s Trichrome stain for the detection of fibrosis 
The Masson’s Trichrome stain was used to identify the deposition of connective tissue. Both 
a 4x image of the entire heart, as well as a 20x enlargement of a region of the left ventricle is 
shown (Figure 3.13). As indicated in the figures below, collagen was only observed in the 
control, vehicle and ghrelin groups when surrounding blood vessels. However, substantial 
blue-stained fibrosis was evident in the DOX-treated group (indicated by a closed 
arrowhead). Co-treatment with ghrelin resulted in a trend towards a decline in collagen 
deposition (indicated by an open arrowhead) when compared to the DOX group. In the DOX 
group, myofibrillar disorganization and fragmentation were also observed, but this was 
reduced in the presence of ghrelin (indicated by an asterisk). 
Using color thresholding (described in section 2.6.3), the areas of blue-stained fibrosis were 
then quantified. No changes were observed between the control, vehicle and ghrelin groups, 
whereas eight weeks of DOX treatment at a cumulative dose of 20 mg/kg resulted in a 
significant increase in fibrosis (40.01 ± 3.03%, p = 0.0002) in DOX-treated hearts when 
compared to the control (11.53 ± 3.00%). Co-treatment with ghrelin resulted in a modest 
reduction in fibrosis, though this result was not significant when compared to the DOX 
group. 
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Figure 3.13: Masson's Trichrome stain for fibrosis. 
The representative images of left ventricular histology from rat 
myocardium stained with Masson’s Trichrome are shown. Blue-
stained fibrosis in the DOX group is indicated by a closed 
arrowhead, and the reduced fibrosis in the DOX+ghrelin group is 
indicated by the open arrowhead. Myofibrillar reorganization is 
indicated by an asterisk (*).Magnification and scale bars: 4x and 500 
µm (entire section), 20x and 100 µm (enlargement), n = 7 – 9. 
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Figure 3.14: Quantification of fibrosis. 
Color-thresholding was performed to quantify the formation of connective tissue in rat myocardial sections. The 
measurement in pixels was used to express the area of blue-stained fibrosis as a percentage of the entire heart. 
All values are presented as mean ± SEM, ***p< 0.001 vs control, n = 7 – 9. 
3.4.2 Cardiomyocyte size 
In an effort to assess the potential morphological changes induced by DOX and ghrelin alone 
or in combination, the H&E histological stain was employed. It is known that repeated 
administration with DOX induces histological changes to the heart in both human patients 
and experimental animal models, and that these changes can ultimately affect heart function. 
Upon the qualitative examination of the H&E slides (Figure 3.15), the control, vehicle and 
ghrelin-treated groups were indistinguishable from one another, showing signs of normal 
cardiac morphology. However, the groups treated with DOX showed signs of cytoplasmic 
vacuolization (asterisk), reduced myocyte size (black arrows) and myofibrillar disarray. 
When ghrelin was administered in combination with DOX, these affects appeared partially 
attenuated, however, it was difficult to determine whether ghrelin had a beneficial effect 
solely based on qualitative analysis.  
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Figure 3.15: H&E analysis of cardiac morphology. 
The representative images of left ventricular histology from rat myocardium stained with H&E are shown. 
Transverse sections were cut to show the overall morphology of the heart. DOX-treated hearts displayed signs 
of vacuolization (indicated by *) and reduced myofiber size (indicated by black arrows). Magnification: 20x, 
scale bar: 100 µm, n = 7 – 9. 
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To further strengthen our data and to determine the effect of ghrelin under these conditions, 
cardiomyocyte size (cross-sectional area) was measured. As described in the Materials and 
Methods (section 2.6.2, Figure 2.2), images were captured at 4x magnification from five 
randomly selected ROIs in the left ventricle of each heart. Then, using ImageJ, the cross-
sectional area of 30 myofibres was measured in each of the five ROIs, giving a total of 150 
myofibres per heart section (n = 7 – 9 sections per group). Our results indicate that DOX 
administration significantly reduced myocyte cross-sectional area by 8.3% (141.90 ± 2.33 
µm2, p< 0.01) when compared to the control (154.70 ± 3.27 µm2). This result correlates with 
the morphological changes observed in the H&E stain, and is indicative of muscle 
degradation, known to be stimulated in this scenario. A modest, but insignificant increase in 
cross-sectional area was observed between the DOX and DOX+ghrelin group. 
 
Figure 3.16: Cross-sectional area. 
The cross-sectional area of 150 myofibers per section was measured. All values are presented as mean ± SEM, 
**p< 0.01 vs control, n = 7 – 9. 
3.5 Ghrelin prevents oxidative stress 
3.5.1 Lipid peroxidation 
Ghrelin has previously been described to possess antioxidant properties. Therefore, considering 
that one of the mechanisms by which DOX induces cardiotoxicity is oxidative stress, this study 
aimed to evaluate the effectiveness of ghrelin against elevated levels of ROS. Lipid peroxidation 
is one of the main events triggered by oxidative stress and can be assessed by measuring the 
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levels of conjugated dienes and thiobarbituric acid reactive substances (TBARS) such as 
malondialdehyde (MDA). These markers, conjugated dienes and MDA, are considered as early 
and late indicators of lipid peroxidation, respectively.  
Almost immediately after free radicals are formed, the non-conjugated double bonds that are 
found in membrane lipids are converted to conjugated double bonds. Figure 3.17 
demonstrates that DOX significantly increased the formation of conjugated dienes (1.64 ± 
0.11 µmol/gram, p = 0.0003) when compared to the control (0.55 ± 0.12 µmol/gram). This 
effect was attenuated in the combination group (0.86 ± 0.18 µmol/gram, p< 0.05) when 
compared to DOX alone. 
 
Figure 3.17: Early lipid peroxidation was assessed using measuring conjugated dienes. 
Conjugated diene content was measured in myocardial tissue after eight weeks of treatment. All values are 
presented as mean ± SEM, ***p< 0.001 vs control; #p< 0.05 vs DOX, n = 5 – 9. 
The TBARS assay measures a late marker of lipid peroxidation, MDA. However, the levels of 
MDA did not change in any of the treatment groups (Figure 3.18). The TBARS assay has been 
criticized for a lack of specificity and sensitivity, therefore HPLC has been deemed a preferred 
method of detection (Moselhy et al., 2013).  
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Figure 3.18: Late lipid peroxidation was assessed using the TBARS assay. 
The TBARS assay measures MDA, a by-product of late lipid peroxidation. MDA was asseseds in heart tissue 
homogenates. All values are presented as mean ± SEM, n = 5 – 9. 
3.5.2 Antioxidant capacity 
Anthracycline administration is known to compromise the protective mechanisms in the heart 
against free radical damage (Saleem et al., 2014). This observation, together with the 
naturally low levels of antioxidants in the heart, makes the heart susceptible to oxidative 
stress-induced damage. Despite elevated lipid peroxidation as described in section 3.5.1, no 
change in antioxidant capacity, as measured by the ORAC assay, was observed in any of the 
treatment groups (Figure 3.19).  
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Figure 3.19: Antioxidant capacity was analysed using the ORAC assay. 
The antioxidant capacity of the test samples is compared to the vitamin E analogue, Trolox, so that the 
ORAC value can be expressed as Trolox equivalents (µmol) per gram of tissue. All values are 
presented as mean ± SEM, n = 5 – 9. 
This result is echoed by the SOD activity assay (Figure 3.20) and in the Western blot analysis 
of SOD1 (CuZn) and SOD2 (MnSOD), where no changes were observed. This may be due to 
the fact that the heart contains naturally low levels of antioxidants like SOD, or that the 
western blot analysis was not performed on mitochondrial and cytosolic fractions.  
 
Figure 3.20: SOD activity. 
SOD activity was measured in heart tissue homogenates. All values are presented as mean ± SEM, n = 5 – 9. 
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Figure 3.21: Protein expression of SOD1 (CuZn) 
The lane analysis and western blots of SOD1 are shown. Protein expression was normalized to the total lane 
protein. The fold change relative to the control was calculated. All values are presented as mean ± SEM, n = 7 – 
9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
 
Figure 3.22: Protein expression of SOD2 (MnSOD) 
The lane analysis and western blots of SOD2 are shown. Protein expression was normalized to the total lane 
protein. The fold change relative to the control was calculated. All values are presented as mean ± SEM, n = 7 – 
9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
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3.5.3 Antioxidant status 
GSH neutralizes free radicals by donating an electron, resulting in a rise in GSSG. An 
increase in GSSG, with the subsequent decrease in the GSH: GSSG ratio is indicative of a 
state of oxidative stress. While no change in GSH was observed (Table 5), treatment with 
DOX significantly increased GSSG levels in the DOX (605.60 ± 45.89 µmol/gram, p< 0.001) 
and DOX+ghrelin groups (477.60 ± 31.09 µmol/gram, p< 0.05) when compared to the 
control (280.30 ± 59.30 µmol/gram). However, the ratio of GSH: GSSG was only 
significantly reduced in the DOX group (2.10 ± 0.47 AU, p< 0.05) when compared to the 
control (9.66 ± 1.08 AU), indicating oxidative stress after DOX treatment. 
Table 5: GSH, GSSG and GSH: GSSG. 
 Control Vehicle Ghrelin DOX DOX+ghrelin 
GSH 
(µmol/gram) 
1526 ± 214.7 1373 ±293.9 1308 ± 275.9 937 ± 173.3 1205 ± 219.0 
GSSG 
(µmol/gram) 
280.3 ± 59.30 384.6 ± 52.13 432.5 ± 50.52 605.6 ± 
45.89*** 
477.6 ± 31.09* 
GSH : 
GSSG (AU) 
9.66 ± 1.08 6.64 ± 2.16 8.03 ± 2.46 2.10 ± 0.47* 3.67 ± 1.01 
All values are presented as mean ± SEM, *p< 0.05; ***p< 0.001 vs control, n = 5 – 9. 
3.6 Ghrelin reduces apoptotic cell death in the rat heart 
3.6.1 Cytochrome c 
In order to determine the contribution of apoptosis to DOX-induced cardiotoxicity, various 
markers for apoptosis were measured. Cytochrome c is released from mitochondria upon 
stimulation of the intrinsic apoptotic pathway. After immunohistochemical staining for 
cytochrome c, the immune reactivity of paraffin-embedded tissue sections was determined 
using the IHC Profiler plugin on Image. As described in section 2.6.4, this software grades 
and assigns an image a score based on the intensity of the pixels. Upon evaluating the images, 
it is clear that there was a strong positive reaction (arrows) for cytochrome c in the DOX 
treated group (Figure 3.23), indicative of apoptotic activation. This was confirmed by the 
digital grading software, which assigned a score of ‘positive/high positive’ to the DOX 
group. The immune reaction of cytochrome c appeared to be modestly reduced when ghrelin 
was administered in combination with DOX, and as such, the digitally assigned score was 
‘low positive’. This suggests an anti-apoptotic effect induced by ghrelin in the presence of 
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DOX. A negative control sample was obtained by omitting the primary antibody in order to 
account for the endogenous peroxidase activity within the heart. 
Quantitative analysis showed a moderate increase in cytochrome c reactivity after DOX 
treatment (Figure 3.24), though this did not differ statistically from the control. Co-treatment 
with ghrelin was accompanied by a modest reduction in cytochrome c reactivity compared to 
DOX alone, though this was not statistically different. Finally, cytochrome c protein 
expression was assessed in heart tissue homogenates using western blot analysis (Figure 
3.25), however, no differences between the groups were observed. This might be explained 
by the fact that cytochrome c is closely associated with the inner mitochondrial membrane, 
and these western blots were performed on tissue lysates instead of mitochondrial fractions. 
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Figure 3.23: Immune reactivity of cytochrome c in heart tissue sections. 
The representative images of left ventricular immunohistochemistry from rat myocardium are shown. 
Cytochrome c immune reactivity was scored using the IHC Profiler plugin for ImageJ. The overall score was 
assigned based on the pixel intensity of each image. Color shades were manually graded and assigned a score 
(high positive: 3+; positive: 2+; low positive: 1+; and negative: 0). Arrows indicate the brown precipitate caused 
by cytochrome c antibody binding. The negative control was obtained by omitting the primary antibody. 
Magnification: 10x, scale bar: 100 µm, n = 7 – 9. Abbreviations: IHC, immunohistochemical. 
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Figure 3.24: Quantification of cytochrome c immunohistochemistry. 
The quantitative analysis of left ventricular immunohistochemistry from rat myocardium is shown. Cytochrome 
c immune reactivity was analysed using the IHC Profiler plugin for ImageJ.  All values are presented as mean ± 
SEM, n = 7 – 9. Abbreviation: IHC, immunohistochemical. 
 
Figure 3.25: Protein expression of cytochrome c. 
The lane analysis and western blots of cytochrome c are shown. Protein expression was normalized to the total 
lane protein. The fold change relative to the control was calculated. All values are presented as mean ± SEM, n 
= 7 – 9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
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3.6.2 Caspase activity 
Once the apoptotic pathway is activated, executioner caspases are recruited to cleave specific 
downstream proteins. The Caspase Glo® 3/7 assay was utilised to determine the activities of 
two executioner caspases that are further down the apoptotic pathway (Figure 3.26). 
Treatment with DOX significantly increased the activity of caspase-3 and -7 (67877 ± 15686 
RLU, p< 0.0001) when compared to the control (13421 ± 1871 RLU). Co-administration of 
DOX and ghrelin significantly reduced caspase activity (36006 ± 3843 RLU, p< 0.05) when 
compared to treatment with DOX alone, confirming the anti-apoptotic activity of ghrelin. 
 
Figure 3.26: Caspase 3/7 activity. 
The luminescent signal produced in this assay is directly proportional to caspase 3/7 activity. Caspase activity 
was determined in heart tissue homogenates. All values are presented as mean ± SEM, ***p< 0.001 
vs control; #p< 0.05 vs DOX, n = 7 – 9. Abbreviations: RLU, relative light units. 
3.6.3 Western blot analysis of cleaved PARP 
One of the terminal events associated with apoptotic cell death is the cleavage and 
inactivation of PARP. Cleaved PARP is then unable to respond to and repair damaged DNA. 
To further validate the anti-apoptotic effects of ghrelin, the protein expression of cleaved 
PARP (Figure 3.27) was assessed with western blotting. Treatment with DOX significantly 
increased PARP cleavage (2.11 ± 0.24 fold change, p = 0.0081) when compared to the 
control (1.00 ± 0.09 fold change), not only indicating apoptosis, but also DNA damage. 
PARP cleavage was moderately reduced in the combination group, suggesting a reduction in 
apoptosis, although this did not differ statistically from the DOX alone group. Taken 
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together, our results confirm the anti-apoptotic effects of ghrelin as reported in previous 
studies. 
 
 
Figure 3.27: Protein expression of cleaved PARP. 
The lane analysis and western blots of cleaved PARP are shown. Protein expression was normalized to the total 
lane protein. The fold change relative to the control was calculated. All values are presented as mean ± SEM, 
**p< 0.01 vs control, n = 7 – 9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, 
DOX+ghrelin. 
3.7 Ghrelin signaling does not involve the RISK pathway 
3.7.1 Protein expression of ERK1/2 and Akt/PKB 
Ghrelin has previously been shown to promote cellular survival by activating the pro-survival 
kinases, ERK1/2 and Akt/PKB (Baldanzi et al., 2002). Similarly, it is ERK1/2 and Akt/PKB 
that prevent the apoptosis and oxidative stress during IRI. Therefore, we aimed to determine 
whether this pathway, the RISK pathway, was responsible for the anti-apoptotic and 
antioxidative effects of ghrelin during DOX treatment.  Using western blot analysis, the 
protein expression of phosphorylated and total ERK1/2 was determined (Figure 3.28), 
however, there was no significant change in phospho- and total-ERK1/2 expression, or the 
phosphorylated to total protein ratio in any of the groups.  
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Figure 3.28: Protein expression of phosphorylated and total ERK1/2. 
The lane analysis and western blots of phosphorylated and total ERK1/2 are shown. The band intensity was 
calculated as the sum of the 42 kDa and 44 kDa bands. Protein expression was normalized to the total lane 
protein, whereafter the results were expressed as the ratio of phosphorylated protein to total protein. The fold 
change relative to the control was calculated. All values are presented as mean ± SEM, n = 7 – 9. AU, arbitrary 
units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
Similarly to ERK1/2, there was no change in the phosphorylated or total forms of Akt in any 
of the treatment groups, however, there was a trend towards increased expression after 
treatment with DOX, although this is not significant. This data echoes the findings of our in 
vitro study (manuscript in preparation), where ERK1/2 and Akt/PKB were not expressed. 
These results suggest that ghrelin does not confer a protective effect via the RISK pathway, 
as we had initially predicted, and that a different pathway is in play. 
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Figure 3.29: Protein expression of phosphorylated and total Akt. 
The lane analysis and western blots of phosphorylated (serine 473) and total Akt are shown. Protein expression 
was normalized to the total lane protein, whereafter the results were expressed as the ratio of phosphorylated 
protein to total protein. The fold change relative to the control was calculated. All values are presented as mean 
± SEM, n = 7 – 9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
3.8 Ghrelin protection involves the SAFE pathway 
3.8.1 Inflammatory markers 
The protein expression of TNF-α, as well as serum TNF-α, was measured not only as a 
marker of inflammation, but also because TNF-α is a known activator of the SAFE pathway. 
The SAFE pathway has also been linked to survival and thus we aimed to assess the role of 
ghrelin in stimulating this pathway during DOX treatment. After eight weeks of treatment, 
the western blot analysis of heart tissue lysates showed a significant increase in TNF-α 
protein expression after DOX treatment (2.77 ± 0.47 fold change, p<0.01) when compared to 
the control (1.00 ± 0.19 fold change). This suggests that treatment with DOX resulted in 
substantial inflammation within the heart. TNF-α expression was moderately reduced in the 
combination group, but this was not statistically different from the DOX group (Figure 3.30). 
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Figure 3.30: Protein expression of TNF-α. 
The lane analysis and western blot of TNF-α are shown. Protein expression was normalized to the total lane 
protein and the fold change relative to the control was calculated. All values are presented as mean ± SEM, 
**p< 0.01 vs control, n = 7 – 9. AU, arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, 
DOX+ghrelin. 
Unlike the western blot analysis of TNF-α, there were no changes in the serum concentration 
of TNF-α between any of the groups (Figure 3.31). This may be because the cardiomyocytes 
have produced the TNF-α protein but have not necessarily secreted it into the blood stream. 
During the processing of western blot samples, the 25 kDa transmembrane form of TNF-α is 
exposed, whereas TNF-α measured in the serum may not be available for antibody binding. 
 
Figure 3.31: TNF-α fluorescent intensity. 
The concentration of serum TNF-α is presented as the mean fluorescent intensity as extrapolation of 
concentration from the standard curve yielded results that were out of range. All data is presented as mean ± 
SEM, n = 7 – 9. AU; arbitrary units. 
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In addition to TNF-α, IL-6 was also measured as a marker of inflammation (Figure 3.32), 
however, no changes between the groups were observed. This may correlate with the serum 
TNF-α, suggesting that the inflammatory response had returned to baseline by the time of 
blood collection (one week after the last injections). 
 
Figure 3.32: Serum concentration of IL-6. 
The concentration of IL-6 was measured in rat serum after eight weeks of treatment. All data is presented as 
mean ± SEM, n = 7 – 9. 
3.8.2 Protein expression of STAT3 
To further explore the possible signaling pathways involved in ghrelin protection, we 
analyzed the protein expression of STAT3, since stimulation of this protein has proven to be 
beneficial during apoptosis and oxidative stress. Our western blot data demonstrates that 
serine727 phosphorylation of STAT3 was markedly reduced after DOX treatment, however, 
this was not significantly different from the control. Co-administration of DOX and ghrelin 
resulted in significantly increased STAT3 phosphorylation at this residue (6.76 ± 2.06 fold 
change, p = 0.02) when compared to DOX alone (0.27 ± 0.05 fold change). Total protein 
remained unchanged. Considering that the effects of TNF-α (detrimental or beneficial) are 
concentration dependent, we can speculate that the high levels of TNF-α observed in Figure 
3.30 became detrimental. Despite high levels of TNF-α, the activation of the SAFE pathway 
was inhibited, possibly through the inhibition of JAK2 or by down-regulating STAT3 
mRNA. In contrast, the moderately reduced levels of TNF-α following ghrelin treatment 
promoted a survival benefit by stimulating the SAFE pathway. Further research needs to be 
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performed in order to determine why the vehicle group elicited such a large response in 
STAT3 phosphorylation. 
 
Figure 3.33: Protein expression of p-STAT3 Serine727 and total STAT3. 
The lane analysis and western blots of phosphorylated (Serine 727) and total STAT3 are shown. The band 
intensity was calculated as the sum of the 79 kDa and 86 kDa bands for total STAT3. Protein expression was 
normalized to the total lane protein, whereafter the results were expressed as the ratio of phosphorylated protein 
to total protein. The fold change relative to the control was calculated. Western blot analysis was performed on 
total protein as no fractionation was done. All values are presented as mean ± SEM, *p< 0.05, n = 7 – 9. AU, 
arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
No changes were observed in tyrosine-phosphorylated STAT3 or total STAT3, however, a 
trend towards increased STAT3 phosphorylation was observed in the combination group. 
Although not part of the analysis of this study, JAK is responsible for the phosphorylation of 
STAT3 at this tyrosine residue (Kisseleva et al., 2002). Phosphorylation at the serine residue 
enhances the transcriptional activity of STAT3 (Boengler et al., 2008). The protein 
expression of p-STATSer727 may therefore be upregulated to compensate for the lower 
expression of p-STATTyr705. 
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Figure 3.34: Protein expression of p-STAT3 Tyrosine705 and total STAT3. 
The lane analysis and western blots of phosphorylated (Tyrosine 705) and total STAT3 are shown. The band 
intensity was calculated as the sum of the 79 kDa and 86 kDa bands. Protein expression was normalized to the 
total lane protein, whereafter the results were expressed as the ratio of phosphorylated protein to total protein. 
The fold change relative to the control was calculated. All values are presented as mean ± SEM, n = 7 – 9. AU, 
arbitrary units; C, control; V, vehicle; G, ghrelin; D, DOX; DG, DOX+ghrelin. 
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Chapter 4  
Discussion 
As the survival rate of cancer patients has improved due to early detection and advanced 
diagnostic tools, cardiovascular diseases associated with chemotherapy has now emerged as 
the leading cause of morbidity and mortality among cancer survivors. The major cause of 
cancer-associated cardiomyopathy is essentially the cardiotoxicity induced by cytotoxic drugs 
such as anthracyclines. Of these anthracyclines, DOX is among the most potent, leading to 
the development of heart failure in patients of both young and old age, and in those with pre-
existing heart disease. While thousands of analogs of DOX have been produced, none have 
proved superior in terms of their cytotoxic action and reduced cardiotoxic side effects. Since 
the cytotoxic mechanisms of action of DOX have been differentiated from the cardiotoxic 
effects, there is hope that treatment strategies can be designed to target the adverse side 
effects of DOX without jeopardizing its anti-neoplastic capacity. With this in mind, this study 
explored the potential cardioprotective effects of ghrelin, a natural ‘brain-gut’ peptide with 
appetite-inducing effects, in a newly established in vivo model of chronic DOX-induced 
cardiotoxicity. Considering that chronic cardiotoxicity is accompanied by a very poor 
prognosis, it is imperative to develop chronic models of this condition in order to simulate the 
clinical effects more effectively. According to Doggrell and Brown (1998), the ideal animal 
model should i) mimic the human disease, ii) allow studies in chronic, stable conditions, iii) 
produce predictable symptoms, iv) meet economical, technical and ethical standards and v) 
allow for the measurement of appropriate cardiac and biochemical parameters. In the 
presented study, we established a rat model of chronic cardiotoxicity by injecting rats weekly 
with DOX for a prolonged period of time. Not only is the dose clinically relevant, but the 
weekly DOX schedule echoes the cumulative, dose-dependent nature of cardiotoxicity. This 
study aimed to simulate chronic cardiotoxicity, which is most commonly observed in the 
survivors of childhood cancers. Ghrelin has been documented to promote cellular protection 
through the activation of survival pathways like ERK1/2 and Akt/PKB. Through the 
activation of these pathways, ghrelin reduces oxidative stress and apoptosis in various models 
of heart failure. In addition, ghrelin promotes weight gain and appetite that may assist with 
maintaining general well-being and increasing tolerance to chemotherapy. These effects 
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therefore highlight a potential role for ghrelin in counteracting DOX-induced cardiotoxicity 
in the clinical setting. 
4.1 Ghrelin induces appetite, maintains body weight and promotes general well-being 
Ghrelin is most well-known for its appetite-inducing (Chang et al., 2005; Hiura et al., 2012; 
Akamizu & Kangawa, 2010) and growth-hormone stimulating actions (Date et al., 2002). 
This is an appealing property in the context of DOX-induced cardiotoxicity, as loss of 
appetite (Matsumura et al., 2004; Kristal et al., 2001) and cachexia (Ng et al., 1993) are 
commonly reported side effects during treatment with this anthracycline. We have also 
shown that rats treated with DOX experienced significantly slowed growth (the change in 
body weight over time) and decreased food intake (Figure 3.1 and Figure 3.3, respectively), 
whereas co-treatment with ghrelin maintained the growth rate and appetite of the rats at levels 
similar to the control. This data is supported by numerous other studies that reported reduced 
weight gain (Desai et al., 2013; Kihara et al., 2016) and food consumption (Chaudhary et al., 
2016) during DOX treatment, and attenuation of these effects when ghrelin is administered 
(Wang et al., 2014; Neary et al., 2004; Hiura et al., 2012; Kihara et al., 2016). Ghrelin 
administration was also shown to prevent the cachexia associated with CHF in rats (Nagaya 
et al., 2001c). It would have also been interesting to measure fat pad mass, especially because 
DOX treatment is known to cause weight loss and ghrelin treatment increases fat storage. The 
reduced weight gain in the DOX treated group may have been as a result of fat loss, whereas 
the maintenance in weight gain in the combination group may have been due to fat gain. 
In our study, food consumption was measured three times a week on the morning before 
injections were administered. Although it was expected that ghrelin alone would cause a 
potent increase in food intake, this effect was not seen in the current study. Similarly, 
Shintani et al., (2001) reported a significant increase in food intake four hours after ghrelin 
administration, but no difference after 24 hours. A reason for this is that food intake after a 
ghrelin injection occurs in under 60 minutes in rodents, which means that daily food intake 
measurements (every 24 hours) can easily be missed (Wren et al., 2000). In addition, the 
orexigenic effects of ghrelin are more powerful when ghrelin is administered centrally 
(intracerebroventricular), rather than peripherally (i.p), as in our study. Nevertheless, ghrelin 
appeared to maintain appetite when administered together with DOX, supporting its role as 
an appetite-stimulating peptide. From the stomach, ghrelin is released into the blood stream 
where it travels to and acts on the anterior pituitary gland after crossing the blood-brain 
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barrier (Kojima et al., 1999; Banks et al., 2002). While the exact mechanisms are still not 
completely understood, ghrelin administration has been shown to stimulate neurons in the 
arcuate nucleus, increasing the mRNA expression of NPY and AgRP, which in turn promote 
appetite (Shintani et al., 2001). In addition to increasing appetite, ghrelin also decreases fat 
utilization (Tschöp et al., 2000), inducing an overall increase in body weight (Strassburg et 
al., 2008). Furthermore, the resulting positive energy balance is needed for maximizing the 
anabolic effects of GH. GH release, together with an increase in food intake, would 
contribute to the increased body weight observed in this study. Ghrelin and its receptors have 
also been identified in other organs of the body such as the liver, the kidneys and the 
pancreas. In the liver, treatment with ghrelin has been shown to reduce inflammation and 
oxidative stress in response to non-alcoholic fatty liver disease (Li et al., 2013). In the 
pancreas, studies have yielded conflicting results, with some indicating that ghrelin inhibits 
insulin release and others suggesting that ghrelin stimulates insulin release (Kageyama et al., 
2005). In the kidney, ghrelin has been demonstrated to reduce renal injury and improve 
excretory function during ischemic renal failure (Vasileiou et al., 2013). Importantly, ghrelin 
administration does not appear to exert any adverse side effects in any of the organs. 
Although other studies administered ghrelin every day, twice a day, we aimed to obtain 
similar results but with a less severe injection protocol, and therefore only administered 
ghrelin three days of a week. Ghrelin still elicited a protective effect in DOX-treated rats, but 
this effect may have been enhanced with an increase in ghrelin administration. Despite 
having a half-life of less than 60 minutes (Tolle et al., 2002), we were able to detect ghrelin 
in rat serum from blood samples that were collected one week after the treatment protocol 
(Figure 3.11). It is possible that the ghrelin that was measured was naturally endogenous 
ghrelin, or that the exogenous ghrelin injections induced lasting effects. As expected, 
significantly higher ghrelin levels were measured in the serum of the ghrelin-treated group, 
however, what was surprising was the undetectable ghrelin levels in the DOX group. 
Considering that DOX-treatment was associated with reduced food intake, ghrelin levels 
should have been increased to signal hunger, however, the undetectable levels suggest that 
many of the negative side effects associated with DOX treatment may occur due to an 
inhibitory effect that DOX has on ghrelin. We can only speculate that DOX may damage the 
ghrelin-producing cells in the stomach or that DOX interferes with ghrelin once it has been 
secreted and is traveling to the brain. When ghrelin was administered in combination with 
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DOX, the level of serum ghrelin increased slightly. It is possibly this restoration of 
endogenous ghrelin that is responsible for its beneficial effects. Supporting our data, Beiras-
Fernandez et al., (2010) also reported significantly reduced ghrelin expression in human 
hearts with CHF, further associating reduced ghrelin levels with maladaptation and the 
development of heart failure. In contrast to this, Nagaya et al., (2001b) and Xu et al., (2007) 
observed an increase in ghrelin levels in models of heart failure and concluded that ghrelin 
increases as a compensatory protective mechanism. This suggests that ghrelin increases to 
overcome the cytotoxic effects induced by DOX. These contradictory findings can be 
explained by the types of models studied, as ghrelin was measured in human myocardial 
biopsies, human plasma and in acute in vivo rat models of cardiotoxicity. The assay used for 
measuring ghrelin does have relatively good sensitivity (1 – 62 pg/mL) and its performance is 
measured using quality controls. However, since this is a multiplex assay that measures 
several different analytes, each with their own optimal conditions for measurement, we may 
have obtained more sensitive results if we had made use of an ELISA specifically for ghrelin. 
Weight loss during chemotherapy can have a poorer outcome for the patient (Ross et al., 
2004), therefore by promoting and maintaining appetite during DOX treatment, ghrelin 
preserves body weight and results in reduced morbidity, an improved quality of life and a 
better prognosis. In our study, DOX-treated rats began to show the clinical signs that are 
indicative of (but not limited to) heart failure approximately half way through the treatment 
protocol. In addition to weight loss, these signs included pale and cool extremities (cyanosis), 
passive behaviour, reduced grooming and boney frame, observations that are in agreement 
with Spivak et al., (2013). The rats that received both DOX and ghrelin did not present with 
these symptoms, highlighting that ghrelin is able to maintain general well-being during 
treatment with chemotherapy. This can possibly be attributed to the effects that are occurring 
on a molecular level, such as reduced cardiomyocyte apoptosis and oxidative stress. 
4.2 Ghrelin improves antioxidant status during DOX treatment 
Oxidative stress is believed to be one of the major contributors to the development of 
cardiotoxicity. The oxidative stress theory remains one of the leading hypotheses for DOX-
induced cardiotoxicity because several antioxidants have proven to be successful in vitro and 
in vivo (Zhang et al., 2013; Alshabanah et al., 2010; Patil & Balaraman, 2011; Panchuk et al., 
2014). However, many antioxidant therapies have failed to offer protection in the clinical 
setting (Ladas et al., 2004; Myers et al., 1983). In an effort to determine the antioxidant 
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properties of ghrelin, oxidative stress, antioxidant capacity and antioxidant status were 
evaluated by numerous mechanisms. As mentioned previously, DOX induces oxidative stress 
by producing free radicals during redox cycling and through interactions with iron. The 
DOX-induced increase in reactive species explains the significant conjugated diene content in 
the heart in the DOX-treated animals (Figure 3.17). In this scenario, ghrelin may quench free 
radicals through unknown mechanisms and thereby limit the oxidation of membrane lipids by 
these radicals, as ghrelin co-treatment significantly reduced the conjugated diene content in 
the heart compared to DOX alone.  This is in agreement with several other studies, including 
studies on DOX-induced cardiotoxicity, which all reported reduced oxidative stress after 
ghrelin treatment (Li et al., 2013; Xu et al., 2008; Li et al., 2006b; Chang et al., 2004b), as 
indicated by reduced conjugated dienes and MDA. In our study however, the level of MDA 
measured by the TBARS assay remained unchanged (Figure 3.18). This result can be 
explained by the fact that MDA is a late marker of lipid peroxidation, and therefore the extent 
of lipid peroxidation at the time of harvesting the heart, was not severe. In obese individuals, 
a state associated with chronic inflammation, the low circulating ghrelin levels have been 
linked to increased oxidative stress (Suematsu et al., 2005). This may extend to 
cardiotoxicity, a disease characterized by similar levels of inflammation, where low ghrelin 
levels during DOX treatment may result in elevated oxidative stress.  
The presence of cellular antioxidants protects against the damaging effects of free radicals, 
and according to Xu et al., (2008), ghrelin’s antioxidative effects are induced through the 
upregulation of endogenous antioxidants. Our study thus evaluated the activity (Figure 3.20) 
and expression of SOD (Figure 3.21 and Figure 3.22) as O2●- is proposed to be the origin of 
most reactive species (Indo et al., 2015; McCord & Fridovich, 1969) and the oxidant 
produced during redox cycling of DOX. Neither the activity nor the expression of SOD1 
(CuZn) and SOD2 (Mn) resulted in any significant changes in this study. While these 
observations are in contrast to what others have shown (Kheradmand et al., 2010; Xu et al., 
2008), a likely possibility for our insignificant results is that this study did not separate the 
cytosolic fraction from the mitochondrial fraction where SOD1 and SOD2 are located, 
respectively. Although the myocardium is known to naturally express relatively low levels of 
this antioxidant (Doroshow et al., 1980), ghrelin itself might be exerting the antioxidative 
effect. In a similar manner, no change was observed in the antioxidant capacity results 
(Figure 3.19) between any of the groups. This may suggest that the free radicals produced did 
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not necessitate a change in the antioxidant capacity of the myocardium. Perhaps when free 
radicals overwhelm the antioxidant defense of the myocardium and MDA, a late marker of 
oxidative stress, is detected will the levels of these parameters change. In addition, the 
activities of other antioxidants such as GSH are not reflected in the ORAC assay. 
GSH is another important antioxidant which exists in both reduced (GSH) and oxidized 
(GSSG) states. GSH acts as a substrate for GSH-Px1, which is involved in detoxifying 
reactive species in the cell. In healthy cells and tissues, approximately 90% of the total GSH 
pool is in the reduced form, whereas 10% exists in the oxidized form. In the reduced state, 
thiol groups from cysteine molecules donate reducing equivalents to ROS, resulting in an 
increase in GSSG (Palwankar et al., 2015). Therefore, an increased GSH: GSSG ratio is 
indicative of oxidative stress. As demonstrated in Table 5, DOX significantly increased 
GSSG while ghrelin, in the presence of DOX, reduced these levels. A similar effect was 
observed when analyzing the ratio of GSH: GSSG, indicating oxidative stress in the DOX-
treated animals, although this was not significant. The myocardial GSH pool has been shown 
to be depleted after DOX treatment (Zhou et al., 2001; Zanwar et al., 2013). The fact that the 
levels of GSSG increased during DOX treatment indicates increased GSH-px1 activity, as 
GSH-Px1 used GSH to detoxify the ROS induced by DOX. Ghrelin, in the presence of DOX, 
may further increase GSH-Px1 activity in an attempt to neutralize reactive species. Ghrelin 
may also reduce oxidative stress by improving the antioxidant status in the cell. We can 
speculate that ghrelin assists in converting GSSG back into GSH by increasing the activity of 
GR (Dobutovic et al., 2014). Ghrelin therefore enhances the hearts ability to neutralize free 
radicals and overcome oxidative stress which, if left uncontrolled, would lead to cell death.  
4.3 Ghrelin reduces myocardial injury by preventing apoptosis 
It is common knowledge that oxidative stress, when in excess, can trigger apoptotic cell 
death. Apoptosis in the myocardium is an essential determinant of the pathogenesis of heart 
failure, as it results in the loss of contractile units and myofibers. In addition, the contribution 
of apoptosis to DOX-induced cardiotoxicity has been extensively reported (Baldanzi et al., 
2002; Chen et al., 2012; Nakamura et al., 2000; Green & Leeuwenburgh, 2002). In 
agreement with these studies, we have also shown a potent increase in apoptotic cell death in 
the myocardium of DOX-treated rats. Considering that cardiac function has been shown to be 
improved once cardiomyocyte apoptosis is inhibited experimentally (Chen et al., 2007), 
inhibiting apoptosis is a potentially effective treatment strategy. Our results are testament to 
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this, as co-treatment with ghrelin attenuated the apoptotic cell death in the myocardium. The 
mitochondria are pivotal in regulating apoptosis, as they respond to signals which trigger the 
release of cytochrome c and the activation of the caspases. In our study, apoptosis was 
measured using cytochrome c (Figure 3.23 - Figure 3.25), caspase-3 and -7 activities (Figure 
3.26) and cleaved PARP (Figure 3.27), indicative of the intrinsic apoptotic pathway (Childs 
et al., 2002). In all cases, DOX increased apoptosis and ghrelin attenuated it. In response to 
stress stimuli such as oxidative stress, cytochrome c is released from the mitochondria, 
triggering the intrinsic apoptotic pathway. The oxidative stress induced by DOX treatment 
results in DNA damage, further enhancing apoptosis. Under normal conditions, this damage 
is usually repaired by PARP (Cohen, 1997), however, the executioner caspases recruited 
during apoptosis cleave PARP, resulting in its inactivation. This explains why each of these 
parameters, cytochrome c, the caspases and cleaved PARP are all increased following DOX 
treatment. Following co-treatment with ghrelin, cytochrome c, caspase activity and PARP 
cleavage were reduced, indicating that ghrelin reduces mitochondrial-dependent apoptosis. It 
is possible that ghrelin prevents depolarization of mitochondrial membrane potential by 
blocking the opening of the mPTP (Chung et al., 2007). It has been shown that even very low 
levels of cardiomyocyte apoptosis (four-fold lower than observed during heart failure in 
humans) are sufficient to induce lethal cardiomyopathy (Wencker et al., 2003). This was 
attributed to caspase activation, which supports our own findings. The reduced apoptosis 
following ghrelin treatment not only improved cell survival, but also maintained cellular 
morphology (Wang et al., 2014). 
4.4 Ghrelin reduces cardiomyocyte fibrosis and atrophy 
Fibrosis typically involves four phases including hemostasis, inflammation, proliferation and 
remodeling (see Diegelmann and Evans, (2004) for full review). During hemostasis and 
inflammation, specific cytokines recruit macrophages and neutrophils to the site of injury, 
where they in turn activate resident fibroblasts. Increased collagen, produced by proliferating 
fibroblasts, then invades and replaces the apoptotic cardiomyocytes (Khan & Sheppard, 
2006). Tissue damage and inflammation increase the production of ROS which further 
enhances the release of factors involved in fibrosis. Fibrosis is therefore an important part of 
repair, but its accumulation can result in organ dysfunction, and eventually failure. In this 
study, we have shown that DOX treatment causes significant fibrosis in the rat heart and that 
co-treatment with ghrelin appears to alleviate this effect (Figure 3.13 and Figure 3.14). This 
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is consistent with several studies that all reported reduced fibrosis by ghrelin in mouse 
models of DOX-induced cardiotoxicity (Pei et al., 2014; Kihara et al., 2016; Wang et al., 
2014). Furthermore, ghrelin has also been shown to reduce fibrosis and collagen formation in 
isoproterenol-induced cardiac injury (Li et al., 2006) and myocardial infarction (Soeki et al., 
2008), respectively. In these studies, fibrosis was assessed using both histological and 
biochemical parameters. The activation of fibroblasts occurs after exposure to profibrotic 
cytokines such as TNF-α and transforming growth factor beta (TGF-β) (Roberts et al., 1986; 
Ihn, 2002). In addition, TGF-β induces the expression of connective tissue growth factor 
(CTGF), which is responsible for enhancing the growth of fibroblasts and the secretion of 
extracellular matrix (Accornero et al., 2015). Pei et al., (2014) showed increased expression 
of CTGF in DOX-treated hearts and reduced transcription of CTGF when ghrelin was 
administered in combination with DOX. This may explain how ghrelin prevents the 
formation of fibrosis during DOX treatment. 
The histological changes associated with DOX treatment consist not only of fibrosis, but also 
of cytoplasmic vacuolization and myofibrillar loss (Šimůnek et al., 2004; Gava et al., 2013). 
Such changes ultimately result in cardiac remodeling and the development of heart failure 
(Rahman et al., 1986; Lefrak et al., 1973). We have shown that DOX treatment significantly 
reduces the size of cardiomyocytes in rat hearts (Figure 3.15 and Figure 3.16), indicative of 
atrophy and a cachectic state. Similar findings have been reported in patients treated with 
Daunorubicin, with signs of atrophic muscle cells (Buja et al., 1973). Treatment with DOX 
induced vacuolization, disorganization of muscle fibers and a loss in the typical striation 
pattern seen in healthy heart cells, whereas treatment with ghrelin maintained cardiomyocyte 
size and restored organization. This has also been reported by Wang et al., (2014) in a mouse 
model of cardiotoxicity. The attenuation of cardiomyocyte atrophy by ghrelin may correlate 
with the increase in body weight that was observed in this group, suggesting an anti-cachectic 
effect. Autophagy is a well-conserved process for degrading and recycling cellular 
components such as organelles and proteins and as such, it can exert pro-survival and pro-
death functions (Dalby et al., 2010). Autophagy was found to be upregulated in both mouse 
hearts and cell cultures following DOX treatment, and this was associated with a reduction in 
cardiomyocyte size (Wang et al., 2014). In fact, autophagy has been observed in atrophic 
cells and therefore plays an important role in the heart (Nishida et al., 2009; Vellai et al., 
2008). Co-treatment with ghrelin significantly reduced the DOX-induced autophagy, which 
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resulted in an increase in the cross-sectional area of the cardiomyocytes (Wang et al., 2014). 
This excessive DOX-induced autophagy was also associated with increased apoptotic cell 
death, which may explain the elevated apoptosis in our own study. Ghrelin may therefore 
attenuate cardiomyocyte atrophy by reducing the levels of autophagy (and apoptosis) in the 
heart. Importantly, ghrelin alone had no effect on myocyte size of fibrosis or atrophy. 
Fibrosis and loss of myofibers has been shown to cause myocardial dysfunction after DOX 
treatment (Miyata et al., 2010; Chatterjee et al., 2010), providing a causal link between the 
pathohistological changes observed in our study and poor cardiac function.  
4.5 Ghrelin maintains cardiac function during DOX treatment 
The molecular events discussed in the preceding sections, namely cachexia, oxidative stress, 
apoptosis and the pathohistological changes observed, all contribute to the development of 
cardiac dysfunction. In the clinical setting, DOX is administered in doses of 50 – 75 mg/m2 
on a three week cycle (Swain et al., 1997b). The lifetime cumulative dose is generally set to 
less than 500 mg/m2 to reduce the risk of cardiomyopathies (Yi et al., 2006). In this study, 
rats were treated with a cumulative dose of 20 mg/kg, which is equivalent to the human dose 
of between 53.3 – 71 mg/kg2 (Desai et al., 2013). This is calculated by multiplying the animal 
dose by a factor that is relative to the animal’s body surface area. Therefore the conditions of 
this study are an appropriate simulation of chronic cardiotoxicity and closely resemble the 
characteristics of heart failure that are observed in a clinical setting. Ghrelin is predominantly 
produced in the stomach, but the fact that ghrelin and its receptor are also located in the heart 
suggests a role for cardioprotection. Functional data is important to confirm a 
cardioprotective role of ghrelin and this was achieved through working heart perfusions. To 
the best of our knowledge, our study and the study by Hayward et al., (2013) are the only two 
that make use of the isolated working heart to study DOX-induced cardiac dysfunction. This 
model is important as it is a more physiologically relevant simulation of a beating heart than 
the Langendorff technique. 
Chronic cardiotoxicity can occur decades after the completion of treatment, which means that 
patients may remain in an asymptomatic state for several years until events such as viral 
infections (Ali et al., 1994) act as stressors that trigger cardiotoxicity. In this study, subjecting 
the heart to 40 minutes of perfusion can be compared to a stressor, and our results clearly 
demonstrate that the DOX-treated hearts are unable to cope with this stress, resulting in a 
gradual decline in function (Xu et al., 2007; Xiong et al., 2006). This was observed in both 
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the measured (aortic output, coronary flow) and calculated (cardiac output, LVDP, RPP, total 
work) parameters (Figure 3.4 - Figure 3.10), confirming the presence of chronic DOX-
induced cardiotoxicity. The consistent trend in dysfunction across all parameters also 
indicates that the perfusion technique was performed correctly. Bell et al., (2011) states that 
coronary flow for a rat should be approximately 20 mL/minute (>10, <28) and that heart rate 
on the perfusion apparatus should be between 250 – 320 beats per minute, which is consistent 
with the results we obtained. Our results also show that ghrelin preserves cardiac function 
during DOX treatment. Aortic flow rate was significantly improved after co-treatment with 
ghrelin, and the moderate improvement in the other parameters of the DOX+ghrelin group 
produced results similar to that of the control hearts. In line with our results, other studies 
have reported that ghrelin administration does not alter heart rate or blood pressure, but 
significantly improves coronary flow after ischemia reperfusion (Chang et al., 2004a), 
cardiac output during CHF (Nagaya et al., 2001c) and left ventricular function in healthy 
humans, isoproterenol-induced myocardial injury and DOX-treated rats (Pei et al., 2014; 
Wang et al., 2014; Xu et al., 2010; Enomoto et al., 2003). Although no change in heart rate 
or blood pressure was observed, co-administration with ghrelin still improved aortic output. 
This can possibly be explained by the fact that DOX has been shown to increase aortic 
stiffness, and ghrelin may therefore maintain the elasticity of the aorta (Jenei et al., 2013). 
Ghrelin has been shown to reduce apoptosis and oxidative stress, which might explain the 
maintained cardiac function that was observed in DOX+ghrelin group. Pei et al., (2014) 
reported that ghrelin reduced the apoptosis caused by DOX treatment and substantially 
improved cardiac dysfunction in a mouse model of DOX-induced cardiomyopathy. The 
results obtained in our study are of value because they were obtained from a chronic model, 
as opposed to the acute studies, however, it seems that regardless of the model used, ghrelin 
treatment is able to ameliorate cardiac dysfunction. Importantly, ghrelin alone did not affect 
the cardiac function in normal rats. Although the lack of fatty acids in the KHB may suggest 
that the hearts were energy starved during the perfusions, the composition of this buffer, with 
glucose instead of fatty acids, relies on the hearts ability to extract energy from multiple 
substrates (Bell et al., 2011). In addition, the relatively short perfusion protocol, and the fact 
that this was not a metabolic study, did not necessitate the use of fatty acids. Not only are 
fatty acids difficult to dissolve, but they can also result in frothing and foaming when the 
buffer is oxygenated. If the hearts were starved of oxygen then this would have been evident 
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in the control rats, but we obtained functional data with values within the recommended 
range. 
Various factors effect cardiac output, including heart rate, contractility, preload and afterload. 
According to Vincent, (2008), cardiac output can be seen as analogous to riding a bicycle. 
The pace at which a cyclist pedals will determine the speed that the bicycle will go. If the 
cyclist pedals too fast for too long, he will tire and be unable to maintain his level of 
pedaling, but if he pedals too slowly, he will not move fast enough to cover his required 
distance. The same applies to the heart, where bradycardia or tachycardia results in impaired 
cardiac output. However, heart rate remained unchanged during DOX treatment, implying 
that it is not a change in heart rate that is responsible for DOX-induced cardiac dysfunction. 
Contractility is also a determining factor of cardiac output: the more a cyclist flexes his 
muscles and pushes on the pedals, the faster the bicycle will go. Too little pedal power, 
equated to reduced contractility of the heart, will result in reduced cardiac output, however, 
too much effort can result in fatigue, forcing the heart to slow down or stop. This may be the 
case for DOX-induced cardiotoxicity, as the decline in cardiac output is gradual and worsens 
over the 40-minute perfusion protocol. In addition, the total work performed by the left 
ventricle declined early on in the perfusion protocol, indicating that the power of the heart 
was reduced. DOX-induced apoptotic cell death of cardiomyocytes might explain a reduction 
in contractility and hence, overall cardiac function. GH and its mediating hormone, IGF-1 
have been shown to promote physiological hypertrophy during CHF in rats, thereby 
improving cardiac function (Cittadini et al., 1997). Nagaya et al., (2004) reported a potent 
increase in GH release following ghrelin administration in patients with CHF. This finding 
may therefore explain one of the mechanisms by which ghrelin maintains cardiac function 
during DOX treatment. In addition, the improvement in cardiac function by ghrelin during 
CHF in rats has been attributed to reduced apoptosis and the production of pro-inflammatory 
cytokines (Huang et al., 2009). 
Supplementary to the functional results, we also examined the levels of various markers of 
damage. Myocardial markers should not only assist with patient diagnosis, but also allow for 
the estimation of the extent of myocardial damage. We reported a significant increase in 
serum CK-MB in all groups treated with DOX. On the one hand, CK-MB became a marker 
of choice due to greater myocardial specificity (it is the isoform that is most abundant in the 
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heart), but on the other hand, it is released in response to both myocardial and skeletal muscle 
injury (Adams et al., 1993a). In fact, studies have shown that CK-MB released from skeletal 
muscle injury persists in the blood for longer periods of time (Adams et al., 1993b). CK-MB 
was measured one week after the last DOX injection in our study, so the fact that we still 
obtained such high levels suggests that it might be of skeletal muscle origin. The troponins 
are another set of useful markers of damage, as they circulate at low concentrations and 
increase rapidly in response to even mild cardiac injury. Therefore, their presence in the 
blood allows for CK-MB elevations as a result of skeletal muscle damage to be distinguished 
from those resulting from cardiac injury. Adams et al., (1993) also reported that cTnI does 
not appear in the blood, even when CK-MB is elevated, unless there is concomitant cardiac 
injury. We did not observe any changes in the troponins in the study, further indicating that 
the elevated CK-MB might be from DOX-induced skeletal muscle injury. However, we did 
not observe any changes in the ratio of gastrocnemius muscle weight to body weight (data not 
shown), suggesting that the elevated CK-MB may have partly arisen from the heart as well. 
In support of our own observations, several other studies also reported elevated CK-MB 
levels in response to DOX treatment (Yagmurca et al., 2003; Mohamed et al., 2004; Mitra et 
al., 2007). In most studies it is reported that CK-MB release does correlate with other 
evidence of myocardial injury, and the reduced cardiac function and apoptotic cell death in 
our study is evidence to support this. It must also be noted that the studies by Adams et al., 
focused on acute myocardial infarction and therefore these markers may be expressed 
differently in other forms of myocardial injury. The  troponins are early markers of damage 
and their levels may have already returned to baseline by the time we collected blood for 
measurement (Dolci et al., 2008). These markers may be useful for predicting the 
development of cardiotoxicity (Cardinale et al., 2000; Kilickap et al., 2005), but offer no 
value when cardiotoxicity is already present. Bertinchant et al., (2003) reported no changes in 
cTnI and only observed an increase in cTnT.  This can be attributed to antibody specificity 
and the sensitivity of the assay used. Holmgren et al., (2015) reported elevated cTnT levels 
one and two days after DOX treatment in vitro, but no differences beyond seven days. 
Furthermore, Childs et al., (2002) reported that cTnT was not increased even just four days 
after DOX treatment in rats. This observation, consistent with our findings, suggests that the 
troponins are released early after damage and that alternative markers should be used when 
assessing signs of damage during chronic cardiotoxicity. 
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Myocardial BNP was also unchanged in all of the treatment groups. BNP has been suggested 
as an early marker that predicts cardiac dysfunction (Skovgaard et al., 2014) and is present 
before the clinical symptoms of heart failure. BNP may therefore not be present when cardiac 
dysfunction is already evident, as in our study and that of Kihara et al., (2016). BNP is 
rapidly produced by the heart in response to ventricular distension (Iwanaga et al., 2006), 
however we have shown a reduction in cardiomyocyte size (as opposed to enlargement), 
which may further explain why there was no change in BNP. Finally, upon damage, BNP is 
released by the heart into the circulation (Nakao et al., 1990). In our study, the hearts were 
flushed with KHB for 40-minutes during the perfusions, and therefore any BNP in the hearts 
circulation may have been washed out in the effluent. Taken together, the measurement of 
markers such as cTnT, cTnI and BNP are useful for predicting the future development of 
cardiac dysfunction, but offer no value when cardiac dysfunction is already present. 
4.6 Ghrelin keeps the heart ‘SAFE’ through STAT3 phosphorylation 
In a previous study (unpublished), we reported that chronic DOX-induced cytotoxicity was 
associated with a reduction in ERK1/2 and Akt phosphorylation in vitro. This was 
accompanied by elevated apoptotic cell death and TNF-α production. In addition, the SAFE 
pathway (JAK2/STAT3) was not activated following exposure to high concentrations of 
DOX. It was concluded that cardiotoxicity occurs as a result of DOX-induced TNF-α 
production and the inhibition of protective signaling pathways. This led us in the search of a 
protective agent that could potentially promote survival by activating these signaling 
pathways. Baldanzi et al., (2002) showed that DOX-induced apoptosis in H9c2 
cardiomyocytes was prevented by ghrelin administration through its ability to activity 
ERK1/2 and Akt. This prompted us to explore these effects in an in vivo model of chronic 
cardiotoxicity. Although many studies have shown that DOX reduces ERK1/2 and Akt 
phosphorylation (Xiang et al., 2009; Pei et al., 2014; Das et al., 2011) and that ghrelin 
promotes survival by activating these pro-survival kinases (Liang et al., 2013; Xiang et al., 
2011; Pei et al., 2014; Yu et al., 2014), we did not observe any changes in the 
phosphorylation of ERK1/2 (Figure 3.28) and Akt (Figure 3.29)  after DOX or DOX+ghrelin 
treatment. Our results may differ from other studies because we made use of a prolonged in 
vivo treatment protocol, as opposed to acute models or cell culture studies (Table 6). 
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Table 6: A summary of the studies reporting DOX-induced reduction of ERK1/2 and Akt. 
Authors Model DOX dose Ghrelin dose ERK1/2 and 
Akt 
Xiang et al., 
(2009) 
Sprague-Dawley 
rats 
2.5 mg/kg/w/6w  ↓ by DOX 
 
Das et al., 
(2011) 
Swiss Albino 
rats 
3 x 3 mg/kg  ↓ by DOX 
 
Yu et al., (2014) C57BL/6 mice 15 mg/kg, single 0.2 mg/kg b.i.d, 
4 days 
↓ by DOX 
↑ by ghrelin 
Pei et al., (2014) C57BL/6 mice 15 mg/kg, single 100 µg/kg b.i.d, 
4 days 
↓ by DOX 
↑ by ghrelin 
Baldanzi et al., 
(2002) 
H9c2 
cardiomyocytes 
 1 µM, 24 hrs ↑ by ghrelin 
Liang et al., 
(2013) 
MC3T3-E1 
osteoblasts 
 10−11 - 10−9 µM, 
48 hrs 
↑ by ghrelin 
Xiang et al., 
(2011) 
HUVECs  10−8 - 10−5 µM, 
24 hrs 
↑ by ghrelin 
Abbreviations: w: week; b.i.d: bis in die (twice daily); HUVEC: human umbilical vein endothelial cells; hrs: 
hours. 
In contrast, Li et al., (2006) found no involvement of Akt during DOX-induced 
cardiomyopathy in mice treated with a single dose of DOX. Similarly, Lou et al., (2005) 
observed an early, transient increase in ERK1/2 phosphorylation in rats after DOX treatment, 
suggesting an early adaptive response. The subsequent failure of this response was associated 
with heart failure. Finally, Wang et al., (2014) observed no change in ERK1/2 
phosphorylation after DOX treatment in mice, and no change in ERK1/2 or Akt expression in 
H9c2 cells when ghrelin was pre-incubated with DOX, substantiating our own results. The 
ERK1/2 and Akt survival kinases are associated with anti-apoptotic and antioxidative effects, 
so the lack of expression of these kinases might explain the poor cardiac function observed in 
the DOX-treated rats, however, the fact that there was improvement in cardiac function and a 
reduction in apoptosis and oxidative stress in the combination group suggests that other 
signaling pathways are in play.  
Stellenbosch University  https://scholar.sun.ac.za
- 95 - 
 
 
Although STAT3 can be linked to skeletal muscle wasting, inflammation and cachexia, 
knock-out of STAT3 results in fibrosis, inflammation and the development of heart failure 
(Jacoby et al., 2003). In the heart, STAT3 has been implicated in inflammation, apoptosis, 
cell death and cell survival (Hilfiker-Kleiner et al., 2004; Fukada et al., 1996). Ourselves and 
others have reported the inhibition of STAT3 phosphorylation by DOX treatment (Mitra et 
al., 2007) and a significant increase in expression when ghrelin is administered. Considering 
the survival benefits that are associated with STAT3 activation, this reduction in expression 
after DOX treatment may be a possible explanation for the side effects of DOX. STAT3 
knock-out mice are more sensitive to the fibrosis and oxidative stress associated with aging, 
and display higher levels of apoptosis after DOX treatment (Jacoby et al., 2003). This 
substantiates our own findings where DOX treatment was accompanied by fibrosis, oxidative 
stress and apoptosis. In the presence of ghrelin, STAT3 phosphorylation was increased and a 
concomitant reduction in fibrosis, oxidative stress and apoptosis was observed. Kunisada et 
al., (2000) reported enhanced heart failure in wild-type mice treated with DOX, whereas mice 
over-expressing STAT3 were protected. Furthermore, STAT3 phosphorylation was found to 
be significantly down-regulated in the hearts of patients with dilated cardiomyopathy 
(Podewski, 2003), which may contribute to the development of heart failure. In our study, 
reduced STAT3 expression in the DOX group can be associated with the poor heart function 
observed, and this was improved when the phosphorylation of STAT3 was increased by 
ghrelin treatment. In the heart, STAT3 activation has been observed during MI and pre-
conditioning, suggesting that it aids in adaptation to stress (Negoro et al., 2001). STAT3 also 
increases the transcription of anti-apoptotic proteins and decreases the transcription of pro-
apoptotic proteins, supporting its role in cell survival (Bolli et al., 2001; Hattori et al., 2001). 
As a result, the enhanced phosphorylation of STAT3 by ghrelin may lead to an increase in 
survival proteins and a decrease in the proteins associated with apoptosis, including 
cytochrome c and the caspases. Furthermore, Tian et al., (2011) demonstrated that the 
activation of the SAFE pathway has been linked with Bcl-2 elevation (not measured in our 
study), which prevents the opening of the mPTP by interacting with Bax (Marie Hardwick & 
Soane, 2013), thereby reducing apoptosis. Therefore, the ghrelin-induced activation of 
STAT3 may be a potential mechanism through which ghrelin reduces apoptotic cell death. To 
the best of our knowledge, there are no other studies that report on the effects of ghrelin 
treatment on STAT3 activation. We have thus highlighted a potential signaling pathway that 
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is responsible for the protective effects of ghrelin. Although this pathway is linked to cell 
survival, one of the cytokines responsible for its activation exerts effects that are not as 
clearly defined. 
For many years, physicians have reported that patients with CHF display similar symptoms to 
patients with chronic inflammation (Ferrari, 1999). Indeed, studies have indicated that 
increased levels of TNF-α are associated with ventricular dysfunction, dilated 
cardiomyopathy and heart failure (Hegewisch et al., 1988; Moe et al., 2004). We have shown 
that treatment with DOX is accompanied by a potent increase in TNF-α protein expression 
(Figure 3.30), indicating the possible activation of the extrinsic apoptotic pathway. The 
extrinsic apoptotic pathway is activated when ligands such as TNF-α bind to death domain-
containing receptors on the cell membrane, leading to caspase activation (Dempsey et al., 
2003). TNFR1 is an example of one of these receptors, and its activation is therefore 
generally associated with detrimental effects. Evidence for this is that TNFR1 expression and 
apoptosis were found to be significantly increased in H9c2 cells after treatment with DOX, 
whereas the expression of TNFR2, associated with beneficial effects, was decreased (Chiosi 
et al., 2007). Although this pathway involves different signaling proteins to the intrinsic 
apoptotic pathway, both pathways converge at caspase-3 and -7 and induce PARP cleavage. 
Therefore, the activation of this pathway might explain the significant apoptosis observed in 
the DOX-treated group, as indicated by caspase-3 and -7 activities and the expression of 
cleaved PARP. By reducing the expression of TNF-α, ghrelin may have also reduced the 
activation of the extrinsic apoptotic pathway. However, further research into the expression 
of the TNF-α receptors, as well as caspase-8 (specific to the death receptor pathway), is 
needed before the involvement of the extrinsic apoptotic pathway can be confirmed. 
Although low levels of TNF-α have been associated with protection (Chiosi et al., 2007; 
Lecour et al., 2002; Mann, 2002), the parallel improvement in several parameters of this 
study upon reduction of TNF-α expression by ghrelin, suggests that TNF-α is detrimental in 
this scenario. Consistently, Huang et al., (2009) reported a reduction in TNF-α mRNA and 
protein by ghrelin, concluding that ghrelin preserves cardiac function by inhibiting an 
inflammatory response. This may also be the case in our study, where a reduction in TNF-α 
by ghrelin is associated with improved cardiac function. Further supporting a detrimental role 
for TNF-α is the fact that intravenous administration of ghrelin exerts beneficial effects 
during myocardial infarction and cardiac cachexia by inhibiting the release of cytokines 
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(Smith et al., 2005). Therefore, the improvement in cardiac function, cardiomyocyte atrophy 
and the increase in body weight may have occurred as a result of the ghrelin-induced 
reduction in TNF-α. The role of TNF-α in muscle atrophy appears to involve NFĸB, the 
levels of which are elevated after exposure to high concentrations of TNF-α (Sishi & 
Engelbrecht, 2011). NFĸB translocates to the nucleus where it increases the transcription of 
MuRF-1 and MAFbx, two ubiquitin ligases involved in the ubiquitin-proteasome pathway 
(UPP) for protein degradation. By reducing the expression of TNF-α, ghrelin decreases the 
activity of the UPP and as a result, muscle atrophy is prevented. TNF-α is an important 
determinant of fibrosis, as it facilitates the activation of collagen-producing fibroblasts (Khan 
& Sheppard, 2006). Its expression may therefore explain the increase in fibrosis that was 
evident in this study. 
Oxidative stress increases the release of pro-inflammatory cytokines. Likewise, pro-
inflammatory cytokines also increase the production of ROS (Suematsu et al., 2003). Over-
expression of TNF-α in the mouse myocardium has been linked to the increased production 
of OH● radicals (Machida et al., 2003). This may provide a link between the elevated protein 
expression of TNF-α and the substantial oxidative stress in our study. When TNF-α is 
inhibited, the level of aldehydes, indicative of oxidative stress, is reduced (Moe et al., 2004). 
Similarly in our study, the presence of ghrelin moderately reduced TNF-α and alleviated 
oxidative stress. This may correspond with ghrelin’s antioxidant effects, or through an 
unknown mechanism by which ghrelin reduces the levels of TNF-α. It has been reported that 
myocytes lacking STAT3 expression exhibit higher levels of TNF-α (Jacoby et al., 2003). 
This correlates well with our study, where DOX treatment reduced the expression of STAT3, 
resulting in higher TNF-α levels. In contrast, ghrelin treatment promoted STAT3 
phosphorylation, reduced the expression of TNF-α and subsequently induced cell survival. 
This lower, safer level of TNF-α may now also be promoting a survival benefit by activating 
the SAFE pathway (Lecour et al., 2002; Lacerda et al., 2009), whereas high levels of TNF-α 
for prolonged periods of time can induce apoptosis and inflammation (Lien et al., 2006; Sack 
et al., 2000). TNF-α activates the SAFE pathway by binding to its receptor on the cell 
membrane. This causes the receptor to dimerize, subsequently activating JAK. By 
phosphorylating the receptor, JAK creates docking sites for STAT3, allowing it to bind and 
also be phosphorylated by JAK. STAT3 then dimerizes and translocates to the nucleus to 
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increase the transcription of anti-apoptotic proteins (Boengler et al., 2008). In this way, TNF-
α and STAT3, induced by ghrelin, can promote cell survival during DOX treatment. 
In our results, we reported increased protein expression of TNF-α but no change in the serum 
concentration. This may be because the TNF-α protein that was produced in response to DOX 
treatment was not secreted into circulation. However, it has also been shown that cytokines 
within the cell appear before the secreted proteins are detected (Kwak et al., 2000). 
Alternatively, blood was collected one week after the last injections and TNF-α may have 
returned to basal levels in the serum. The Milliplex® MAP Multiplex kit used for TNF-α 
analysis may also have lacked sensitivity for measuring the TNF-α which was still in the 
serum. Further research is needed in order to establish the levels of TNF-α during different 
time points in the study, to fully elucidate how its secretion is linked to the SAFE pathway. 
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Chapter 5  
Conclusion 
DOX is a chemotherapeutic drug that has drastically improved the outcome of patients 
suffering from several different cancers, however, severe cardiotoxicity is a common side 
effect that impacts on the quality of life and survival of these patients.  Although the 
mechanisms are still undefined almost sixty years later, oxidative stress and apoptotic cell 
death remain the top contenders. The chemical structure of DOX allows for the production of 
free radicals, resulting in a condition of oxidative stress, apoptotic cell death and ultimately 
heart failure. Despite effectively treating several cancers, these side effects limit the 
therapeutic potential of DOX. Because of its high efficacy, much research has been prompted 
to develop cardioprotective agents that do not interfere with the anti-neoplastic action of 
DOX, but many, being synthetic compounds, exhibit their own detrimental side effects. 
Therefore, the potential cardioprotective effects of ghrelin, an endogenous appetite-
stimulating gut peptide, were assessed in the current study.  
Although further correlation studies are needed, Figure 5.1A summarizes the effects induced 
by DOX, while Figure 5.1B indicates the potential pathways that may be influenced by 
ghrelin treatment to protect against cardiotoxicity. DOX treatment was accompanied by 
undetectable levels of ghrelin, suggesting that DOX exerts an inhibitory effect on ghrelin 
production, secretion or receptor binding. The absence of ghrelin may account for the 
deleterious effects of DOX. We have shown that treatment with DOX reduces body weight 
gain and appetite, whereas ghrelin attenuates these effects. Ghrelin also maintains cardiac 
function, which was attributed to the anti-apoptotic and antioxidant activity of ghrelin, 
supporting the two most widely accepted mechanisms of action of DOX. Oxidative stress, 
further amplified by inflammation, may be responsible for the activation of apoptosis, leading 
to cell death, cardiomyocyte atrophy and ultimately, cardiac dysfunction. Ghrelin prevents 
cardiomyocyte atrophy and reduces ventricular fibrosis, most likely through an anti-
inflammatory response, as ghrelin was shown to reduce TNF-α expression. TNF-α activates 
fibroblasts which replace apoptotic cells with fibrotic tissue, contributing to the development 
of cardiac dysfunction. Although we originally hypothesized that the protective effects of 
ghrelin would be mediated through ERK1/2 and Akt signaling, we have shown that these 
pathways are not activated in this model, and that protection is instead offered by the SAFE 
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pathway. DOX treatment was associated with down-regulation of STAT3 which may result 
in enhanced sensitivity to oxidative stress, cell death and fibrosis.  
 
Figure 5.1: A unifying schematic of the effects of DOX treatment alone (A) and DOX+ghrelin treatment 
(B) in DOX-induced cardiotoxicity. 
A summary of the research findings indicating the possible pathways influenced by DOX and ghrelin. Flat 
arrowhead: inhibits;             : leads to; ↑: increases; ↓: decreases. 
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Considering that the oxidative stress theory is still under debate, it is possible that the 
inhibition of STAT3 by DOX may be another mechanism by which cardiotoxicity develops. 
This is also an appealing property in terms of tumorigenesis, as cancer cell proliferation may 
be reduced if a pro-survival transcription factor is inhibited. STAT3 upregulates the 
transcription of many genes that will assist in cell survival and its stimulation by ghrelin 
promotes this effect, however, whether ghrelin will also promote tumorigenesis through 
STAT3 activation needs to be determined (Rébé et al., 2013). Although the LD50 of ghrelin 
(the dose required to kill 50% of a test sample) is not known, it is important to note that 
ghrelin alone did not exert any negative effects. This is an appealing property as many 
adjuvant therapies eventually result in toxicity. In addition, all of the ghrelin studies 
administered ghrelin twice a day, whereas we were able to obtain a similar effect with fewer 
injections, reducing animal suffering and discomfort. Future studies should consider making 
use of osmotic pumps in order to deliver ghrelin to the animal, as this may allow for a higher 
dosage to be used and possibly result in an enhanced protective effect. This study has 
provided a basic overview of the signaling pathways involved in the protective effects of 
ghrelin during chronic DOX-induced cardiotoxicity, but further research is needed to gain an 
in-depth understanding into the mechanisms behind ghrelin’s protection.  
Limitations and future directions 
To the best of our knowledge, this is one of very few studies examining the chronic side 
effects of DOX treatment. This, together with the fact that we utilised clinically relevant 
doses of DOX, adds to the novelty of this study. Although this research has achieved its aims, 
there are still some limitations of the study that should be improved upon in the future. These 
include using a larger sample size so that trends can be strengthened and so that some hearts 
can be used for analysis and others can be used for perfusions. A reason for this is that many 
of the markers released by the heart into circulation might have been washed out in the 
effluent therefore, if we had hearts specifically for analysis of these markers, they might be 
detectable in the tissue. If a larger sample size is not possible, then the effluent should be 
collected so that these markers can be measured in the effluent using more sensitive methods 
such as high performance liquid chromatography. We also only measured markers in the 
blood one week after the end of treatment, meaning that many of these markers might already 
have been degraded or returned to baseline levels by the time of measurement. In future I 
would draw blood at various intervals throughout the treatment protocol so that a better 
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image can be drawn of the expression of these markers during the course of cardiotoxicity. 
Since CK-MB can include the damage in skeletal muscle, I would measure both CK and CK-
MB so that this discrepancy can be differentiated. This will indicate the relative contribution 
of CK-MB to total CK. Although the markers of damage measured in this study are valuable 
predictive markers, other markers such as LDH, galectin 3 and ST-2 need to be measured to 
detect damage that is already present. 
In the future I would fractionate tissue lysates to yield cytosolic, mitochondrial and nuclear 
fractions so that the localisation and measurement of proteins in these compartments is more 
accurate. In terms of the animal model, I would like to test the effects of ghrelin in a tumor-
bearing rat model so that the effect of cancer on cardiotoxicity and the protection offered by 
ghrelin can be determined. It is also important to determine the effect of ghrelin on cancer 
growth and try to determine the best time during the course of treatment that ghrelin should 
be administered (before, during or after). This study was conducted on male rats, however, 
the effects of DOX and ghrelin on female rats should also be determined. For future studies I 
would suggest having a group of rats that is monitored for a longer period after the last 
injection, to determine when heart function begins to decline. Finally, I would like to 
investigate whether protection can be offered by ghrelin, but through periods of fasting, 
instead of injections. This would provide insight into a potential mode of ‘ghrelin 
administration’ for human subjects. We have highlighted the many cardioprotective effects of 
ghrelin and the possible mechanisms by which this occurs. Collectively, our data suggests 
that the anti-apoptotic, antioxidative and cardioprotective effects of ghrelin are mediated 
through STAT3 signaling. Our findings emphasize that the potential clinical implications of 
the cardioprotective effects of ghrelin during DOX chemotherapy are worth exploring further. 
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Appendix A 
In vitro analysis of the effect of ghrelin on cancer cell proliferation 
Introduction 
Oncologists are often asked by their patients if there is anything they can supplement with to 
reduce the toxic side effects associated with their chemotherapy, without interfering with the 
anti-neoplastic effects of the treatment. While there is extensive evidence that demonstrates 
how antioxidants and vitamins protect non-cancer cells against chemotherapy (Srdjenovic et 
al., 2010; Patil & Balaraman, 2011; D’Andrea, 2005; Ladas et al., 2004), it is crucial to 
determine whether cancer cells are also being protected. If this is the case then the 
effectiveness of chemotherapy would be reduced. The results of studies have been 
conflicting, with some stating that antioxidants are selectively protective to normal cells but 
cytotoxic to cancer cells, and others reporting enhanced survival of cancer cells. Since our 
study investigated the potential cardioprotective effects of ghrelin during DOX treatment, we 
felt it necessary to evaluate the effect of ghrelin on cancer cell proliferation.  
Materials and Methods 
MDA MB 231 cells (estrogen receptor negative, aggressive metastatic breast 
adenocarcinoma) and MCF7 cells (estrogen receptor positive, non-metastatic 
adenocarcinoma, responds to chemotherapy) were cultured and then treated daily with either 
0.2 µM DOX (LKT Laboratories, D5794), 1 µM ghrelin (LKT Laboratories, G2869) or a 
combination of the two for a period of 120 hours. This treatment protocol was based on our 
previously established in vitro model of DOX-induced cytotoxicity. One day after the last 
treatment, cell viability, which was used as an indication of proliferation, was determined 
using the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay. MTT 
(Sigma-Aldrich, M2128, Johannesburg, South Africa) was prepared as a 0.01 g/mL solution 
in sterile phosphate buffered saline (PBS) at room temperature, and after a two hour 
incubation period at 37 °C, the supernatant was carefully discarded and an isopropanol 
(1%)/triton (0.1%) solution was added. Following a short agitation period, absorbance was 
determined at 540 nm using the EL800 Universal Microplate reader (Bio-Tek Instruments 
Inc., Vermont, USA). Cell viability was expressed as the percentage of treated cells relative 
to the untreated (control) cells. 
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Results 
As indicated in Figure A0.1, ghrelin alone significantly reduced the cell viability of MDA 
MB 231 cells (86.23 ± 2.85%, p< 0.05) when compared to the control (100 ± 4.87), as did 
DOX (39.66 ± 1.72%, p< 0.001) and DOX+ghrelin (63.69 ± 1.89%, p< 0.001). Interestingly, 
the viability of the cells that received both treatments (DOX+ghrelin) was significantly 
increased when compared to the DOX alone, albeit remaining lower than the control. 
 
Figure A0.1: MTT reductive capacity of MDA MB 231 cells 
MDA MB 231 cells were treated daily for five days with ghrelin, DOX or DOX+ghrelin. The cell viability was 
quantified by the cells ability to reduce MTT. All values are expressed as a percentage of the control (100%) 
and presented as mean ± SEM. *p< 0.05 versus control, ***p< 0.001 versus control, ###p< 0.001 versus DOX, 
n = 4. 
In contrast to the MDA MB 231 cells, ghrelin alone had no effect on cell viability in the MCF7 
cells (Figure A0.2), whereas DOX (35.06 ± 6.38%, p< 0.001) and DOX+ghrelin (34.81 ± 4.92%, 
p< 0.01) significantly reduced cell viability compared to the control (100 ± 11.05%). These 
results therefore suggest that the cytotoxic effect of ghrelin is dependent on the type and nature of 
the cancer cells. 
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Figure A0.2: MTT reductive capacity of MCF7 cells 
MCF7 cells were treated daily for five days with ghrelin, DOX or DOX+ghrelin. The cell viability was 
quantified by the cells ability to reduce MTT. All values are expressed as a percentage of the control (100%) 
and presented as mean ± SEM., ***p< 0.001 versus control, n = 4. 
Discussion and Conclusion 
There is no need to reiterate that an adjuvant therapy cannot be tested on humans when it is 
based solely on positive results from cell culture studies, as even reductions of only a few 
percent in the efficacy of a chemotherapeutic agent such as DOX may still lead to substantial 
morbidity and mortality. Like our own observations, the results of studies on ghrelin and 
cancer have proven to be controversial. While some studies report that ghrelin stimulates 
cancer cell proliferation, others have indicated that it may inhibit proliferation (see Chopin et 
al., 2011 for a full review).These discrepancies can be attributed to the fact that different 
concentrations of ghrelin were used, and different end-points were measured.  
 
We have shown that in MDA MB 231 cells, ghrelin alone reduced cell proliferation, but 
when combined with DOX, the cell proliferation was increased. This finding is peculiar 
because ghrelin alone appears to be cytotoxic to cancer cells, but in the presence of a more 
cytotoxic agent, DOX, ghrelin promotes cell survival. This also suggests that ghrelin interferes 
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with the ability of DOX to kill this cancer cell line. This cell line is fairly resistant to DOX (Sonia 
et al., 2009), so it is possible that ghrelin provides a boost that promotes resistance. It is not the 
result we were hoping for but it still provides vital information about the safety of ghrelin 
supplementation during cancer. In contrast, ghrelin in combination with DOX significantly 
reduced the proliferation of the MCF7 cells, which is a cell line that responds well to 
chemotherapy. In this cell line, ghrelin may enhance the cytotoxic action of DOX whilst 
simultaneously protecting the non-cancerous cells. While Cassoni et al., (2001) demonstrated 
that 1 µM ghrelin (alone) decreased the cell number of MCF7 cells after 96 hours of 
treatment, Jeffery et al., (2005) reported that ghrelin stimulated proliferation in MDA MB 
231 cells but had no effect on MCF7 cells. Although there is huge potential for ghrelin as a 
cardioprotective agent, there is also evidence to suggest that ghrelin should be used with 
caution during cancer treatment. With the above in mind, further research is required to 
determine the timing of ghrelin administration (pre-treatment or post-treatment, allowing 
DOX to be used alone) and the effects thereof. The fact that there is a latency period between 
the cessation of treatment and the onset of cardiotoxicity may indicate that the anti-neoplastic 
activity of DOX can be uncoupled from the toxic effects observed in the myocardium by 
administering a cardioprotective post-treatment regimen. However, if ghrelin alone is 
exerting an inhibitory effect or no effect on cancer cells, then ghrelin can be administered 
together with DOX to protect the non-cancerous cells. Although this study performed a single 
experiment in the context of cancer, we would have liked to continue and expand our 
experimental methods, however, this was beyond the scope of the current study. 
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Author: Carvalho et al., (2014) 
JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Jul 05, 2017 
 
This Agreement between Miss. Toni Goldswain ("You") and John Wiley and Sons ("John Wiley and Sons") consists of 
your license details and the terms and conditions provided by John Wiley and Sons and Copyright Clearance Center. 
License Number 4142540582720 
License date Jul 05, 2017 
Licensed Content Publisher John Wiley and Sons 
Licensed Content Publication Medicinal Research Reviews 
Licensed Content Title Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy 
Licensed Content Author Filipa S. Carvalho,Ana Burgeiro,Rita Garcia,António J. Moreno,Rui A. Carvalho,Paulo J. Oliveira 
Licensed Content Date Mar 11, 2013 
Licensed Content Pages 30 
Type of use Dissertation/Thesis 
Requestor type University/Academic 
Format Print and electronic 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table 
number(s) Figure 2 
Will you be translating? No 
Title of your thesis / dissertation Ghrelin: a multifunctional hunger hormone that ‘satisfies’ several conditions 
associated with Doxorubicin-induced cardiotoxicity 
Expected completion date  Dec 2017 
Expected size (number of pages) 200 
Requestor Location 
Miss. Toni Goldswain 
Physiological Sciences 
Stellenbosch university 
 
Stellenbosch, Western Cape 7600 
South Africa 
Attn: Miss. Toni Goldswain 
 
Publisher Tax ID EU826007151 
Billing Type Invoice 
  
Billing Address 
Miss. Toni Goldswain 
Physiological Sciences 
Stellenbosch university   
Stellenbosch University  https://scholar.sun.ac.za
- 137 - 
 
 
 
Stellenbosch, South Africa 7600 
Attn: Miss. Toni Goldswain 
Total 0.00 USD 
  
Terms and Conditions 
  
TERMS AND CONDITIONS  
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one of its group companies 
(each a"Wiley Company") or handled on behalf of a society with which a Wiley Company has exclusive publishing rights 
in relation to a particular work (collectively "WILEY"). By clicking "accept" in connection with completing this licensing 
transaction, you agree that the following terms and conditions apply to this transaction (along with the billing and 
payment terms and conditions established by the Copyright Clearance Center Inc., ("CCC's Billing and Payment terms 
and conditions"), at the time that you opened your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
 
Terms and Conditions 
• The materials you have requested permission to reproduce or reuse (the "Wiley Materials") are protected by 
copyright.  
• You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-transferable, 
worldwide, limited license to reproduce the Wiley Materials for the purpose specified in the licensing process. 
This license, and any CONTENT (PDF or image file) purchased as part of your order, is for a one-time use 
only and limited to any maximum distribution number specified in the license. The first instance of 
republication or reuse granted by this license must be completed within two years of the date of the grant of this 
license (although copies prepared before the end date may be distributed thereafter). The Wiley Materials shall 
not be used in any other manner or for any other purpose, beyond what is granted in the license. Permission is 
granted subject to an appropriate acknowledgement given to the author, title of the material/book/journal and 
the publisher. You shall also duplicate the copyright notice that appears in the Wiley publication in your use of 
the Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission. 
• With respect to the Wiley Materials, all rights are reserved. Except as expressly granted by the terms of the 
license, no part of the Wiley Materials may be copied, modified, adapted (except for minor reformatting 
required by the new Publication), translated, reproduced, transferred or distributed, in any form or by any 
means, and no derivative works may be made based on the Wiley Materials without the prior permission of the 
respective copyright owner.For STM Signatory Publishers clearing permission under the terms of the 
STM Permissions Guidelines only, the terms of the license are extended to include subsequent editions 
and for editions in other languages, provided such editions are for the work as a whole in situ and does 
not involve the separate exploitation of the permitted figures or extracts, You may not alter, remove or 
suppress in any manner any copyright, trademark or other notices displayed by the Wiley Materials. You may 
not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-
alone basis, or any of the rights granted to you hereunder to any other person. 
• The Wiley Materials and all of the intellectual property rights therein shall at all times remain the exclusive 
property of John Wiley & Sons Inc, the Wiley Companies, or their respective licensors, and your interest 
therein is only that of having possession of and the right to reproduce the Wiley Materials pursuant to Section 2 
herein during the continuance of this Agreement. You agree that you own no right, title or interest in or to the 
Wiley Materials or any of the intellectual property rights therein. You shall have no rights hereunder other than 
the license as provided for above in Section 2. No right, license or interest to any trademark, trade name, service 
mark or other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall 
not assert any such right, license or interest with respect thereto 
• NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY 
KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO 
THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, 
INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, 
ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
  
Stellenbosch University  https://scholar.sun.ac.za
- 138 - 
 
 
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY 
EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
• WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement by you. 
• You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, officers, 
agents and employees, from and against any actual or threatened claims, demands, causes of action or 
proceedings arising from any breach of this Agreement by you. 
• IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR 
ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, 
INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE 
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, 
BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS 
OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN 
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY 
PROVIDED HEREIN.  
• Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, invalid, or 
unenforceable, that provision shall be deemed amended to achieve as nearly as possible the same economic 
effect as the original provision, and the legality, validity and enforceability of the remaining provisions of this 
Agreement shall not be affected or impaired thereby.  
• The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of 
either party's right to enforce each and every term and condition of this Agreement. No breach under this 
agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed 
by the party granting such waiver or consent. The waiver by or consent of a party to a breach of any provision 
of this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach 
by such other party.  
• This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's 
prior written consent. 
• Any fee required for this permission shall be non-refundable after thirty (30) days from receipt by the CCC. 
• These terms and conditions together with CCC's Billing and Payment terms and conditions (which are 
incorporated herein) form the entire agreement between you and WILEY concerning this licensing transaction 
and (in the absence of fraud) supersedes all prior agreements and representations of the parties, oral or written. 
This Agreement may not be amended except in writing signed by both parties. This Agreement shall be binding 
upon and inure to the benefit of the parties' successors, legal representatives, and authorized assigns.  
• In the event of any conflict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions shall prevail. 
• WILEY expressly reserves all rights not specifically granted in the combination of (i) the license details 
provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) 
CCC's Billing and Payment terms and conditions. 
• This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was misrepresented 
during the licensing process. 
• This Agreement shall be governed by and construed in accordance with the laws of the State of New York, 
USA, without regards to such state's conflict of law rules. Any legal action, suit or proceeding arising out of or 
relating to these Terms and Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of America and each party 
hereby consents and submits to the personal jurisdiction of such court, waives any objection to venue in such 
court and consents to service of process by registered or certified mail, return receipt requested, at the last 
Stellenbosch University  https://scholar.sun.ac.za
- 139 - 
 
 
known address of such party. 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription journals offering Online Open. 
Although most of the fully Open Access journals publish open access articles under the terms of the Creative Commons 
Attribution (CC BY) License only, the subscription journals and a few of the Open Access Journals offer a choice of 
Creative Commons Licenses. The license type is clearly identified on the article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and transmit an article, adapt the 
article and make commercial use of the article. The CC-BY license permits commercial and non- 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use, distribution and reproduction in 
any medium, provided the original work is properly cited and is not used for commercial purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) permits use, distribution and 
reproduction in any medium, provided the original work is properly cited, is not used for commercial purposes and no 
modifications or adaptations are made. (see below) 
Use by commercial "for-profit" organizations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit 
permission from Wiley and will be subject to a fee 
• Figure 2: Cumulative risk of developing DOX-induced heart failure 
Author: Barrett-Lee et al., (2009) 
OXFORD UNIVERSITY PRESS LICENSE 
TERMS AND CONDITIONS 
Jul 05, 2017 
 
This Agreement between Miss. Toni Goldswain ("You") and Oxford University Press ("Oxford University Press") 
consists of your license details and the terms and conditions provided by Oxford University Press and Copyright 
Clearance Center. 
License Number 4142500177293 
License date Jul 05, 2017 
Licensed content publisher Oxford University Press 
Licensed content 
publication Annals of Oncology 
Licensed content title Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac 
risk 
Licensed content author Barrett-Lee, P. J.; Dixon, J. M. 
Licensed content date Jan 19, 2009 
Type of Use Thesis/Dissertation 
Stellenbosch University  https://scholar.sun.ac.za
- 140 - 
 
 
Institution name 
 
Title of your work  Ghrelin: a multifunctional hunger hormone that ‘satisfies’ several conditions associated with Doxorubicin-induced cardiotoxicity 
Publisher of your work  n/a 
Expected publication date Dec 2017 
Permissions cost 0.00 USD 
Value added tax 0.00 USD 
Total 0.00 USD 
Requestor Location 
Miss. Toni Goldswain 
Physiological Sciences 
Stellenbosch university 
 
Stellenbosch, Western Cape 7600 
South Africa 
Attn: Miss. Toni Goldswain 
Publisher Tax ID GB125506730 
Billing Type Invoice 
  
Billing Address 
Miss. Toni Goldswain 
Physiological Sciences 
Stellenbosch university 
 
Stellenbosch, South Africa 7600 
Attn: Miss. Toni Goldswain 
  
Total 0.00 USD 
  
Terms and Conditions 
  
 
STANDARD TERMS AND CONDITIONS FOR REPRODUCTION OF MATERIAL FROM AN OXFORD 
UNIVERSITY PRESS JOURNAL 
1. Use of the material is restricted to the type of use specified in your order details. 
2. This permission covers the use of the material in the English language in the following territory: world. If you have 
requested additional permission to translate this material, the terms and conditions of this reuse will be set out in clause 
12. 
3. This permission is limited to the particular use authorized in (1) above and does not allow you to sanction its use 
elsewhere in any other format other than specified above, nor does it apply to quotations, images, artistic works etc that 
have been reproduced from other sources which may be part of the material to be used. 
4. No alteration, omission or addition is made to the material without our written consent. Permission must be re-cleared 
with Oxford University Press if/when you decide to reprint. 
5. The following credit line appears wherever the material is used: author, title, journal, year, volume, issue number, 
pagination, by permission of Oxford University Press or the sponsoring society if the journal is a society journal. Where a 
journal is being published on behalf of a learned society, the details of that society must be included in the credit line. 
6. For the reproduction of a full article from an Oxford University Press journal for whatever purpose, the corresponding 
author of the material concerned should be informed of the proposed use. Contact details for the corresponding authors of 
all Oxford University Press journal contact can be found alongside either the abstract or full text of the article concerned, 
accessible from www.oxfordjournals.org Should there be a problem clearing these rights, please contact 
journals.permissions@oup.com 
7. If the credit line or acknowledgement in our publication indicates that any of the figures, images or photos was 
reproduced, drawn or modified from an earlier source it will be necessary for you to clear this permission with the 
original publisher as well. If this permission has not been obtained, please note that this material cannot be included in 
your publication/photocopies. 
  
Stellenbosch University  https://scholar.sun.ac.za
- 141 - 
 
 
8. While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process 
for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (either by Oxford University Press or by Copyright 
Clearance Center (CCC)) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received 
on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if 
never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and 
Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials 
as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may 
constitute copyright infringement and Oxford University Press reserves the right to take any and all action to protect its 
copyright in the materials. 
9. This license is personal to you and may not be sublicensed, assigned or transferred by you to any other person without 
Oxford University Press’s written permission. 
10. Oxford University Press reserves all rights not specifically granted in the combination of (i) the license details 
provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC’s 
Billing and Payment terms and conditions. 
11. You hereby indemnify and agree to hold harmless Oxford University Press and CCC, and their respective officers, 
directors, employs and agents, from and against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this license.  
 
• Figure 3: The process of redox cycling 
Author: Tokarska-Schlattner et al., (2006) 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
Jul 05, 2017 
 
This Agreement between Miss. Toni Goldswain ("You") and Elsevier ("Elsevier") consists of your license details and the 
terms and conditions provided by Elsevier and Copyright Clearance Center. 
License Number 4142521353091 
License date Jul 05, 2017 
Licensed Content Publisher Elsevier 
Licensed Content 
Publication Journal of Molecular and Cellular Cardiology 
Licensed Content Title New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics 
Licensed Content Author Malgorzata Tokarska-Schlattner,Michael Zaugg,Christian Zuppinger,Theo Wallimann,Uwe Schlattner 
Licensed Content Date Sep 1, 2006 
Licensed Content Volume 41 
Licensed Content Issue 3 
Licensed Content Pages 17 
Start Page 389 
End Page 405 
Type of Use reuse in a thesis/dissertation 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 1 
Format electronic 
Are you the author of this No 
Stellenbosch University  https://scholar.sun.ac.za
- 142 - 
 
 
Elsevier article? 
Will you be translating? No 
Order reference number 
 
Original figure numbers Figure 2 
Title of your 
thesis/dissertation  
Ghrelin: a multifunctional hunger hormone that ‘satisfies’ several conditions associated with 
Doxorubicin-induced cardiotoxicity 
Expected completion date Dec 2017 
Estimated size (number of 
pages) 200 
Elsevier VAT number GB 494 6272 12 
Requestor Location 
Miss. Toni Goldswain 
Physiological Sciences 
Stellenbosch university 
 
Stellenbosch, Western Cape 7600 
South Africa 
Attn: Miss. Toni Goldswain 
  
Publisher Tax ID ZA 4110266048 
Total 0.00 USD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in connection with completing this 
licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing 
and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened 
your Rightslink account and that are available at any time at http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions 
indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with 
credit or acknowledgement to another source, permission must also be sought from that source.  If such permission is not 
obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must 
be made, either as a footnote or in a reference list at the end of your publication, as follows: 
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright 
(Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special 
credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier." 
4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to 
serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior 
written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be 
made to any Lancet figures/tables and they must be reproduced in full.  
6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future 
requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details 
provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's 
Billing and Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the 
  
Stellenbosch University  https://scholar.sun.ac.za
- 143 - 
 
 
license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate 
details of your proposed use, no license is finally effective unless and until full payment is received from you (either by 
publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If full payment is not received on 
a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never 
granted.  Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment 
terms and conditions, the license is automatically revoked and shall be void as if never granted.  Use of materials as 
described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may 
constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the 
materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, 
directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to 
any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in 
the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, 
acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and 
conditions or CCC's Billing and Payment terms and conditions.  These terms and conditions, together with CCC's Billing 
and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction.  In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, 
these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole 
discretion, for any reason or no reason, with a full refund payable to you.  Notice of such denial will be made using the 
contact information provided by you.  Failure to receive such notice will not alter or invalidate the denial.  In no event 
will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as 
a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or 
Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless your license was granted 
for translation rights. If you licensed translation rights you may only translate this content into the languages you 
requested. A professional translator must perform all translations and reproduce the content word for word preserving the 
integrity of the article. 
16. Posting licensed content on any Website: The following terms and conditions apply as follows: Licensing material 
from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of 
each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com; 
Central Storage: This license does not include permission for a scanned version of the material to be stored in a central 
repository such as that provided by Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at 
http://www.elsevier.com . All content posted to the web site must maintain the copyright information line on the bottom 
of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web 
site must be password-protected and made available only to bona fide students registered on a relevant course. This 
Stellenbosch University  https://scholar.sun.ac.za
- 144 - 
 
 
permission is granted for 1 year only. You may obtain a new license for future website posting.  
17. For journal authors: the following clauses are applicable in addition to the above: 
Preprints: 
A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any 
other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.). 
Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order 
to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv 
or RePEc with their Accepted Author Manuscript (see below). 
If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. 
Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, 
access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have 
different preprint policies. Information on these policies is available on the journal homepage. 
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for 
publication and which typically includes author-incorporated changes suggested during submission, peer review and 
editor-author communications. 
Authors can share their accepted author manuscript: 
• immediately 
o via their non-commercial person homepage or blog 
o by updating a preprint in arXiv or RePEc with the accepted manuscript 
o via their research institute or institutional repository for internal institutional uses or as part of an 
invitation-only research collaboration work-group 
o directly by providing copies to their students or to research collaborators for their personal use 
o for private scholarly sharing as part of an invitation-only work group on commercial sites with which 
Elsevier has an agreement 
• After the embargo period 
o via non-commercial hosting platforms such as their institutional repository 
o via commercial sites with which Elsevier has an agreement 
In all cases accepted manuscripts should: 
• link to the formal publication via its DOI 
• bear a CC-BY-NC-ND license - this is easy to do 
• if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our 
hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published 
journal article. 
Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research 
that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-
ordination, copy-editing, formatting, (if relevant) pagination and online enrichment. 
Policies for sharing publishing journal articles differ for subscription and gold open access articles: 
Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of 
researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, 
and use the best available version. 
Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the 
awarding institution with DOI links back to the formal publications on ScienceDirect. 
If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' 
Stellenbosch University  https://scholar.sun.ac.za
- 145 - 
 
 
research accessed under that agreement. This includes use for classroom teaching and internal training at the institution 
(including use in course packs and courseware programs), and inclusion of the article for grant funding purposes. 
Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a 
CrossMark logo, the end user license, and a DOI link to the formal publication on ScienceDirect. 
Please refer to Elsevier's posting policy for further information. 
18. For book authors the following clauses are applicable in addition to the above:   Authors are permitted to place a 
brief summary of their work online only. You are not allowed to download and post the published electronic version of 
your chapter, nor may you scan the printed edition to create an electronic version. Posting to a repository: Authors are 
permitted to post a summary of their chapter only in their institution's repository. 
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution 
in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These 
requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the 
complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. 
Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain 
embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back 
to the formal publications on ScienceDirect. 
Elsevier Open Access Terms and Conditions 
You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription 
journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the 
author's choice of Creative Commons user license. See our open access license policy for more information. 
Terms & Conditions applicable to all Open Access articles published with Elsevier:  
Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be 
modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes 
must be clearly indicated. 
The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the 
formal publication on ScienceDirect. 
If any part of the material to be used (for example, figures) has appeared in our publication with credit or 
acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and 
conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter 
and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by 
commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant 
DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the 
use made of the work. The full details of the license are available at http://creativecommons.org/licenses/by/4.0. 
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the 
Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives 
appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates 
if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works 
must be made available on the same conditions. The full details of the license are available at 
http://creativecommons.org/licenses/by-nc-sa/4.0. 
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for 
commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and 
provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link 
to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license 
are available at http://creativecommons.org/licenses/by-nc-nd/4.0. Any commercial reuse of Open Access articles 
Stellenbosch University  https://scholar.sun.ac.za
- 146 - 
 
 
published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes: 
• Associating advertising with the full text of the Article 
• Charging fees for document delivery or access 
• Article aggregation 
• Systematic distribution via e-mail lists or share buttons 
Posting or linking by commercial companies for use by customers of those companies. 
• Figure 4: The pathways involved in free radical scavenging 
Author: own art work 
• Figure 5: A summary of the known biological actions of ghrelin 
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• Figure 6: Structure of acyl-ghrelin (left) and des-acyl ghrelin (right) 
Author: Orbetzova, (2012) 
© 2012 Orbetzova, licensee InTech. This is an open access chapter distributed under the 
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Email: suljic@intechopen.com 
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• Figure 7: Ghrelin regulates energy balance and appetite by at least two mechanisms 
Author: own art work 
• Figure 8: The Intrinsic Apoptotic Pathway  
Author: own art work 
• Figure 9: The Potential Signaling Pathways Induced by Ghrelin 
Author: own art work 
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Appendix C 
Animal Ethics 
 
Stellenbosch University  https://scholar.sun.ac.za
- 149 - 
 
 
Appendix D 
Detailed Protocols 
Protocol 1: Milliplex® MAP Kit (Rat Cardiac Injury Magnetic Bead Panel 1) 
STORAGE CONDITIONS UPON RECEIPT  
Recommended storage for kit components is 2 - 8°C.  
Avoid multiple (>2) freeze/thaw cycles.  
DO NOT FREEZE Antibody-Immobilized Beads, Detection Antibody, and 
Streptavidin-Phycoerythrin 
   
Reagents Supplied  Catalog Number  Volume  Quantity  
Rat Cardiac Injury 
Panel 1 Standard  
RCI1-8087-1  Lyophilized  1 vial  
Rat Cardiac Injury 
Panel 1 Quality 
Controls 1 and 2  
RCI1-6087-1  Lyophilized  1 vial each  
Serum Matrix  
Note: Contains 0.08% 
Sodium Azide  
LHPT-SM  Lyophilized  1 vial  
Set of one 96-Well 
Plate with 2 sealers  
-----------  -----------  1 plate  
2 sealers  
Assay Buffer  L-AB  30 mL  1 bottle  
10X Wash Buffer  
Note: Contains 0.05% 
Proclin  
L-WB  60 mL  1 bottle  
Rat Cardiac Injury 
Panel 1 Detection 
Antibodies  
RCI1-1087-1  3.2 mL  1 bottle  
Streptavidin-
Phycoerythrin  
L-SAPE4  3.2 mL  1 bottle  
Mixing Bottle  -----------  -----------  1 bottle  
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Bead/Analyte Name  Luminex Magnetic Bead Region  Customizable 7 Analytes  
(20X concentration, 200 µL)  
Available Cat. #  
Anti-Rat Cardiac 
Troponin I Bead  
22  RTRPNTI-MAG  
Anti-Rat Cardiac 
Troponin T Bead  
25  RTRPNT-MAG  
Anti-Rat CKM Bead  39  RCKM-MAG  
 
PREPARATION: 
A. Dilute serum samples 1: 5 by adding 15 µL of each sample to 60 µL assay buffer. 
 
B. Preparation of Antibody-Immobilized Beads  
For individual vials of beads, sonicate each antibody-bead vial for 30 seconds; vortex 
for 1 minute. Add 150 µL from each antibody-bead vial to the Mixing Bottle and 
bring final volume to 3.0 mL with Assay Buffer. Vortex the mixed beads well. 
Unused portion may be stored at 2-8°C for up to one month. (Note: Due to the 
composition of magnetic beads, you may notice a slight color in the bead solution. 
This does not affect the performance of the beads or the kit). Example: When using 3 
antibody-immobilized beads, add 150 µL from each of the 3 bead vials to the Mixing 
Bottle. Then add 2.55 mL Assay Buffer.  
 
C. Preparation of Quality Controls  
Before use, reconstitute Quality Control 1 and Quality Control 2 with 250 µL 
deionized water. Invert the vial several times to mix and vortex. Allow the vial to sit 
for 5-10 minutes. Unused portion may be stored at -20°C for up to one month.  
 
D. Preparation of Wash Buffer  
Bring the 10X Wash Buffer to room temperature and mix to bring all salts into 
solution. Dilute 60 mL of 10X Wash Buffer with 540 mL deionized water. Store the 
unused portion at 2-8°C for up to one month.  
 
E. Preparation of Serum Matrix 
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Add 1 mL deionized water to the bottle containing lyophilized Serum Matrix. Mix 
well. Allow at least 5 minutes for complete reconstitution. Dilute reconstituted Serum 
Matrix 1:15 by adding 60 µL of reconstituted Serum Matrix to 885 µL of assay buffer. 
Discard leftover diluted Serum Matrix, leftover undiluted Serum Matrix should be 
stored at -20°C for up to one month.  
 
F. Preparation of Rat Cardiac Injury Panel 1 Standard  
Prior to use, reconstitute the Rat Cardiac Injury Panel 1 Standard with 250 µL 
deionized water. Refer to table below for analyte concentrations. Invert the vial 
several times to mix. Vortex the vial for 10 seconds. Allow the vial to sit for 5-10 
minutes. This will be used as Standard 7; the unused portion may be stored at -20°C 
for up to one month.  
 
G. Preparation of Working Standards  
Label 6 polypropylene microfuge tubes Standard 1 through Standard 6. Add 200 µL 
of Assay Buffer to each of the 6 tubes. Prepare serial dilutions by adding 100 µL of 
the reconstituted standard to the Standard 6 tube, mix well and transfer 100 µL of 
Standard 6 to the Standard 5 tube, mix well and transfer 100 µL of Standard 5 to the 
Standard 4 tube, mix well and transfer 100 µL of Standard 4 to the Standard 3 tube, 
mix well and transfer 100 µL of Standard 3 to the Standard 2 tube, mix well and 
transfer 100 µL of Standard 2 to the Standard 1 tube and mix well. The 0 pg/mL 
standard (Background) will be Assay Buffer.  
 
Preparation 
of Standards 
Standard  
MYL3 
(pg/mL)  
CKM  
(pg/mL)  
FABP3, 
TIMP-1  
(pg/mL)  
Cardiac 
Troponin T, 
Follistatin-
like 1  
(pg/mL)  
Cardiac 
Troponin I  
(pg/mL)  
Standard 1  4  21  41  82  123  
Standard 2  12  62  123  247  370  
Standard 3  37  185  370  741  1,111  
Standard 4  111  556  1,111  2,222  3,333  
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Standard 5  333  1,667  3,333  6,667  10,000  
Standard 6  1,000  5,000  10,000  20,000  30,000  
Standard 7  3,000  15,000  30,000  60,000  90,000  
 
IMMUNOASSAY PROCEDURE  
1. Allow all reagents to warm to room temperature (20-25°C) before use in the assay.  
2. Diagram the placement of Standards 0 (Background), Standard 1 through 7, Controls 
1 and 2, and Samples on Well Map Worksheet in a vertical configuration. It is 
recommended to run the assay in duplicate.  
3. Add 200 µL of wash buffer into each well of the plate to pre-wet the wells.  
4. Decant wash buffer and remove the residual amount from all wells by inverting the 
plate and tapping it smartly onto absorbent towels several times.  
5. Add 25 µL of each Standard or Control into the appropriate wells. Assay buffer 
should be used for 0 pg/mL standard (Background).  
6. Add 25 µL of assay buffer to the sample wells.  
7. Add 25 µL of appropriate matrix solution to the background, standards, and control 
wells. When assaying serum or plasma, use the serum matrix.  
8. Add 25 µL of Sample (diluted) into the appropriate wells.  
9. Vortex Mixing Bottle and add 25 µL of the Mixed Beads to each well. (Note: During 
addition of Beads, shake bead bottle intermittently to avoid settling.)  
10. Seal the plate with a plate sealer. Wrap the plate with foil and incubate with agitation 
(550 rpm) on a plate shaker overnight (16-18 hours) at 2-8°C.  
11. Gently remove well contents and wash plate 3 times using the Bio-Rad Bio-Plex 
Pro™ wash station.  
12. Add 25 µL of Detection Antibodies into each well.  
13. Seal, cover with foil and incubate with agitation on a plate shaker (600 rpm) for 1 
hour at room temperature (20-25°C). DO NOT ASPIRATE AFTER 
INCUBATION. TAKE NOTE OF TIME ON COMPUTER. 
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14. Add 25 µL Streptavidin-Phycoerythrin to each well containing the 25 µL of Detection 
Antibodies.  
15. Seal, cover with foil and incubate with agitation on a plate shaker for 30 minutes at 
room temperature (20-25°C). TAKE NOTE OF TIME ON A COMPUTER. 
16. Gently remove well contents and wash plate 3 times 
17. Add 150 µL of Drive Fluid (EMD Millipore, MPXDF-4PK) to all wells. Resuspend 
the beads on a plate shaker for 5 minutes.  
18. Run plate on MAGPIX® with xPONENT® software.  
19. Save and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter 
logistic or spline curve-fitting method for calculating analyte concentrations in 
samples. (Note: For diluted samples, final sample concentrations should be multiplied 
by the dilution factor. For samples diluted as per protocol instructions, multiply by 5.  
Protocol 2: Milliplex® MAP Kit (Rat Metabolic Hormone Magnetic Bead Panel) 
Reagents Supplied  Catalog Number  Volume  Quantity  
Rat Metabolic 
Hormone Standard  
RMH-8084  lyophilized  1 vial  
Rat Metabolic 
Hormone  
Quality Controls 1 
and 2  
RMH-6084  lyophilized  2 vials  
Set of one 96-Well 
black Plate with 2 
sealers  
-----------  -----------  1 plate  
2 sealers  
Assay Buffer  LE-ABGLP  30 mL  1 bottle  
Serum Matrix  LRGT-SM  1 mL  1 bottle  
Bead Diluent  LE-BD  3.5 mL  1 bottle  
10X Wash Buffer  
Note: Contains 
0.05% Proclin  
L-WB  60 mL  1 bottle  
Rat Metabolic RMH-1084  5.5 mL  1 bottle  
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Hormone  
Detection Antibodies  
Streptavidin-
Phycoerythrin  
L-SAPE12  5.5 mL  1 bottle  
Mixing Bottle  -----------  -----------  1 bottle  
 
Bead/Analyte Name  Luminex Magnetic 
Bead Region  
Cat. #  
Anti-Ghrelin Beads  20  HGRLN-MAG  
Anti-Glucagon Beads  33  HGLU-MAG  
Anti-IL-6 Beads  35  RIL6-MAG  
Anti-Insulin Beads  37  RMINS-MAG  
Anti-Leptin Beads  38  RMLPTN-MAG  
Anti-TNFα Beads  65  RMTNFA-MAG  
 
PREPARATION  
A. Centrifuge samples at 3000xg for five minutes prior to assay setup. 
DO NOT DILUTE 
B. Preparation of Antibody-Immobilized Beads  
Sonicate each antibody-bead vial for 30 seconds; vortex for 1 minute. Add 150 µL 
from each antibody bead vial to the Mixing Bottle and bring final volume to 3.0 mL 
with Bead Diluent. Vortex the mixed beads well. Unused portion may be stored at 2-
8°C for up to one month. (Note: Due to the composition of magnetic beads, you may 
notice a slight color in the bead solution. This does not affect the performance of the 
beads or the kit.)  
C. Preparation of Quality Controls  
Before use, reconstitute Quality Control 1 and Quality Control 2 with 250 µL 
deionized water. Invert the vial several times to mix and vortex. Allow the vial to sit 
for 5-10 minutes, vortex and then transfer the controls to appropriately labeled 
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polypropylene microfuge tubes. Unused portion may be stored at -20°C for up to one 
month.  
D. Preparation of Wash Buffer  
Bring the 10X Wash Buffer to room temperature and mix to bring all salts into 
solution. Dilute 60 mL of 10X Wash Buffer with 540 mL deionized water. Store 
unused portion at 2-8°C for up to one month.  
E. Preparation of Serum Matrix  
Add 1.0 mL deionized water to the bottle containing lyophilized Serum Matrix. Mix 
well. Allow at least 10 minutes for complete reconstitution. Leftover reconstituted 
Serum Matrix can be stored at -20°C for up to one month.  
F. Preparation of Rat Metabolic Hormone Standard  
Prior to use, reconstitute the Rat Metabolic Hormone Standard with 250 µL deionized 
Water. Invert the vial several times to mix. Vortex the vial for 10 seconds. Allow the 
vial to sit for 5-10 minutes, vortex and then transfer the standard to appropriately 
labeled polypropylene microfuge tube. This will be used as Standard 7.  
G. Preparation of Working Standards  
Label 6 polypropylene microfuge tubes tubes “Standard 6,” “Standard 5,” “Standard 
4,” “Standard 3,” “Standard 2,” and “Standard 1.” Add 200 µL Assay Buffer to each 
of the six tubes. Perform 3 times serial dilutions by adding 100 µL of the “Standard 7” 
to the “Standard 6” tube, mix well and transfer 100 µL of the “Standard 6” to the 
“Standard 5” tube, mix well and transfer 100 µL of the “Standard 5” to “Standard 4” 
tube, mix well and transfer 100 µL of the “Standard 4” to the “Standard 3” tube, mix 
well and transfer 100 µL of the “Standard 3” to the “Standard 2” tube, mix well and 
transfer 100 µL of the “Standard 2” to the “Standard 1” tube. The 0 Standard 
(background) will be assay buffer. 
 
Standard 
Tube #  
Ghrelin 
(pg/ml)  
Glucagon, TNFα (pg/ml)  IL-6, Insulin, Leptin, (pg/ml)  
1  6.9  14  69  
2  21  41  206  
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3  62  124  617  
4  185  370  1,852  
5  556  1,111  5,556  
6  1,667  3,333  16,667  
7  5,000  10,000  50,000  
 
IMMUNOASSAY PROCEDURE  
1. Allow all reagents to warm to room temperature (20-25°C) before use in the assay.  
2. Diagram the placement of Standards [0 (Background), 1, 2, 3, 4, 5, 6, and 7], Controls 
1 and 2, and Samples on Well Map Worksheet in a vertical configuration. It is 
recommended to run the assay in duplicate.  
3. Add 200 µL of Assay Buffer into each well of the plate to pre-wet the well. 
4. Decant Assay Buffer and remove the residual amount from all wells by inverting the 
plate and tapping it smartly onto absorbent towels several times.  
5. Add 25 µL of appropriate matrix solution to the background, standards, and control 
wells. When assaying serum or plasma, use the Serum Matrix provided in the kit. 
6.  Add 25 µL of Assay Buffer to the background (0 pg/ml standard) and sample wells.  
7. Add 25 µL of each Standard or Control into the appropriate wells.  
8. Add 25 µL of sample into the appropriate wells.  
9. Vortex Mixing Bottle and add 25 µL of the Mixed to each well. (Note: During 
addition of Beads, shake bead bottle intermittently to avoid settling.)  
10. Seal the plate with a plate sealer. Wrap the plate with foil and incubate with agitation 
on a plate shaker overnight (18-20 hours) at 4°C. 
11. The next day, allow reagents and assay plate to come to room temperature. Gently 
remove well contents and wash plate 3 times 
12. Add 50 µL of Detection Antibodies into each well. 11. Seal, cover with foil and 
incubate with agitation on a plate shaker for 30 minutes at room temperature (20-
25°C). DO NOT ASPIRATE AFTER INCUBATION.  
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13. Add 50 µL Streptavidin-Phycoerythrin to each well containing the 50 µL of Detection 
Antibodies. 
14. Seal, cover with foil and incubate with agitation on a plate shaker for 30 minutes at 
room temperature (20-25°C). 
15. Gently remove well contents and wash plate 3 times 
16. Add 100 µL of Drive Fluid to all wells. Resuspend the beads on a plate shaker for 5 
minutes. 
17. Run plate on MAGPIX® with xPONENT software.  
18. Save and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter 
logistic or spline curve-fitting method for calculating analyte concentrations in 
samples. 
 
Protocol 3: Tissue processing and sectioning 
Processing: 
• Prepare various concentrations of alcohol (70%, 96%,  99.9%) and xylene in 1L 
Schott bottles 
• Pour the solutions into the jars of the tissue processor 
• Place formalin-fixed tissues into a cassette in the correct orientation. 
• Close the lid and label with a pencil. 
• On the tissue processor, switch the dial to “manual” to allow the rotor with basket 
hook to move to position 1  
• Move circular dial to “start” position (arrow). 
• Place the closed casettes into the basket. 
• Turn the dial to “auto” to check that upon dipping, all casettes are fully submerged (if 
not, rearrange) 
• Return switch to auto and allow the processing cycle to take place. 
• Processing will proceed in the following sequence:  
Step Solution Time (minutes) Temperature (°C) 
1 10% formalin 30 Room temperature 
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2 70% ethanol 30 Room temperature 
3 96% ethanol 30 Room temperature 
4 96% ethanol 30 Room temperature 
5 99.9% ethanol 30 Room temperature 
6 99.9% ethanol 30 Room temperature 
7 99.9% ethanol 30 Room temperature 
8 Xylene 30 Room temperature 
9 Xylene 30 Room temperature 
10 Paraffin 60 60 
11 Paraffin 60 60 
12 Paraffin 60 60 
 
• When the tissue has been processed, remove the casettes from the basket and pour the 
solutions back into the Schott bottles using a funnel. 
• Relabel new cassettes. 
• Fill the top compartment of the Leica tissue embedding station with wax (do not cover 
hole). 
• Place the piece of tissue into a warm metal embedding mould, in the correct 
orientation 
• Break the lid of the new cassette off and put the basket of the cassette on top of the 
sample/mould. 
• Fill the basket of the cassette with wax and leave to set for one hour on a cooling 
block. 
• Once it is set, the embedding mold can be removed to yield a tissue block. 
Sectioning: 
• Place tissue blocks into the freezer two hours prior to sectioning. 
• The tissue block was first trimmed until the tissue started to appear, and then 
sectioned into uniform 5 µm sections using a microtome. 
• Carefully lift the sectioned ‘ribbons’ using a paint brush and place on top of a 
microscope slide. 
• Partially rehydrate using a 50% alcohol solution 
Stellenbosch University  https://scholar.sun.ac.za
- 159 - 
 
 
• Gently place the sections onto the surface of a warm floatation bath (40 °C) to flatten 
and unravel them. 
• Pick up the sections onto a clean, labelled microscope slide and allow them to dry 
thoroughly on a 20 °C heating block. 
*During sectioning, it is important that the blade of the microtome does not become 
blunt. 
Protocol 4: H&E Stain 
• Mayer’s hematoxylin: commercially available Mayer’s Hematoxylin (Merck 
Millipore, SAAR2822001LC) was filtered through Whatman’s number 2 filter paper 
before each stain and placed into the correct position of the automated staining 
machine. Stock was stored at room temperature. 
• Eosin: commercially available alcoholic Eosin (Leica Biosystems, 3801600E) was 
further diluted (5% in 95% ethanol) and placed in the correct position of the 
automated staining machine. Stock was stored at room temperature. 
• Xylene (clearing agent): commercially available xylene (Merck, 1086619190) was 
stored at room temperature and used when required. 
• Ethanol: stored at room temperature and used for the dehydration steps in the 
automated staining apparatus. 
 
1. Section heart tissue and allow sections to adhere to microscope slides 
2. Prior to sectioning, place the slides into an oven to allow the wax surrounding the 
tissue to melt. 
3. Load the slides into the ‘holders’ of the Leica Auto Stainer XL 
4. Press ‘start’ and then immediately press ‘pause’ to indicate that there are additional 
slides to load. After two minutes, the first ‘rack’ will move to the second jar, allowing 
a new rack to be placed into the first jar. Repeat this process until all four racks are 
submerged in reagents, followed by ‘start’. 
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Step Solution Time (minutes) 
1 Xylene 5 
2 Xylene 5 
3 Ethanol (99%) 2 
4 Ethanol (99%) 2 
5 Ethanol (96%) 2 
6 Ethanol (70%) 2 
7 Tap water 2 
8 Mayer’s Hematoxylin 8 
9 Running water 5 
10 Eosin (0.1%) 4 
11 Running water 1 
12 Ethanol (70%) 0.5 
13 Ethanol (96%) 0.5 
14 Ethanol (96%) 0.5 
15 Ethanol (99%) 0.5 
16 Xylene 1 
 
5. Mount using DPX mountant, and allow the slides to dry for 48 hours. 
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Protocol 5: Masson’s staining reagents  
• Mayer’s hematoxylin: commercially available Mayer’s Hematoxylin (Merck 
Millipore, SAAR2822001LC) was filtered through Whatman’s number 2 filter paper 
before each. Stock was stored at room temperature. 
• Acetic acid water: add 2 mL glacial acetic acid (Radchem, 600113) to 1000 mL 
distilled water 
• Masson’s Fuchsin Ponceau-Orange G: prepare a stock solution by adding 2 g 
Ponceau (2R) de xylidine (Sigma-Aldrich, P2395), 1 g acid fuchsin (Sigma-Aldrich, 
F8129) and 2 g Orange G (Sigma-Aldrich, 861286) to 300 mL 0.2% acetic acid water. 
Then prepare a working solution by combining 10 mL of the stock solution with 90 
mL 0.2% acetic acid water. 
• Light Green Solution: add 0.1 g Light Green to 100 mL 0.2% acetic acid water 
• Phosphotungstic acid solution: add 5 g phosphotungstic acid to 100 mL distilled 
water 
• Xylene (clearing agent): commercially available xylene (Merck, 1086619190) was 
stored at room temperature and used when required. 
Briefly warm the slides in an oven to melt surrounding wax. 
Perform the Masson’s Trichrome stain in the follow sequence: 
Step Reagent Time required 
1 Xylene 5 minutes 
2 Xylene 5 minutes 
3 99% alcohol 5 minutes 
4 99% alcohol 5 minutes 
5 96% alcohol 5 minutes 
6 96% alcohol 5 minutes 
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7 96% alcohol 5 minutes 
8 70% alcohol 5 minutes 
9 Running tap water 5 minutes 
10 Rinse in distilled water 10 seconds 
11 Hematoxylin 5 minutes 
12 Running tap water until blue 5 minutes 
13 Rinse in distilled water 10 seconds 
14 Fuchsin Ponceau Orange 20 minutes 
15 Acetic acid water 10 seconds 
16 Phosphotungstic acid 5 minutes 
17 Acetic acid water 1 minutes 
18 Light Green solution 20 minutes 
19 Acetic acid water 5 minutes 
20 70% alcohol 5 dips 
21 96% alcohol 5 dips 
22 96% alcohol 5 dips 
23 96% alcohol 5 dips 
24 99% alcohol 5 dips 
25 99% alcohol 5 dips 
26 Xylene 1 minute 
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27 Xylene At least 5 minutes 
Lastly, mount with DPX mounting medium. 
 
Protocol 6: Immunohistochemistry 
Leica Bond Max Autostainer 
Step Solution Incubation Time 
(minutes) 
Temperature 
1 Peroxide block 5 Ambient 
2 Bond wash solution 0 Ambient 
3 Bond wash solution 0 Ambient 
4 Bond wash solution 0 Ambient 
5 Primary antibody 15 Ambient 
6 Bond wash solution 0 Ambient 
7 Bond wash solution 0 Ambient 
8 Bond wash solution 0 Ambient 
9 Post primary 8 Ambient 
10 Bond wash solution 2 Ambient 
11 Bond wash solution 2 Ambient 
12 Bond wash solution 2 Ambient 
13 Poly-HRP IgG 8 Ambient 
14 Bond wash solution 2 Ambient 
15 Bond wash solution 2 Ambient 
16 Deionized water 0 Ambient 
17 Deionized water 0 Ambient 
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18 Mixed DAB Refine 10 Ambient 
19 Deionized water 0 Ambient 
20 Deionized water 0 Ambient 
21 Deionized water 0 Ambient 
22 Hematoxylin 5 Ambient 
23 Deionized water 0 Ambient 
24 Deionized water 0 Ambient 
25 Deionized water 0 Ambient 
 
Protocol 7: Western blotting 
Protein extraction 
• Work on ice at all times to prevent protein degradation 
• Thaw lysates and homogenise on ice in 450 µL RIPA buffer 
• Rinse the tip of the homogeniser between each sample. 
• Allow the foam to settle for at least one hour 
• Centrifuge the lysates at 11 000 RPM (11.2 x g) for 2 x 15 minutes, at 4 °C, 
transferring to new microfuge tubes after each centrifugation 
 
Protein determination using the Direct Detect® Infrared Spectrometer 
• Switch on the laptop and infrared spectrometer to allow the machine to warm upand 
calibrate the level of humidity. 
• Initiate the Direct Detect program, select ‘operator’, click to select ‘proteins’ and 
‘lipids’ (if applicable), choose correct buffer for standard curve. Choose ‘extended 
drying cycle’. 
• Apply 2 µL of sample solution (position 2-4) and sample buffer blank (position 1) on 
the card. 
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• Insert the card vertically into the slot in the top of the sampling accessory. The card 
notch should face towards the center of the instrument (align arrows on card and 
instrument). 
• The instrument dries samples, then measures each spot. 
• After the first measurement, select ‘use previous blank’ 
Preparation of assembly and gels 
• Clean glass plates with 70% alcohol and place into casting frames 
• Clean rubber with 70% alcohol to remove any debris 
• Place the frames with rubber gaskets into casting stands and firmly clip into place. 
• Check for leaks with distilled water, then discard water 
• Make up the separating gel (% determined by size of proteins or FastCast kit) 
• Using a Pasteur pipette, pour the separating gel between the glass plates, to the top of 
the green door - avoid making bubbles by pipetting into the corner of the plate 
• Pour a layer of iso-butanol onto the gel (if pouring own gel) to prevent oxidation and 
to ensure a straight line (otherwise make stacking gel). 
• Allow the gel to set (± 30 minutes) 
• Wash off the iso-butanol using distilled water 
• Prepare the 4% stacking gel 
• Using a Pasteur pipette, pour the stacking gel onto the top on the separating gel 
• Immediately insert the appropriate comb (10- or 15-well) 
• Allow to set for +-30 minutes. 
• Denature samples by boiling at 95 °C for 5 minutes 
• Centrifuge samples briefly. 
• Carefully remove combs from the set gel. 
• Place gels into the U-shaped adaptor. 
• Place the apparatus into a tank and add running buffer into the middle compartment 
until it overflows into the wells 
Loading samples 
• Pipette 5 µL BLUeye Prestained protein ladder into the first well of the gel 
• Pipette samples in the rest of the wells using a new tip for each one. 
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• Once all samples are loaded, pour running buffer into the outer compartments 
• Place a lid onto the tank and ensure the electrodes are correctly orientated – red to red 
and black to black 
• Run samples for 10 minutes at 400 mA and 100 V (constant) 
• Then run samples at 400 mA, 120 V for about 50 minutes 
 Membrane transfer 
• Place the ready-to-assemble transfer stacks into transfer buffer to equilibrate. 
• Place PVDF membrane into methanol, and then into transfer buffer to equlillibrate. 
• Place the transfer stack onto a cassette, followed by the membrane. 
• Roll out any air bubbles 
• Carefully place the gel on top of the membrane. 
• Again roll out any bubbles 
• Place the top transfer stack on top of the gel 
• Roll out any bubbles 
• Put the lid back on and lock into place. 
• Set the transfer for 7 – 12 minutes. 
• Once the transfer is complete, put the membrane into methanol, then allow to dry, 
then wet in methanol, and lastly place into TBS-T for a short rinse. 
• Finally, place into blocking solution 
Antibodies 
• Wash the membrane 3 x 3 minutes with TBS-T 
• Make up the primary antibody solution in a 50 mL falcon tube and roll the membrane 
inside the tube 
• Rotate in a 4 °C fridge overnight. 
• The next day, wash 3 x 3 minutes with TBS-T. 
• Make up secondary antibody solution in a 50 mL falcon tube and roll the membrane 
inside the tube 
• Leave on roller for 1 hour at room temperature 
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Exposure 
• Wash membrane 3x 3 minutes with TBS-T 
• Prepare a 1:1 solution of ECL substrate (must be room temperature) 
• Evenly pipette the ECL over the membrane 
• Expose in the ChemiDoc until desired bands appear. 
Stripping membranes 
• Wash membrane for 5 minutes in distilled water 
• Wash for 5 minutes in NaOH 
• Wash for 5 minutes in distilled water. 
OR 
• Wash membrane in stripping buffer for 2 x 5 minutes 
• Wash for 2 x 10 minutes in distilled water 
• Block in milk solution 
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Protocol 8: ORAC Assay 
Use BLACK fluorescence plates 
Do not use the first two columns (1, 2) and the last column of plate (12) – inaccurate read 
The assay runs at 37 °C so no need for ice 
Switch on the plate reader and Fluoroskan 30 minutes before starting: 
 
Fanie’s profile 
Fluoroskan 
Open session 
ORAC 
Open 
General tab, layout – check plate layout 
Measure tab 
Excitation – 485 nm 
Emission – 538 nm 
 
Phosphate buffer 75 mM, pH 7.4: 
Weigh 1.035g sodium di-hydrogen orthophosphate-1-hydrate in 100 mL ddH2O and mix until 
dissolved. 
Weigh 1.335g di-sodium hydrogen orthophosphate dehydrate (Merck, 5822880EM) in 100 
mL ddH2O and mix until dissolved. 
Mix 18 mL of 1st solution with 82 mL 2nd solution 
Check pH – adjust with phosphate buffer to pH 7.4 
Store at 4 °C 
 
Fluorescein Stock: Sigma #F6377 
Dissolve 0.0225g in 50 mL phosphate buffer (made above) 
Store at 4 °C in a brown bottle (can be reused for one year) 
 
Fluorescein Working Solution: 
Take 10 µL of the stock and add it to 2 mL phosphate buffer (into an epi) 
Take 240 µL of this and dilute in 15 mL phosphate buffer (into a 15 mL falcon) 
 
Peroxyl radical: Sigma #440914 25 mg/mL 
Weigh 150 mg of AAPH into a 15 mL falcon tube 
Only add 6 mL phosphate buffer later on 
 
Trolox (standard): 250 µM stock    Sigma #238831 
Weigh 0.00312 g and add 50 mL phosphate buffer 
Mix until dissolved 
Should give an absorbance of 0.670 at 289nm 
 
 
Procedure: 
Spin down samples at 14 000 RPM for ten minutes – they must not be turbid 
Deproteinize with perchloric acid at a 1: 1 ratio 
Add 6 mL phosphate buffer to the AAPH weighed earlier, mix well. 
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Put in water bath at 37 °C 
Label 6 epi’s A – F 
Prepare standards as follows: 
 Concentration 
(uM) 
Trolox stock 
(uL) 
Phosphate buffer 
(uL) 
Well 
1 0 0 750 A3-5 
2 83 125 625 A6-8 
3 167 250 500 A9-11 
4 250 375 375 A3-5 
5 333 500 250 B6-8 
6 417 625 125 B9-11 
 
• Add 12 µL standards to each well 
• Add 12 µL of samples per well, in triplicate 
• Add 138 µL of fluorescein working solution to each well using a multichannel 
• Add 50 µL of the AAPH solution to each well using a multichannel (AT the plate 
reader) 
• Put the plate into the plate reader 
• Read for 2 hours 
Protocol 9: TBARS Assay 
Before you start: 
Set waterbath to 90 °C (fill it to 80%) 
Use 2 mL epi’s and punch holes in their lids 
 
• Put 50 µL of sample into an epi. 
• Add 6.25 µL of BHT dissolved in 100% ethanol (to give a concentration of 4mM) to 
each sample 
• Add 50 µL ortho-phosphoric acid (0.2M)* to each sample 
• Vortex 
• Add 6.25 µL TBA reagent to each sample (concentration of 0.11M in 0.1M NaOH)** 
• Vortex 
• Heat at 90 °C for 45 minutes (be strict with time and degrees for each repeat) 
• Place samples in an ice bath for 2 minutes (or until needed) 
• Transfer to wells, use butanol as the blank and read A532 – A572 
 
 
*14.6M stock of O-Phosphoric acid, therefore: 
C1V1 = C2V2 
(14.6M)(V1) = (0.2M)(50mL)  (made 50mL for bulk) 
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V1 = 684.93 uL in 50 mL water 
 
**( = 	 *+, ……. - = ./	0	(  1 =	
2
3 …….. ( = 14  therefore m(g) =  
 
MR x C x V 
g = MR x C x V 
= 144.15 x 0.11M x 0.05L 
= 0.792g in 50 mL  0.1M NaOH 
 
EQUATIONS: 
Ԑ = 1.54 x 105 
Inter-assay CV = <8% 
C = A/ Ԑ 
Protocol 10: GLUTATHIONE ASSAY 
(Asensi et al., 1999a) 
Reagents: 
Buffer A (500 mM NaPO4, 1mM EDTA, pH 7.5) 
NADPH (1mM, 0.83 mg/mL) in buffer A (add 12 mL directly to vial)* NADPH, disodium salt, Cat 
nr. N6785 (10 vials) Sigma 
M2VP (30 mM in 0.1 M HCL )   measures GSSG Cat nr. 69701 (100mg) Sigma 
DTNB (0.3 mM (0.12 mg/mL) in buffer A) 
Standard solution (GSH - 3 µM) (GSSG – (1.5 µM), in buffer A 
Glutathione reductase (16 µL in 984 µL buffer = 1 mL)    x5 for one plate) Cat nr. G3664 (500 
Units) Sigma 
Procedure: 
To a test run to check whether samples need to be diluted. The curve needs to be steeper than 
the blank, but less steep than the higher standard. 
Prepare standards as follows: 
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 Blank 1 2 3 4 5 
GSH (µL) 0 167 333 500 667 833 
Buffer A (µL) 1000 833 667 500 333 167 
 
• Add 50 µL standards/samples to the wells of a 96-well plate 
• Add 50 µL of the DTNB using a multichannel 
• Add 50 µL of the glutathione reductase using a multichannel 
• Mix briefly and incubate for 5 minutes at 25 °C in a preheated BioTek plate reader 
• Add 50 µL NADPH to each well as quickly as possible (30 seconds max) 
• Measure absorbance at 412 nm every 30 seconds for 3 minutes 
• Use linear slope of the standards to calculate concentration of samples 
*10 mg per vial 
10 mg/x mL = 0.83 mg/1mL 
X = 12 mL 
NADPH + glutathione reductase  GSSG  GSH 
GSH binds to DTNB  yellow 
Protocol 11: SOD activity assay 
Prepare 50 mM NaPO4 SOD buffer, without Triton-X-100, at pH 7.4 
Prepare 1.6 mM 6-hydroxydopamine by adding 50 µL perchloric acid to 10 mL distilled 
water. Then add 4 mg of 6-HD to 1- mL of the solution made above. Wrap in foil, store on 
ice and use as soon as possible. 
Prepare 0.1 mM DETAPAC by adding 0.4 mg to 10 mL SOD assay buffer. Store at -20 °C. 
Prepare different dilutions of test samples.  
Add 12 µL of each sample in triplicate to a 96-well plate. 
Then add 15 µL 6-HD to each well. 
At the plate reader, add 170 µL DETAPAC 
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Then record the auto-oxidation at 490 nm for four minutes, at one minute intervals. 
Protocol 12: Conjugated Dienes 
o Weigh 100 mg tissue 
o Add 100 ul chloroform + 200 ul methanol  
o Homogenise for 2 mins  
o Then add 100 ul chloroform  
o Homogenise for 30 seconds   
o Add 100 ul dH2O 
o Homogenise for 30 seconds  
o Centrifuge at 10 000 rpm for 10 mins  
 Should be 2 layers – chloroform layer = bottom 
o Transfer bottom layer to new eppie [RECORD AMOUNT] 
o Add 100 ul NaCl until suspended properly 
o Leave open eppies in 4°C walk-in fridge [~ 2 days / weekend] 
 Freeze what is left in eppie 
• Once all eppies are dry, add 700 ul cyclohexane into each eppie 
• The add 150 ul of each eppie into each well on plate  
• (Blanks = 150 ul cyclohexane)  
Protocol 13: BNP ELISA 
Equilibrate all kit components to room temperature 
Preparation of Reagents and Samples: 
• Diluent (10x) 
Prepare a 1x diluent solution by mixing 30 mL diluent with 270 mL distilled water. 
 
• Wash buffer (20x) 
Prepare 1x wash buffer by mixing 30 ml buffer with 570 mL distilled water 
 
• Biotinylated detector antibody (50x) 
Dilute 105.6 uL detector antibody with 5174.4 uL diluent. 
 
• SP Conjugate (100x) 
Prepare 1x SP conjugate by adding 80 uL to 7920 uL diluent 
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• Prepare the standards by resuspending the powder in the vial (8 ng) in 8000 uL 
diluent to give 1 ng/mL. This is standard 1. Allow it to sit for 10 minutes with gentle 
agitation. 
 
• Label tubes 2 – 7 and pipette 120 uL of diluent into each one. Then pipette 120 uL 
standard 1 into tube 2. Mix thoroughly. Then pipette 120 uL tube 2 into tube 3 – 
repeat until tube 6. Tube 7 serves as the blank (diluent). 
• Homogenise samples in 0.1M PBS containing 1% Triton-X-100. Centrifuge at 14 000 
x g for 20 minutes at 4 °C. Measure the protein concentration in the supernatant, then 
assay. 
 
1. Add 50 uL of each standard and sample into the 96-well plate, in duplicate. Seal and 
incubate for two hours. 
2. Wash five times with wash buffer 
3. Add 50 uL biotinylated detector antibody to each well. Cover the plate and incubate 
for two hours. 
4. Wash the plate five times 
5. Add 50 uL SP conjugate to each well and incubate for 30 minutes. Set up the plate 
reader during this time 
6. Wash the plate five times 
7. Add 50 uL chromogen substrate and incubate for about ten minutes. Tap to mix. 
8. Add 50 uL STOP solution to each well and read the plate immediately at 450 nm. 
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Appendix E 
Preparation of Reagents 
Protocol 1: DOX preparation (2.5 mg/kg): 
Resuspend 50 mg DOX in 12.5 mL sterile saline to give a stock of 4 mg/mL =  4 µg/µL 
Vortex thoroughly. 
Example: 
Animal weight: 118.1 g 
→ 118.1 g x 2.5 µg/g 
→ 295.25 µg DOX 
 
Stock = 4 µg/ µL 
→ 
#	56	
7	58 =	
!9:.!:	56
;  
x = 73.8125 µL DOX stock (4 µg/ µL) in 200 µL saline (200 uL is the injection volume) 
BUT… multiply by 2 to account for bubbles and wastage 
→ 73.8125 x 2 = 147.625 µL DOX in 252.375 µL saline. 
Vortex thoroughly. 
Inject 200 µL. 
 
Protocol 2: Ghrelin preparation 
Resuspend 5 mg ghrelin in 5 mL sterile saline to give a stock solution of 1 mg/mL = 1 µg/µL 
Vortex thoroughly. 
Example: 
Animal weight: 118.1 g 
→ 118.1 g x 0.1 µg/g 
→ 11.81 µg ghrelin 
 
Stock = 1 µg/ µL 
→ 
7	56	
7	58 =	
77.<7	56
;  
Animal dose = 2.5 mg/kg 
= 2.5 µg/g 
Animal dose = 100 µg/kg 
= 0.1 µg/g 
Stellenbosch University  https://scholar.sun.ac.za
- 175 - 
 
 
x = 11.81 µL ghrelin stock (1 µg/ µL) in 200 µL saline (200 uL is the injection volume) 
… multiply by 2 to account for bubbles and wastage 
→ 11.81 x 2 = 23.62 µL ghrelin in 376.38 µL saline. 
Vortex thoroughly. 
Inject 200 µL. 
 
Protocol 3: Krebs Henseleit Buffer 
• Stock 1 
- 279 g NaCl in 2 L distilled water 
- MR: 58.44, Radchem, S1327B 
• Stock 2 
- 83.6 g NaHCO3 in 2 L distilled water 
- MR: 84.01, Merck, K45372729428 
• Stock 3: 
- 17.6 g KCL 
- MR: 74.56, Kimix,  
- 8.10 g KH2PO4 
- MR: 136.09, Saarchem, 5043600EM 
• Stock 4: 
- 7.4 g MgSO4.7H2O 
- MR: 246.48, Saarchem, SAAR4124000EM 
- 4.2 g Na2SO4 
- MR: 142.04, Saarchem, 5825260EM 
• Additives: 
- 1.76 g CaCl2.2H2O (MR: 147.02, Saarchem, SAAR1524820EM) 
- 9 g glucose anhydrous (MR: 180.16, Radchem) 
Buffer: 
1. 250 mL stock 1 
2. 250 mL stock 2 
3. 100 mL stock 3 
4. 100 mL stock 4 
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5. Fill up with distilled water to approximately 3 L 
6. Add 1.76 g CaCl2.2H2O to a small amount of water 
7. Mix well to avoid crystalisation 
8. Add to the buffer and mix well 
9. Mix 9g glucose to the buffer while mixing vigorously. 
10. Top up to 5 L mark. 
 
Protocol 4: Phosphate Buffered Saline 1X (PBS) 
Dissolve the following in 1L of distilled water: 
16 g NaCl 
0.4 g KCl 
2.88 g Na2HPO4 
0.48 g KH2PO4 
• Adjust the pH to 7.4 
• Fill up to the 2L mark with distilled water 
• Autoclave 
Protocol 5: 95% alcohol (1L) 
• Dilute 950 mL 100% ethanol in 50 mL distilled water 
Protocol 6: 90% alcohol (1L) 
• Dilute 900 mL 100% ethanol in 100 mL distilled water 
Protocol 7: 70% alcohol (1L) 
• Dilute 700 mL 100% ethanol in 300 mL distilled water 
Protocol 8: RIPA Buffer (100 mL) 
• Prepare 50 mM Tris-HCl: add 790 mg Tris to 75 mL distilled water. Add 900 mg 
NaCl and stir. Adjust pH to 7.4 using HCl. Pour the prepared Tris-HCl into a 100 mL 
beaker. 
• Add the following in the same order that they appear: 
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 Volume (mL) Final Concentration 
NP-40 10  1% 
Na-deoxycholate 2.5  0.25% 
EDTA 1  1 mM 
Phenylmethylsulponyl Fluoride 
(PMSF) 
1  1 mM 
Leupeptin 1 (µL) 1 µg/mL 
SBTI-1 80 (µL) 4 µg/mL 
Benzamidine 100 (µL) 1 mM 
Na3VO4 1 1 mM 
NaF 500 (µL) 1 mM 
 
• Add 1000 µL Triton-X-1000 to the solution and fill up to the mL mark with distilled 
water. 
• Mix thoroughly. 
• Aliquot the RIPA into 1 mL microfuge tubes and store at -20 °C. 
Protocol 9: Laemmli’s Sample Buffer (stock) 
• 3.8 mL distilled water 
• 1 mL 0.5M Tris-HCl, pH 6.8 
• 0.8 mL glycerol 
• 1.6 mL 10% (w/v) SDS 
• 0.4 mL 0.05% (w/v) Bromophenol blue 
Note: For use in western blotting, make a working solution by adding 150 µL β-
mercaptoethanol to 850 µL Laemmli’s stock solution. 
Protocol 10: 10% Sodium dodecyl sulphate (SDS) 
• Weigh out 50 g SDS and add 500 mL distilled water 
Protocol 11: 10X Running Buffer 
• Weigh off 60.6 g Tris 
• Weigh off 288 g glycine 
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• Add to ± 1.5L distilled water 
• Add 20 g SDS 
• Adjust the pH to 8.6 
• Fill up to the 2L mark with distilled water. 
Protocol 12: 10X TBS 
• Dissolve 24.2g Tris and 80g NaCl in 600 mL distilled water. 
• Adjust pH to 7.6 with HCl 
• Fill up to 1L mark with distilled water. 
• For use in Western Blotting, make up 1X TBS-T by thoroughly mixing 100 mL TBS 
in 900 mL distilled water, with 1mL Tween 
Protocol 13: 10% Ammonium persulphate 
• Weigh out 0.1 g APS into an microfuge tube and add 1000 µL distilled water 
Protocol 14: Tris pH 8.8 
• Weigh out 68.1 g Tris (1.124M) and 1.5 g SDS (0.3%) and place into a beaker 
• Add 400 mL distilled water, mix and then adjust pH to 8.8 using HCl 
• Make the final volume up to 500 mL 
Protocol 15: Tris pH 6.8 
• Weigh out 30.3 g (0.5M) Tris and 2 g SDS (0.4%) and place into a beaker 
• Add 400 mL distilled water, mix and adjust pH to 6.8 with HCl 
• Make final volume up to 500 mL 
Protocol 16: Tris pH 6.7 
• Weigh out 6.057 g Tris (100 mM) and place in a beaker 
• Add 400 mL distilled water, mix and adjust the pH to 6.7 using HCl 
• Make final volume up to 500 mL 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
- 179 - 
 
 
Protocol 17: Acrylamide Resolving Gels (makes enough for 2 gels) 
Gel Constituent 6% 8% 10% 12% 15% 
dH2O 5.88 mL 7.84 mL 9.8 mL 11.76 mL 14.70 mL 
30% Acrylamide 3 mL 4 mL 5 mL 6 mL 7.5 mL 
1.5M Tris-HCl, pH 8.8 3 mL 4 mL 5 mL 6 mL 7.5 mL 
20% w/v SDS 60 µL 80 µL 100 µL 120 µL 150 µL 
10% w/v APS 60 µL 80 µL 100 µL 120 µL 150 µL 
TEMED (last!!) 24 µL 32 µL 40 µL 48 µL 60 µL 
Protocol 18: 4% Acrylamide Stacking Gel (makes enough for 2 gels) 
Gel Constituent  
dH2O 7.5 mL 
30% Acrylamide 1.5 mL 
0.5M Tris-HCl, pH 6.8 3 mL 
20% w/v SDS 60 µL 
10% w/v APS 80 µL 
TEMED (last!!) 40 µL 
Protocol 19: Milk blocking solution 
• Measure out 5 mL fat-free milk and add 95 mL of TBS-T 
• Mix well on a magnetic stirrer 
• This is enough for one membrane 
Protocol 20: Primary (1°) Antibody 
• Pipette 5 µL of the primary antibody into a falcon tube containing 5 mL TBS-T. 
• Prepare just before use 
Protocol 21: Secondary (2°) Antibody 
• Pipette 0.5 µL secondary antibody into a falcon tube containing 5 mL TBS-T. 
Protocol 22: Stripping Buffer 
• 7.5 g glycine 
• 0.5 g SDS 
• 5 mL Tween 
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• Dissolve in +- 300 mL distilled water 
• Adjust pH to 2.2 
• Fill up to the 500 mL mark with dH2O 
 
Protocol 23: 50 mM phosphate buffer (Na2HPO4) with 1 mM EDTA 
m (g) = C x V x MR 
m (g) = 50 x 10-3 x 0.1L x 141.96 
m (g) = 0.7098g Na2HPO4 in 100 mL distilled water 
 
m (g) = C x V x MR 
m (g) = 1 x 10-3 x 0.1L x 292.24 
m (g) = 0.029g EDTA in 100 mL distilled water 
Add 0.7098g Na2HPO4 and 0.029g EDTA to approximately 50 mL distilled water. Adjust the 
pH to 7.5. Mix thoroughly and then fill up the volume to 100 mL. 
Protocol 24: M2VP 
Prepare 0.1M HCL by adding 4.91 mL of 32% HCL to 500 mL distilled water. 
Add 100 mg M2VP to 12.5 mL 0.1M HCL.  
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Appendix F 
Reagents 
Reagents Catalogue # Company 
2-Propanol UN1219 Merck 
32% Hydrochloric acid UN1789 Merck 
2,2’-Azobis (2-methylpropionamidine) dihydrochloride 
(AAPH) 
440914 Sigma-Aldrich 
Absolute alcohol 32221 Riedel deHaën 
Acrylamide UN3426 Merck 
Acrylamide A3699 Sigma-Aldrich 
Ammonium Persulphate (APS) UN1444 Merck 
Antibiotic antimycotic (AA) 15240-062 Gibco 
Bovine Serum Albumin A4503 Sigma-Aldrich 
Bromophenol Blue 32400A UnivAR 
Caspase Glo 3/7 G8091 Promega 
Coomassie Brilliant Blue G 27815 Fluka 
D-(+)-Glucose G7021 Sigma-Aldrich 
Di-sodium hydrogen orthophosphate dehydrate 5822880EM Merck 
Doxorubicin D1515 Sigma-Aldrich 
DTNB D21820 Sigma-Aldrich 
Dulbecco’s Modified Eagles Medium (DMEM) D5796 Sigma-Aldrich 
Fetal Bovine Serum 10270-106 Invitrogen Gibco 
Fluorescein sodium salt F6377 Sigma-Aldrich 
Glutathione standard G4251 Sigma-Aldrich 
Glutathione reductase (GR) G3664 Sigma-Aldrich 
Glycerol G5516 UnivAR 
Glycine G8898 Sigma-Aldrich 
Horse Serum S9133 Biochrom 
Iso-butanol UN1212 Merck 
LDH Cytoxicity Kit G1780 Promega 
Malondialdehyde 805797 Merck 
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Methanol UN1250 Merck 
Mouse Quantikine TNF-α ELISA Kit MTA00B R&D Systems 
MTT (Thiazolyl Blue Tetrazolium Bromide M2128 Sigma-Aldrich 
M2VP 69701 Sigma-Aldrich 
NADPH disodium salt N6785 Sigma-Aldrich 
Ortho-phosphoric acid UN1805 Merck 
PenStrep 15140-122 Invitrogen Gibco 
Pierce® ECL Western Blotting Substrate 32106 Thermo Scientific 
Ponceau S Solution P7170 Sigma-Aldrich 
Rat Quantikine TNFα ELISA Kit RTA00 R&D Systems 
Sodium Dodecyl Sulphate (SDS) L3771 Sigma-Aldrich 
Thiobarbituric acid T5500 Sigma-Aldrich 
TEMED T9281 Sigma-Aldrich 
TNF-α 400-14 PeproTech Inc. 
Trolox 238831 Sigma-Aldrich 
Triton-X-100 BB306324 BDH 
Trizma-Base 93304 Fluka 
Trypsin EDTA 25200-012 Invitrogen Gibco 
Tween®20 P1379 Sigma-Aldrich 
β-Mercaptoethanol M3148 Sigma-Aldrich 
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Appendix G 
Turnitin Report 
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